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 At a Glance Commentary: 
Scientific Knowledge on the Subject 
The standard of care for patients with new pulmonary tuberculosis is a six-month, four-drug 
regimen that includes rifampin for the full course of therapy. Attempts to further shorten 
tuberculosis therapy in the 1970s with higher, intermittent doses of rifampin were unsuccessful 
due to an apparent increase in toxicity. Renewed interest in tuberculosis treatment shortening 
developed earlier this century, with trials of fluoroquinolones, rifapentine, and a shortened 
regimen in patients at lower risk for poor outcomes. We sought to systematically examine the 
concept that increased daily doses of rifampin could shorten standard therapy for tuberculosis 
and improve treatment outcomes without increased toxicity. 
What This Study Adds to the Field 
This blinded, randomized, controlled Phase II clinical trial assessed differences across three daily 
oral doses of rifampin (10, 15, and 20 mg/kg) in change in elimination rate of Mycobacterium 
tuberculosis in sputum and frequency of rifampin-related adverse events. We found that doses of 
15 and 20 mg/kg/day resulted in more rapid change in counts of M. tuberculosis and a similar 
frequency of rifampin-related adverse events. This is the first controlled study to show both 
dose-and exposure-response of rifampin on sputum sterilization. Our findings support the 
continued investigation of higher doses of rifampin, beyond 20 mg/kg, for potential treatment 
shortening. 
Running title: High-dose rifampin for pulmonary tuberculosis 
Descriptor number: 11.6 (Treatment of Tuberculosis or Latent Infection) 
Total word count (excluding abstract, references, legends; max 3,500): 3,500 
At a Glance word count (max 200): 200
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 Abstract 
Rationale: We examined whether increased rifampin doses could shorten standard therapy for 
tuberculosis without increased toxicity. 
Objectives: To assess the differences across three daily oral doses of rifampin in change in 
elimination rate of Mycobacterium tuberculosis in sputum and frequency of rifampin-related 
adverse events. 
Methods: We conducted a blinded, randomized, controlled Phase II clinical trial of 180 adults 
with new smear-positive pulmonary tuberculosis, susceptible to isoniazid and rifampin. We 
randomized 1:1:1 to 10, 15, and 20 mg/kg/day of rifampin during the intensive phase. We report 
the primary efficacy and safety endpoints: change in elimination rate of M. tuberculosis log10 
colony forming units and frequency of grade 2 or higher rifampin-related adverse events. We 
report efficacy by treatment arm and by primary (AUC/MIC) and secondary (AUC) 
pharmacokinetic exposure. 
Measurements and Main Results: Each 5 mg/kg/day increase in rifampin dose resulted in 
differences of -0.011 (95%CI, -0.025 – +0.002;P=0.230) and -0.022 (95%CI, -0.046 – -
0.002;P=0.022) log10 colony forming units/mL/day in the modified intention-to-treat and per-
protocol analyses, respectively. Elimination rate in the per-protocol population increased 
significantly with rifampin AUC0-6 (P=0.011) but not with AUC0-6/MIC99.9 (P=0.053). Grade 2 
or higher rifampin-related adverse events occurred with similar frequency across the three 
treatment arms: 26(43.3%), 31(51.7%), and 23(38.3%) participants had at least one event 
(P=0.7092) up to 4 weeks after the intensive phase. Treatment failed or disease recurred in 
11(6.1%) participants. 
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 Conclusions: Our findings of more rapid sputum sterilization and similar toxicity with higher 
rifampin doses support investigation of increased rifampin doses to shorten tuberculosis 
treatment. 
 
Abstract word count (max 250): 250 
Keywords: tuberculosis, rifampin, randomized controlled trial, treatment efficacy, adverse drug 
event  
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 Introduction 
Tuberculosis is the leading infectious cause of death worldwide, killing 1.7 million in 2016 (1). 
Standard treatment for the annual estimated 10.4 million patients with new pulmonary 
tuberculosis is a six-month, four-drug regimen including rifampin throughout (2). 
 
Combining rifampin and pyrazinamide in the early 1970s shortened tuberculosis treatment from 
18 to 6 months (3). Further attempts to shorten tuberculosis therapy in the 1970s were guided by 
perceived cost constraints: any increase of the dose was matched by decreased frequency of 
administration. The resulting higher, intermittent doses of rifampin led to increased toxicity (4-
6). Ultimately, the 600 mg daily dose of rifampin was selected as the standard (7). Renewed 
interest in tuberculosis treatment shortening developed over the last 20 years, with preclinical 
and clinical studies of fluoroquinolones and one trial of a further-shortened regimen in patients 
with noncavitary disease and rapid bacteriological response (8-14). Prior to the initiation of the 
present study, a Phase II trial of treatment shortening with another rifamycin, rifapentine, was 
published; further work on treatment shortening with rifapentine was subsequently pursued (15-
17). 
 
Daily dose optimization of rifampin remained a priority. Unlike moxifloxacin and rifapentine, 
rifampin is an established first-line drug, available throughout the world, from multiple suppliers, 
now for pennies a capsule. It is also available in combination formulations. Of the four current 
first-line agents, rifampin has the most potent sterilizing activity and has been established as key 
to the continuation phase of treatment (18, 19). At the 600 mg daily dose, rifampin is well-
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 tolerated (20-23). However, concern about the toxicity of rifampin at higher doses persists 
pursuant to trials of intermittent dosing (6, 20, 24). 
 
While multiple controlled trials began to evaluate higher rifampin doses in African populations 
(25-27), and a single observational study evaluated rifampin concentrations in routine conditions 
in Peru (28), none evaluated, under controlled conditions, the concentration of rifampin and its 
concentration-dependent activity in Latin American patients. Prior evidence indicates important 
population variability in these measures for antituberculous drugs (29-32). No other late-stage 
clinical study has explored efficacy as a function of the pharmacokinetic/pharmacodynamic 
parameter thought to best predict rifampin efficacy (AUC/MIC) (22, 33-35). The present clinical 
trial entitled “Evaluation of high-dose rifampin in patients with new, smear-positive 
tuberculosis” (HIRIF) was designed to examine the concept that increased rifampin doses could 
shorten standard therapy for tuberculosis and improve treatment outcomes without increased 
toxicity. The primary objectives of this study were to assess the differences across three daily 
oral doses of rifampin (10, 15, and 20 mg/kg) in: plasma concentrations of rifampin; change in 
elimination rate of Mycobacterium tuberculosis in sputum; and frequency of grade 2 or higher 
adverse events (AEs) related to rifampin. Here we report the primary efficacy and safety 
endpoints. The pharmacokinetic results have been previously published (36), and some of the 
results of this study have been previously reported in the form of abstracts (37-39). 
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 Methods 
Design 
HIRIF was a blinded, randomized, controlled Phase II clinical trial registered under an 
investigational new drug application with the U.S. Food and Drug Administration (106635) and 
with ClinicalTrials.gov (NCT01408914) investigating the pharmacokinetics, efficacy, and safety 
of higher doses of rifampin in patients with pulmonary tuberculosis. Participants were identified 
and referred for enrollment from health centers in Lima, Peru between September 2013 and 
February 2015. Eligible participants were previously untreated adults (18-60 years old) with 
smear-positive disease (≥2+) and strains susceptible to isoniazid and rifampin. Exclusion criteria 
included a contraindication to rifampin and certain extrapulmonary manifestations of 
tuberculosis. All participants provided written informed consent. Additional details on study 
methods are provided in the published protocol (40) and online supplement. 
 
Intervention 
Participants were randomly allocated (1:1:1) in blocks of varying size to receive 10, 15, or 20 
mg/kg/day of rifampin during the 8-week intensive phase (see Table E1 for dosing by weight 
band). The randomization sequence was generated by the unblinded study statistician and 
programmed into the electronic data capture (EDC) system. All other study staff (including 
laboratory staff) were blinded, except pharmacy staff who received the arm assignment from the 
EDC and prepared study-drug kits. Standard doses of rifampin and companion drugs (isoniazid, 
pyrazinamide, ethambutol) were delivered through fixed-dose combinations (FDCs) supplied by 
MacLeods Pharmaceuticals (Mumbai, India) (2). These were supplemented by 150 mg capsules 
of rifampin and matched placebo donated by Sanofi (Paris, France). During the 18-week 
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 continuation phase, participants received isoniazid supplied by Micro Labs Limited (Bangalore, 
India) and rifampin, both dosed at 10 mg/kg thrice weekly. Participants received pyridoxine 50 
mg thrice weekly throughout treatment. Treatment was ambulatory and directly observed. 
 
Protocol-defined safety halts occurred when rifampin-related serious AEs met prespecified 
halting criteria (Table E2) (40). During safety halts, all subjects were treated with a standard 
regimen according to local guidelines (with an intensive phase rifampin dose of 10 mg/kg/day). 
When the sponsor and the data safety and monitoring board determined that the study could 
resume, participants in the intensive phase of treatment reinitiated their assigned experimental 
doses. 
 
Outcomes 
The primary pharmacokinetic/pharmacodynamic (PK/PD) endpoint, area under the 
concentration-time curve (AUC) of rifampin in plasma at steady state divided by the minimum 
inhibitory concentration of 99.9% of M. tuberculosis (MIC99.9), has been previously reported 
(36). The primary efficacy endpoint was the change in elimination rate of M. tuberculosis log10 
colony forming units (CFU) per mL in overnight pooled sputum samples collected throughout 
the intensive phase and cultured on 7H11 Middlebrook medium. Secondary efficacy endpoints 
included proportion of culture conversion in Löwenstein-Jensen (LJ) medium at 8 weeks, and 
proportion of unfavorable outcomes (treatment failure, recurrence after cure, or death) at 12 
months. We classified recurrent disease with identical 24-locus mycobacterial interspersed 
repetitive units–variable number tandem repeat (MIRU-VNTR) sequencing as relapsed disease, 
and nonidentical MIRU-VNTR as reinfection. The primary safety endpoint was the frequency of 
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 grade 2 or higher rifampin-related AEs, per the Division of Microbiology and Infectious 
Diseases’ Adult Toxicity Table (41), during the intensive phase and up to 4 weeks thereafter. 
 
Statistical Analysis 
We defined the intention-to-treat (ITT) population as all participants who received at least one 
dose of study medication. The modified intention-to-treat (mITT) population (prespecified as 
primary for efficacy) included those in the ITT population with more than one non-missing, 
detectable, and plausible quantitative culture result. The per-protocol (PP) population included 
those in the mITT population whose experimental rifampin dose was not affected by study halts. 
Sensitivity analyses were performed on all participants with at least one log10CFU/mL count. We 
analyzed log10CFU/mL using linear and nonlinear mixed effects models in NONMEM 7.2 
(ICON plc, Dublin, Ireland), Perl-speaks-NONMEM 4.4.0 (Uppsala University, Uppsala, 
Sweden) and R version 3.3.2 (R Foundation for Statistical Computing, Vienna, Austria). 
Monophasic and biphasic structural models were fitted, by treatment arm and pharmacokinetic 
exposure, using the M3 partial likelihood method and Laplacian estimation with interaction. 
 
We used the one-sided Cochran-Armitage test for trend with 5% significance to compare 
proportions of participants who experienced at least one grade 2 or higher rifampin-related AE. 
We used the log-rank test to compare the time to AEs. We performed similar tests for secondary 
analyses of rifampin-related hepatic AEs and serious AEs (SAEs). A sensitivity analysis 
excluded AEs that occurred during study halts in the 15 and 20 mg/kg arms. We performed all 
safety analyses in Stata/SE 14.2 (StataCorp LLC, College Station, TX). 
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 Results 
We screened 351 patients for eligibility; of these, 180 were randomized to receive study drug, 60 
to each arm (Figure 1). Three study halts occurred during the study. The data safety and 
monitoring board recommended restarting enrollment and study dosing after each of the halts. 
Details on the study halts are provided in Table E2. The trial ended when all enrolled participants 
completed follow-up. 
 
The mITT dose-efficacy analysis included 174 participants. Six participants were excluded for 
inadequate data: four had only one CFU observation; one had all CFU observations below the 
limit of detection (<10 CFU/mL); and one had implausibly discrepant CFUs in two samples 
obtained 9 days apart. The PP dose-efficacy analysis included 132 patients in the mITT 
population whose intensive phase rifampin dosing was unaffected by study halts. The mITT and 
PP exposure-efficacy analyses included 163 and 126 patients from the respective dose-efficacy 
populations who completed a PK sampling visit (Figure 1). All 180 participants were included in 
the safety analysis. Most participants were young (median age 25) and male (63.3%). Median 
weight was slightly higher in the 15 mg/kg arm, 55.4 kg (interquartile range [IQR], 49.2-60.5 kg) 
compared to 53.5 kg (IQR, 50.6-59.6 kg) and 54.9 kg (IQR, 50.3-61.7 kg) in the 10 and 20 
mg/kg arms, respectively. Over half of participants had a baseline smear grade of 3+ (51.7%); 
slightly more patients in the 15 mg/kg arm (60.0%) than in the 10 mg/kg (46.7%) and in the 20 
mg/kg (48.3%) arms had a 3+ smear grade. The mean baseline mycobacterial load was 5.2 
log10CFU/mL. The mean baseline loads were 4.8 and 5.5 log10CFU/mL among participants with 
2+ and 3+ smear grades, respectively. Cavitary disease was present in 66 (37.1%). HIV 
coinfection and diabetes were rare, present in 5 (2.8%) and 1 (0.6%) participants respectively. 
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 Other than weight and smear grade, the distribution of sociodemographic characteristics, 
comorbidities, clinical indicators of disease severity, and mycobacterial load were similar across 
arms. Participants received median rifampin doses of 450 mg (IQR, 450-600 mg), 900 mg (IQR, 
600-900 mg), and 975 mg (IQR, 750-1200 mg) in the 10, 15, and 20 mg/kg arms, respectively 
(Table 1). 
 
Efficacy 
Efficacy outcomes are shown in Tables 2 and 3, and Figure 2. A monophasic model of bacterial 
elimination best described the data. We estimated the difference in elimination rate between the 
treatment arms as -0.011 (95% confidence interval [CI], -0.025 – 0.002) log10CFU/mL/day for 
each 5 mg/kg increase in rifampin dose in the mITT population (P=0.230). In the PP population, 
the difference was -0.022 (95% CI, -0.046 – -0.002; P=0.022). Elimination rate in the mITT 
population did not increase with plasma rifampin AUC0-6 (-0.001 log10CFU/mL/day per 1 log 
increase in AUC0-6; 95% CI, -0.003 – 0.001; P=0.750) or AUC0-6/MIC99.9 (-0.002 
log10CFU/mL/day per 1 log increase in AUC0-6/MIC99.9; 95% CI, -0.005 – 0.002; P=0.330). 
Elimination rate in the PP population increased with plasma rifampin AUC0-6 (-0.017 
log10CFU/mL/day per 1 log increase in AUC0-6; 95% CI, -0.029 – -0.007; P=0.011), but not with 
AUC0-6/MIC99.9 (-0.010 log10CFU/mL/day per 1 log increase in AUC0-6/MIC99.9; 95% CI, -0.021 
– 0.000; P=0.053). These results were not affected by adjustment for important baseline 
covariates including age, sex, and extent of radiological disease. The proportion of participants 
with 8-week culture conversion in LJ medium was nearly identical across the three treatment 
arms (76.7%, 73.3%, and 75.0%, respectively). Eleven (6.1%) participants experienced 
unfavorable outcomes by the end of the 12-month follow-up (7.5% of the 147 participants in 
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 whom 12-month status could be assessed). Five (2.8%) participants experienced treatment 
failure. Of these, three (60%) were in the 10 mg/kg arm. Six (3.3%) more experienced recurrent 
disease, three (50%) in the 10 mg/kg arm; two (33%) were confirmed relapses by MIRU-VNTR 
sequencing. There were no deaths during the study. A detailed description of all treatment failure 
and recurrence outcomes is provided in Table E3. 
 
Safety 
The frequency of grade 2 or higher rifampin-related AEs was similar across treatment arms: 26 
(43.3%), 31 (51.7%), and 23 (38.3%) of participants in the 10, 15, and 20 mg/kg arms 
respectively had at least one event (P=0.7092) (Tables 4 and E4). Time to first grade 2 or higher 
rifampin-related AE was also similar across arms (P=0.3610; Figure E1). The frequency and 
time to grade 2 or higher rifampin-related hepatic AEs and the frequency of SAEs were similar 
across arms (Tables 4-5). Results were similar when we excluded AEs that occurred during study 
halts in the experimental arms (Table E5). 
 
The distribution of participants with at least one AE stratified by organ system is shown in Table 
E6. The most common AEs were hepatic (24.4%), gastrointestinal (14.4%), musculoskeletal 
(12.2%), and respiratory (11.7%). Nine SAEs occurred in eight participants during the entire 
study. Of these, six SAEs occurred in five participants during the safety period; four were 
rifampin-related (Table 5). A detailed description of all SAEs is provided in Table E7. 
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 Discussion 
The present study is the first clinical trial to show dose- and exposure-response of higher doses 
of rifampin under conditions of combination therapy. Higher rifampin doses and exposure 
resulted in an increase in the rate of sputum culture sterilization. These findings build on 
pharmacokinetic results from the present study and others showing that rifampin exposure 
increases at least proportionally with higher doses (25, 36), by clearly demonstrating that 
elimination rate is also related to rifampin AUC0-6. These dose- and exposure-related efficacy 
findings are consistent with the results of the PanACEA MAMS-TB-01 trial (NCT01785186). 
This latter study found that rifampin doses of 20 mg/kg are unlikely to permit treatment 
shortening and that the optimal dose of rifampin is likely higher than 20 mg/kg (26). The 
statistically nonsignificant increase in culture negativity in the 20 mg/kg arm of the RIFATOX 
trial (ISRCTN55670677) also suggests that this dose may not be sufficient for treatment 
shortening (42). 
 
The present study characterized the consistent impact of both rifampin dose and exposure on 
efficacy. Other analyses were not statistically significant: the analysis of 8-week culture 
conversion in LJ medium, the mITT analysis of dose and exposure as measured by AUC0-6 and 
AUC0-6/MIC99.9 on the primary endpoint of change in log10CFU/mL, and the PP analysis of 
exposure as measured by AUC0-6/MIC99.9. There are several potential explanations for these 
findings. First, the study was not powered for the 8-week binary, relatively insensitive, 
secondary endpoint. Second, the mITT efficacy estimates were affected by protocol-defined 
study halts. The use of standard rifampin dosing among all participants during study halts may 
have diminished the effect of the higher doses, biasing the effect estimate of dose towards the 
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 null. This explanation is supported by the significant effect of dose detected in the PP analysis, 
which includes only the 132 (73.3%) participants who received their assigned rifampin dose for 
the full intensive phase. Study halts may have also biased the effect of exposure towards the null 
in the mITT population. Since rifampin exposure was not measured during study halts, the 
estimates of rifampin exposure in experimental arm participants who received standard rifampin 
dosing during study halts likely overestimate overall rifampin exposure. Given the effect of study 
halts on both dose- and exposure-response estimates in the mITT population, we feel that the PP 
population is less biased than the mITT population for the efficacy analysis, even though the PP 
population was the prespecified secondary analysis population. 
 
Third, 1:1:1 randomization yielded median rifampin doses of 450, 900, and 975 mg in the 10, 15, 
and 20 mg/kg arms, respectively. Since median weights for all three arms fell in the 53-55 kg 
range, we expected that median rifampin doses would approach 600, 900, and 1200 mg, the 
assigned rifampin doses for the 55-70 kg weight band. However, more than half of study 
participants in the 10 mg/kg arm were in the two lowest rifampin weight bands, more than half in 
the 15 mg/kg arm were in the two highest weight bands, and the 20 mg/kg arm had the same 
number of participants in the two lowest and two highest weight bands. Consequently, the 
median difference in dose between the 15 mg/kg and 20 mg/kg arms was only 75 mg. These 
subtle differences in assigned rifampin doses (and consequent exposures) could have biased our 
results, reducing the apparent activity of the 20 mg/kg arm and the ability to distinguish a dose-
response effect. 
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 The effect of rifampin AUC0-6/MIC99.9 (the primary PK/PD endpoint) on sputum culture 
sterilization was of only borderline statistical significance. Prior preclinical studies have 
suggested that rifampin AUC/MIC is a strong predictor of concentration-dependent killing (22, 
33). Clinical studies of patients receiving combination therapy have shown mixed results. Others 
have shown that rifampin AUC alone is an important predictor of clinical outcomes (32), and 
that its predictive ability may be bolstered by MIC information (34). However, a more recent 
study found no relationship between rifampin AUC/MIC and 2-month culture conversion (35). 
The distribution of susceptible rifampin MICs in our sample was higher than in the latter study 
(35), albeit within previously published ranges (34, 43). We did not find that rifampin MICs 
varied across levels of AUC to suggest that the effect of rifampin AUC0-6/MIC99.9 was attenuated 
by selection bias. Our findings suggest that rifampin AUC0-6/MIC99.9 was not as strong of a 
predictor of sputum sterilization as rifampin AUC0-6, and that there may be a role for higher 
doses of rifampin in populations with susceptible rifampin MICs on the higher end of the 
distribution. In addition, the present analysis of rifampin MIC99.9 does not capture the activity of 
rifampin metabolites which may contribute to treatment efficacy. 
 
Despite our inclusion criterion of baseline sputum smear grade of 2+ or higher, we found a mean 
baseline mycobacterial load of 5.2 log10CFU/mL, approximately tenfold lower than in previous 
studies (8, 44). Low baseline loads have been reported in other settings, such as Hong Kong, 
Tanzania, and South Africa (25, 27, 45, 46). In the present study, low baseline loads may have 
contributed to the selection of a monophasic model of elimination by rifampin dose. This is 
distinct from the biphasic model selected to best represent the data in a study of fluoroquinolone-
containing regimens (8). Our findings are consistent with those of a 14-day early bactericidal 
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 activity study by the TB Alliance, which did not show a pronounced initial fall in the 
mycobacterial load among patients receiving standard therapy who had a mean baseline load of 
5.399 log10CFU/mL (47), and by a recent observation that the 0-2 day early bactericidal activity 
of isoniazid-based treatments is strongly correlated with pretreatment mycobacterial load (46). 
 
We found no difference in the secondary efficacy outcomes of 8-week culture conversion or in 
the frequency of treatment failure and disease recurrence across arms. The frequencies of 
treatment failure and recurrence we observed are comparable to those of standard therapy in 
other clinical trials (16, 19, 48). However, these relatively rare events occurred 
disproportionately in the 10 mg/kg arm, in which the median rifampin dose was 450 mg daily. 
We previously reported that 81% of the patients in the 20 mg/kg arm and only 33% of those of in 
the 10 mg/kg arm achieved a Cmax of >8 mg/L, the low end of the targeted range (36). Others 
have reported that standard rifampin dosing through FDCs has resulted in suboptimal Cmax <8 
mg/L (35). Taken together, these findings suggest that standard doses of rifampin at 10 mg/kg 
may have compromised treatment efficacy and that the 20 mg/kg dose should be considered for 
dosing to maximize efficacy pending results of studies evaluating even higher doses. This has 
important implications for the use of FDCs, which are currently recommended over separate 
drug formulations in the treatment of drug-susceptible tuberculosis (49). Current guidelines 
recommend maximum rifampin doses of 600 mg daily (2), or 750 mg daily when using FDCs 
containing 150 mg of rifampin each (50). Under programmatic settings, supplementation with 
loose rifampin would be required to achieve higher doses. 
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 We did not observe an increased risk of toxicity with rifampin doses up to 20 mg/kg delivered 
over 8 weeks. We found similar results when we excluded adverse events that occurred during 
study halts in the experimental arms. Our power calculation assumed a 10% frequency of grade 2 
or higher rifampin-related AEs in the control arm. With 43.3% of control arm participants having 
at least one event, there was increased power over what was anticipated: we had more than 80% 
power to rule out a toxicity difference of 20% between the control arm and experimental arms. 
Our safety findings are consistent with recently published data from several studies. The 
maximum-dose tolerability study, HIGHRIF1 (NCT01392911), found no SAEs among 
participants who received rifampin doses up to 35 mg/kg over 14 days (25). The RIFATOX 
Phase II trial found that rifampin doses up to 20 mg/kg delivered over 16 weeks did not result in 
a significant increase in AEs (42). Finally, the more recent MAMS-TB-01 trial found that a 
rifampin dose of 35 mg/kg delivered as part of combination therapy over 12 weeks resulted in 
similar frequencies of grade 3 or higher AEs to standard therapy (26). Taken together, there is a 
growing body of evidence from controlled studies to suggest that concerns about the toxicity of 
rifampin may have taken on too much importance – relative to efficacy. In a future publication, 
we plan to pool data from this trial with those from another Phase II trial of high-dose rifampin 
conducted by PanACEA, HIGHRIF2 (NCT00760149) (27), with the goal of improving statistical 
power for efficacy and safety evaluations. 
 
In summary, this is the first controlled trial to show dose- and exposure-response of higher doses 
of rifampin on sputum culture sterilization under conditions of combination therapy. Rifampin 
doses of up to 20 mg/kg/day were safe compared to the standard dose. These findings support 
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 reconsideration of currently recommended standard dosing guidelines and the continued 
investigation of higher doses of rifampin, beyond 20 mg/kg, for potential treatment shortening. 
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 Figure 1. Study flow for efficacy analyses. 
*One patient had an indeterminate Hain result. 
†
Clinical or radiological signs suggestive of pericardial, pleural, or miliary TB. 
‡
Serum alanine aminotransferase > 2 times the upper limit of normal. 
§
Hemoglobin concentration < 7.0 g/dL or platelet count < 150,000/mm
3
. 
||
Screening was not completed in four patients due to the implementation of protocol-defined 
study halts, and in one patient due to an inoperative Hain machine. 
CFU = colony forming units; ET = early termination; INH = isoniazid; LTFU = lost to follow 
up; PK = pharmacokinetics; RIF = rifampin; TB = tuberculosis. 
 
Figure 2. Predictions of bacillary elimination for the three treatment arms derived from the 
partial likelihood model showing observed data (dark grey) and model predictions (light grey) 
above and below the limit of detection of colony counting, respectively.  
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 Table 1. Participant characteristics by treatment arm.* 
 Rifampin Dose  
Characteristic 
10 mg/kg 
N = 60 
15 mg/kg 
N = 60 
20 mg/kg 
N = 60 
Total 
N = 180 
Age (years), median (IQR) 24 (21-37) 25 (20-35) 27 (22-37) 25 (21-37) 
Female 21 (35.0) 19 (31.7) 26 (43.3) 66 (36.7) 
Weight (kg), median (IQR)
†
 53.5 (50.6-
59.6) 
55.4 (49.2-
60.5) 
54.9 (50.3-
61.7) 
54.1 (50.5-
60.8) 
BMI (kg/m
2
), median (IQR)
†
 21.2 (19.2-
23.3) 
21.2 (19.5-
23.9) 
21.4 (19.9-
24.2) 
21.2 (19.6-
23.7) 
Cavitary disease (n = 178) 23 (39.0) 22 (37.3) 21 (35.0) 66 (37.1) 
HIV positive 2 (3.3) 2 (3.3) 1 (1.7) 5 (2.8) 
Diabetes (n = 179) 0 (0) 0 (0) 1 (1.7) 1 (0.6) 
Smear grade at baseline     
++ 32 (53.3) 24 (40.0) 31 (51.7) 87 (48.3) 
+++ 28 (46.7) 36 (60.0) 29 (48.3) 93 (51.7) 
Baseline log10CFU/mL, 
median (IQR) (n = 175) 
5.0 (4.4-5.8) 5.0 (4.5-6.2) 5.1 (4.6-5.8) 5.0 (4.5-5.9) 
Baseline TTP (days), median 
(IQR) 
4.3 (1.6-5.0) 4.0 (0.1-5.2) 4.4 (0.1-5.0) 4.3 (0.1-5.0) 
MIC99.9, median (IQR) 0.2 (0.1-0.2) 0.2 (0.1-0.3) 0.2 (0.1-0.2) 0.2 (0.1-0.2) 
AUC0-6/MIC99.9, median 
(IQR) (n = 168) 
115.7 (59.1-
197.6) 
202.0 (144.1-
460.3) 
284.4 (175.3-
399.2) 
193.8 (112.0-
344.4) 
Rifampin dose (mg), median 
(IQR) 
450 (450-
600) 
900 (600-900) 975 (750-
1200) 
750 (600-900) 
Definition of abbreviations: AUC, area under the plasma concentration-time curve; BMI, body 
mass index; CFU, colony forming units; HIV, human immunodeficiency virus; MIC, minimum 
inhibitory concentration; TTP, time-to-positivity in BACTEC MGIT 960. 
* Values shown are number (%) unless otherwise specified. 
† Values for weight and BMI shown were those obtained at the randomization visit. 
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 Table 2. Decrease in viable CFU counts of M. tuberculosis by rifampin dose or exposure to 
rifampin. 
Dose/Exposure Variable N 
∆log10 
CFU/mL/day 95% CI* 
P 
value 
5 mg/kg increase in rifampin dose     
mITT population 174 -0.011 -0.025 – 0.002 0.230 
PP population 132 -0.022 -0.046 – -0.002 0.022 
1 log increase in rifampin AUC0-6     
mITT population 163 -0.001 -0.003 – 0.001 0.750 
PP population 126 -0.017 -0.029 – -0.007 0.011 
1 log increase in rifampin AUC0-6/MIC99.9     
mITT population 163 -0.002 -0.005 – 0.002 0.330 
PP population 126 -0.010 -0.021 – 0.000 0.053 
Definition of abbreviations: AUC, area under the plasma concentration-time curve; CFU, colony 
forming units; CI, confidence interval; mITT, modified intention-to-treat; MIC, minimum 
inhibitory concentration; PP; per-protocol. 
* 95% CI were obtained using the sandwich estimator.  
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 Table 3. Secondary efficacy outcomes.* 
 
 Rifampin Dose  
Outcome 
10 mg/kg 
N = 60 
15 mg/kg 
N = 60 
20 mg/kg 
N = 60 
Total 
N = 180 
Culture conversion in Löwenstein-Jensen medium at 8 weeks 
Converted 46 (76.7) 44 (73.3) 45 (75.0) 135 (75.0) 
Did not convert 3 (5.0) 5 (8.3) 7 (11.7) 15 (8.3) 
Contaminated week 8 cultures 4 (6.7) 1 (1.7) 0 (0) 5 (2.8) 
Week 8 cultures not available 7 (11.7) 10 (16.7) 8 (13.3) 25 (13.9) 
Early discontinuation 6 (10.0) 9 (15.0) 8 (13.3) 23 (12.8) 
Lost to follow up 1 (1.7) 1 (1.7) 0 (0) 2 (1.1) 
Treatment outcome at 12 months 
Recurrence-free cure 44 (73.3) 46 (76.7) 46 (76.7) 136 (75.6) 
Treatment failure 3 (5.0) 1 (1.7) 1 (1.7) 5 (2.8) 
Recurrence after cure 3 (5.0) 1 (1.7) 2 (3.3) 6 (3.3) 
Relapse
†
 2 (3.3) 0 (0) 0 (0) 2 (1.1) 
Reinfection
‡
 0 (0) 1 (1.7) 0 (0) 1 (0.6) 
Recurrence
§
 1 (1.7) 0 (0) 2 (3.3) 3 (1.7) 
Death 0 (0) 0 (0) 0 (0) 0 (0) 
Outcome not evaluable 10 (16.7) 12 (20.0) 11 (18.3) 33 (18.3) 
Early discontinuation 8 (13.3) 11 (18.3) 10 (16.7) 29 (16.1) 
Lost to follow up 2 (3.3) 1 (1.7) 1 (1.7) 4 (2.2) 
*Values shown are No. (%). 
†
2 patients had relapse diagnosed by identical pre-treatment and post-treatment M. tuberculosis 
isolates, with 24/24 matching MIRU-VNTR loci. 
‡
1 patient had reinfection diagnosed by nonidentical pre-treatment and post-treatment M. 
tuberculosis isolates, with 9/20 matching MIRU-VNTR loci. 
§
Recurrent tuberculosis was diagnosed without positive culture (and without MIRU-VNTR) in 3 
patients: 2 were diagnosed by a positive sputum smear, and 1 was diagnosed clinically.
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 Table 4. Participants experiencing grade 2 or higher rifampin-related adverse events and hepatic 
adverse events during the safety period, by treatment arm.* 
 Rifampin Dose  
Variable 
10 mg/kg 
N = 60 
15 mg/kg 
N = 60 
20 mg/kg 
N = 60 P value 
≥ 1 grade 2+ RIF-related AE 26 (43.3) 31 (51.7) 23 (38.3) 0.7092
†
 
Time to first grade 2+ RIF-related 
AE (days), median (IQR) 
29.5 (14-39) 26 (9-42) 25 (13-37) 0.3610
‡
 
≥ 1 grade 2+ hepatic RIF-related AE 16 (26.7) 14 (23.3) 14 (23.3) 0.6645
†
 
Time to first grade 2+ RIF-related 
hepatic AE (days), median (IQR) 
31.5 (14-
40.5) 
36.5 (26-
57) 
42.5 (26-
63) 
0.8357
‡
 
Definition of abbreviations: AE, adverse event; RIF, rifampin. 
* Values shown are No. (%) unless otherwise specified. The safety period was defined as 12 
weeks after randomization or 4 weeks after the last experimental rifampin dose, whichever 
occurred later. 
† One-sided Cochran-Armitage test for trend with 5% significance. 
‡ Global log-rank test.  
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 Table 5. Participants experiencing serious adverse events by treatment arm.* 
 Rifampin Dose  
Variable 
10 mg/kg 
N = 60 
15 mg/kg 
N = 60 
20 mg/kg 
N = 60 P value
†
 
≥ 1 SAE during entire study 2 (3.3) 1 (1.7) 5 (8.3) 0.0919 
≥ 1 SAE during safety period
‡
 1 (1.7) 1 (1.7) 3 (5.0) 0.1333 
≥ 1 RIF-related SAE during safety period
‡
 1 (1.7) 1 (1.7) 2 (3.3) 0.2679 
Definition of abbreviations: RIF, rifampin; SAE, serious adverse event. 
* Values shown are No. (%). 
† One-sided Cochran-Armitage test for trend with 5% significance. 
‡ The safety period was defined as 12 weeks after randomization or 4 weeks after the last 
experimental rifampin dose, whichever occurred later. 
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Intention-to-treat 
Allocated to RIF dose 
Modified intention-to-treat 
Analyzed for dose-efficacy 
- Excluded for insufficient CFU data
Analyzed for exposure-efficacy 
- Excluded for insufficient CFU data
- Excluded for LTFU before PK
- Excluded for ET/toxicity before PK
- Excluded for PK scheduling error
- Late exclusion before PK
Per-protocol 
Analyzed for dose-efficacy 
- Excluded for reduced RIF during halt
Analyzed for exposure-efficacy 
- Excluded for reduced RIF during halt
60 
56 
4 
55 
4 
1 
-
-
-
,, 
56 
-
55 
-
10 mg/kg 
Assessed for eligibility 
(n = 351) 
Randomized 1:1:1 
(n = 180) 
,, 15 mg/kg 
60 
, 
58 
2 
55 
2 
-
2 
1 
-
,, 
38 
20 
38 
17 
Excluded (n=171) 
- Did not meet inclusion criteria (n = 162)
- Not sensitive to both INH and RIF on Hain (n = 60)*
- Sputum smear grade < 2+ (n = 40)
- Clinical or radiological signs of extrapulmonary TB (n = 6)t
- History of viral hepatitis, liver disease, or liver enzymes
outside range for inclusion (n = 19):j: 
- Hematology results outside range for inclusion (n = 2)§
- Glycated hemoglobin> 7.5% (n = 14)
- Body weight < 30 kg (n = 1)
- Pregnant or breastfeeding (n = 6)
- Current use of prohibited concomitant medication (n = 1)
- Investigator-assessed likely difficulty adhering to study
protocol (n = 8) 
- Screening not completed (n = 5)11
- Declined to participate (n = 9)
20 mg/kg 
60 
, 
60 
-
53 
-
-
5 
-
2 
', 
38 
22 
33 
20 
Figure 1. Study flow for efficacy 
analyses. 
Page 31 of 207  AJRCCM Articles in Press. Published on 29-June-2018 as 10.1164/rccm.201712-2524OC 
 Copyright © 2018 by the American Thoracic Society 
  
 
 
Figure 2. Predictions of bacillary elimination for the three treatment arms derived from the partial likelihood 
model showing observed data (dark grey) and model predictions (light grey) above and below the limit of 
detection of colony counting, respectively.  
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Online Data Supplement 
 
Methods 
 
Study setting and design 
 
The study protocol for “Evaluation of high-dose rifampin in patients with new, smear-positive 
tuberculosis” (HIRIF) has been published previously (E1). We conducted a multi-site, triple-
blind, randomized, controlled Phase II clinical trial and here we report trial findings in 
accordance with CONSORT guidelines (E2). A CONSORT checklist and the full study protocol 
are provided with the online supplement. 
 
We enrolled patients with newly diagnosed, previously untreated, smear-positive (grade 2+ or 
higher) pulmonary tuberculosis with susceptibility to isoniazid and rifampin detected by Hain 
GenoType MTBDRplus (Hain Lifescience GmbH, Nehren, Germany) between September 12, 
2013 and February 18, 2015 from two health districts of Lima, Peru (Lima Ciudad and Lima 
Este). Participants were identified and referred from 43 health centers to Hospital Nacional 
Hipólito Unanue (HNHU) or Hospital Sergio Bernales (HNSEB) for eligibility screening. 
 
Exclusion criteria 
Exclusion criteria were weight <30 kg; age <18 years or >60 years; rifampin resistance; previous 
tuberculosis treatment for ≥1 month; extrapulmonary manifestations (central nervous system, 
miliary, pericardial, or pleural tuberculosis); significant hemoptysis; study drug intolerance, 
hypersensitivity, or contraindication; pregnancy or breastfeeding; alanine aminotransferase >2 
times the upper limit of normal (ULN); total bilirubin >2.5 times ULN; creatinine >2 times ULN 
or clearance <60 mL/min; hemoglobin <7.0 g/dL; platelets <150,000/mm
3
; white blood cell 
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count <4500 cells/µL; hepatitis B surface antigen or hepatitis C antibody seropositive; glycated 
hemoglobin >7.5%; or Karnofsky score <50. Additional criteria for study withdrawal included 
any patient without culture confirmation of M. tuberculosis, or whose isolate was found to be 
resistant to any of the study drugs after study treatment was initiated. If a participant’s isolate 
tested resistant to ethambutol or pyrazinamide, in the absence of resistance to isoniazid or 
rifampin, confirmation of the resistant result was required prior to termination from the study. 
 
Tuberculosis treatment 
Participants received directly observed ambulatory treatment administered by treatment 
supporters and were randomized 1:1:1 in blocks (of varying size) to receive 10, 15, and 20 mg/kg 
of rifampin delivered orally, 7 days per week for 8 weeks. Participants also received standard 
oral doses of isoniazid 5 mg/kg/day, pyrazinamide 25 mg/kg/day, and ethambutol 20 mg/kg/day 
for 8 weeks; a continuation phase of isoniazid 10 mg/kg/day and rifampin 10 mg/kg thrice 
weekly for 18 weeks; and pyridoxine 50mg thrice weekly throughout treatment. 
 
Pharmacokinetic methods 
We performed pharmacokinetic (PK) measurements on a single day after steady state rifampin 
exposure was achieved, between 14 and 56 days after randomization. We randomized 
participants in a 2:1 ratio to sparse versus intensive PK measurements. Patients were asked to 
fast for four hours prior to measurements and for two hours after drug administration. Sparse PK 
measurements involved blood draws at three time points at 0, 2, and 6 hours after the last dose. 
Intensive PK measurements involved blood draws at four additional time points up to 14+ hours 
after the last dose. Blood samples were stored at -80°C and assayed at the University of Florida. 
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Rifampin concentrations were measured with a validated high-performance liquid 
chromatography assay and triple-quadrupole mass spectrometry. Phoenix v6.2 (Certara LP, 
Princeton, NJ) was used for noncompartmental analysis to derive rifampin PK parameters (E3). 
 
Culture methods 
We conducted study mycobacteriology at the Socios En Salud laboratory (Lima, Peru), which 
performs external quality assurance annually through proficiency panels from the Peruvian 
National Reference Laboratory and the College of American Pathologists (Northfield, Illinois). 
We obtained duplicate pretreatment samples through early-morning spot sputum and overnight 
sputum collections. Participants were followed at scheduled study visits once weekly for the first 
eight weeks of the intensive phase of treatment and monthly thereafter until 12 months after 
randomization. Participants provided sputum samples at baseline and at five time points during 
the first two months of treatment, depending on random assignment to one of two collection 
groups (at days 1-2, 3-7, 8-10, 14-16, and 40-44 for collection group 1; at days 1-2, 3-7, 9-11, 
26-30, and 54-66 for collection group 2). We obtained additional early-morning sputum samples 
for smear microscopy (at week 8) and culture in Löwenstein-Jensen (LJ) medium (at weeks 2, 4, 
8, and monthly thereafter until month 12). We also used the BACTEC™ MGIT™ 960 (MGIT) 
method (BD Diagnostics, Sparks, MD) on neat samples to estimate time-to-positivity (TTP) at 
baseline. We obtained four measures of rifampin minimum inhibitory concentration ([MIC], two 
replicates each from one pretreatment spot sputum and one pretreatment overnight sputum 
sample) and used the arithmetic mean of the pretreatment overnight collection MICs for the 
pharmacodynamic analyses. We used 7H11 Middlebrook medium to quantify M. tuberculosis 
colony forming units per mL of sputum (CFU/mL) in sputum culture to estimate sterilization. 
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We assumed that contaminated Middlebrook cultures were missing at random. The limit of 
detection of the colony counting method was 10 CFU/mL. For participants with recurrent 
disease, we sent the baseline strain and the post-recurrence strain to GenoScreen (Lille, France) 
for 24-locus mycobacterial interspersed repetitive units-variable number tandem repeat (MIRU-
VNTR) sequencing using standard methods (E4). 
 
Safety methods 
Study staff, including treatment supporters, triaged solicited and unsolicited adverse events 
(AEs) at every participant contact, which occurred at scheduled study visits, daily treatment 
support visits during the intensive phase, and thrice weekly treatment support visits during the 
continuation phase of treatment. Staff recorded the use of concomitant medications, pregnancy, 
and breastfeeding at scheduled study visits. Safety assessments included complete blood count 
with differential, urinalysis, serum alanine aminotransferase, serum aspartate aminotransferase, 
serum alkaline phosphatase, total bilirubin, albumin, creatinine, and clinician-observed and 
unsolicited adverse events reported at or between study visits. Clinical investigators graded 
clinical and laboratory AEs according to the Adult Toxicity Table by the Division of 
Microbiology and Infectious Diseases of the National Institute of Allergy and Infectious 
Diseases (E5), and determined the relatedness of AEs to study drugs. 
 
Efficacy and safety outcome classification 
The primary efficacy endpoint was change in M. tuberculosis log10CFU/mL in sputum at 8 
weeks on 7H11 Middlebrook medium. The secondary efficacy endpoint reported here is culture 
negativity at 8 weeks on LJ medium. We classified patients who had two contaminated samples 
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as not having culture conversion. The primary safety endpoint was the frequency of grade 2 or 
higher rifampin-related adverse events during the 8-week intensive phase of treatment and up to 
4 weeks later. Secondary efficacy endpoints included time to grade 2 or higher rifampin-related 
adverse events, and the frequency and timing of grade 2 or higher rifampin-related hepatic 
adverse events. 
 
Power and sample size 
As stated in the protocol, a sample size of 180 participants, randomized in a 1:1:1 allocation 
across three arms and with 17% expected loss to follow-up, afforded 90% power to detect a 14 
mcg/mL*hr expected difference in AUC between the lowest and highest rifampin dose, 80% 
power to detect a 0.025 log10CFU/mL expected difference in colony counts, and 68% power to 
rule out a two-fold difference in frequency of grade 2 or higher AEs between the control 
(assuming frequency of 10%) and intervention arms. 
 
Interim analyses 
An early safety evaluation by the data safety and monitoring board (DSMB) was performed after 
the first 60 patients completed 4 weeks of study treatment. Safety data were reviewed again 
during protocol-defined study halts. In addition, the DSMB reviewed trial progress after 120 
participants completed 4 weeks of study treatment. An interim, blinded PK analysis was 
performed by G.R.D. when PK data were available for half of the patients to check: [1] the PK 
sampling, handling, and laboratory processing procedures, and [2] that the assumptions of the PK 
sampling scheme (especially for sparse sampling) were correct. This interim analysis was not 
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performed to make comparisons between groups. No interim efficacy analysis was planned or 
performed. 
 
Protocol changes 
After trial commencement, the protocol was changed to specify that resistance to ethambutol and 
pyrazinamide in the absence of resistance to isoniazid and rifampin would be confirmed prior to 
termination from the study. There were no changes to trial outcomes after the trial commenced. 
 
Model building strategy for primary efficacy analysis 
Fitted monophasic (A) and biphasic (B) structural models for colony counting data used a 
doubly-exponentiated parameterization to enforce positivity of the rate constants and improve 
numerical stability: 
 
 = log 	
 × 
×
     (A) 
 
 = log 	
 × 
×
 + 
 × 
×   (B) 
 
Additive, combined additive and proportional and variance function error models were tested as 
were different random effect structures. Nested structural and covariate models were compared 
using the likelihood ratio test based on the change in the value of the objective function and the 
function pchisq in R. Standard errors were derived using the sandwich estimator implemented in 
the NONMEM covariance step and confirmed by nonparametric bootstrapping. Regression 
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diagnostics included examination of correlation and covariance matrices and condition numbers, 
plots of population and individual predictions against the data, and visual predictive checks. 
 
Ethics statement 
The study protocol and informed consent documents were reviewed and approved by the 
Partners HealthCare Human Research Committee (approval number 2011P001577), the 
Liverpool School of Tropical Medicine Research Ethics Committee and the University of 
Liverpool Research Support Office (approval number RETH000725), Institutional Ethics 
Committees at HNHU and University of San Martin de Porres (under ceding agreement with the 
study hospital, HNSEB), the Peruvian National Institute of Health (approval number 081–12) 
and the Division of Microbiology and Infectious Diseases, National Institutes of Allergy and 
Infectious Diseases, U.S. National Institutes of Health (protocol number 11–0050). The study 
received exemption from the University of Florida Institutional Review Board (exemption 
number IRB201200199). 
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Table E1. Dosing of rifampin and companion drugs in milligrams, by study arm and weight 
band. 
 
  Study arm 
 Companion drugs Control Experimental 1 Experimental 2 
Weight band (kg) INH PZA EMB RIF 10 mg/kg RIF 15 mg/kg RIF 20 mg/kg 
30-37 150 800 550 300 450 600 
38-54 225 1200 825 450 600 750 
55-70 300 1600 1100 600 900 1200 
>70 375 2000 1375 750 1200 1500 
Definition of abbreviations: EMB = ethambutol; INH = isoniazid; PZA = pyrazinamide; RIF = 
rifampin. 
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Table E2. Description of study halts.* 
 
Halt No. Halt Duration Reason for Halt 
1 1.9 weeks 2 or more SAEs of the same type which were related to rifampin 
2 2.3 weeks 6 or more grade 3 or higher AEs which were related to rifampin, of 
which 3 or more were due to elevated transaminases and had clinical 
symptoms of hepatotoxicity 
3 5.4 weeks 6 or more grade 3 or higher AEs which were related to rifampin, of 
which 3 or more were due to elevated transaminases and had clinical 
symptoms of hepatotoxicity 
Definition of abbreviations: AEs = adverse events; SAEs = serious adverse events. 
* Study halts occurred respectively from December 27, 2013 to January 8, 2014; April 23 to May 
8, 2014; and August 13 to September 19, 2014.  
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Table E3. Description of all treatment failure and recurrence outcomes during study. 
 
Patient 
No. 
Treatment 
Arm 
Rifampin 
Dose 
Baseline 
Smear log10CFU/mL Outcome* Months
†
 
1 10 mg/kg 450 mg +++ 4.66 Treatment failure 4.7 
2 10 mg/kg 450 mg +++ 6.34 Treatment failure 4.7 
3 10 mg/kg 450 mg +++ 8.05 Treatment failure 5.7 
4 10 mg/kg 450 mg +++ 4.31 Relapse (pan-susceptible) 11.8 
5 10 mg/kg 450 mg +++ 4.99 Recurrence
‡
 11.7 
6 10 mg/kg 600 mg +++ 7.22 Relapse (pan-susceptible) 10.8 
7 15 mg/kg 900 mg +++ 6.29 Treatment failure 5.9 
8 15 mg/kg 900 mg ++ 5.47 Reinfection 8.8 
9 20 mg/kg 750 mg +++ 5.09 Recurrence
‡
 12.1 
10 20 mg/kg 1200 mg ++ 4.93 Treatment failure 5.1 
11 20 mg/kg 1500 mg +++ 7.17 Recurrence
‡
 8.7 
*Drug-susceptibility testing was not routinely performed for treatment failure at the study 
laboratory. 
†
Months from date of randomization to date of outcome. 
‡
Recurrent tuberculosis was diagnosed without positive culture (and without MIRU-VNTR) in 3 
patients: One patient had a positive sputum smear at week 14; one patient had a positive sputum 
smear at week 15; and one patient had neither positive smear nor culture but was diagnosed 
clinically and restarted treatment outside the catchment area of the study.  
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Table E4. Participants experiencing grade 2 or higher rifampin-related adverse events and 
hepatic adverse events during the safety period, by treatment arm.* 
 
 Rifampin Dose  
Variable 
10 mg/kg 
N = 60 
15 mg/kg 
N = 60 
20 mg/kg 
N = 60 
Total 
N = 180 
No. of grade 2+ RIF-related AEs     
None 34 (56.7) 29 (48.3) 37 (61.7) 100 (55.6) 
One 21 (35.0) 22 (36.7) 16 (26.7) 59 (32.8) 
Two 4 (6.7) 7 (11.7) 5 (8.3) 16 (8.9) 
Three or more 1 (1.7) 2 (3.3) 2 (3.3) 5 (2.8) 
No. of grade 2+ hepatic RIF-related AEs     
None 44 (73.3) 46 (76.7) 46 (76.7) 136 (75.6) 
One 15 (25.0) 14 (23.3) 14 (23.3) 43 (23.9) 
Two 1 (1.7) 0 (0) 0 (0) 1 (0.6) 
Definition of abbreviations: AE = adverse event; RIF = rifampin. 
*Values shown are No. (%) unless otherwise specified. The safety period was defined as 12 
weeks after randomization or 4 weeks after the last experimental rifampin dose, whichever 
occurred later. 
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Figure E1. Time to first grade 2 or higher rifampin-related adverse event during the safety 
period, by treatment arm.* 
 
 
*The number of events per arm were 26 (10 mg/kg), 31 (15 mg/kg), and 23 (20 mg/kg). The 
global log-rank test comparing the three arms showed a P = 0.3610. The safety period was 
defined as 12 weeks after randomization or 4 weeks after the last experimental rifampin dose, 
whichever occurred later. 
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Table E5. Sensitivity analysis of participants experiencing grade 2 or higher rifampin-related 
adverse events, hepatic adverse events, and serious adverse events during the safety period, 
excluding events occurring during study halts in the 15 and 20 mg/kg arms.* 
 
 Rifampin Dose  
Variable 
10 mg/kg 
N = 60 
15 mg/kg 
N = 60 
20 mg/kg 
N = 60 P value 
≥ 1 grade 2+ RIF-related AE 26 (43.3) 30 (50.0) 22 (36.7) 0.7694
†
 
Time to first grade 2+ RIF-related 
AE (days), median (IQR) 
29.5 (14-39) 25.5 (9-42) 25.5 (13-37) 0.3642
‡
 
≥ 1 grade 2+ hepatic RIF-related AE 16 (26.7) 12 (20.0) 14 (23.3) 0.6670
†
 
Time to first grade 2+ RIF-related 
hepatic AE (days), median (IQR) 
31.5 (14-40.5) 36.5 (20-57.5) 42.5 (26-63) 0.6379
‡
 
≥ 1 RIF-related SAE 1 (1.7) 1 (1.7) 2 (3.3) 0.2679
†
 
Definition of abbreviations: AE = adverse event; RIF = rifampin. 
*Values shown are No. (%) unless otherwise specified. The safety period was defined as 12 
weeks after randomization or 4 weeks after the last experimental rifampin dose, whichever 
occurred later. 
†
One-sided Cochran-Armitage test for trend with 5% significance. 
‡
Global log-rank test. 
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Table E6. Participants experiencing at least one grade 2 or higher adverse event during the 
safety period, by organ system and treatment arm.* 
 
 Rifampin Dose  
Organ System 
10 mg/kg 
N = 60 
15 mg/kg 
N = 60 
20 mg/kg 
N = 60 
Total 
N = 180 
Dermatological 7 (11.7) 2 (3.3) 10 (16.7) 19 (10.6) 
Gastrointestinal 6 (10.0) 15 (25.0) 5 (8.3) 26 (14.4) 
Hematological 3 (5.0) 4 (6.7) 5 (8.3) 12 (6.7) 
Hepatic 16 (26.7) 14 (23.3) 14 (23.3) 44 (24.4) 
Immunological 0 (0) 0 (0) 1 (1.7) 1 (0.6) 
Musculoskeletal 7 (11.7) 7 (11.7) 8 (13.3) 22 (12.2) 
Neurological 3 (5.0) 3 (5.0) 2 (3.3) 8 (4.4) 
OB-GYN 0 (0) 1 (1.7) 0 (0) 1 (0.6) 
Psychiatric 1 (1.7) 0 (0) 0 (0) 1 (0.6) 
Respiratory 5 (8.3) 8 (13.3) 8 (13.3) 21 (11.7) 
Urological 1 (1.7) 2 (3.3) 2 (3.3) 5 (2.8) 
Other NOS 7 (11.7) 7 (11.7) 6 (10.0) 20 (11.1) 
Definition of abbreviations: OB-GYN = obstetric and gynecological; NOS = not otherwise 
specified. 
*Values shown are No. (%). The safety period was defined as 12 weeks after randomization or 4 
weeks after the last experimental rifampin dose, whichever occurred later. 
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Table E7. Description of all serious adverse events during study. 
 
SAE 
No. 
Patient 
No. 
Treatment 
Arm 
SAE in Safety 
Period* 
RIF 
Related 
Organ 
System SAE Category Description 
1 1 10 mg/kg No No Respiratory Required hospitalization or emergency 
care 
Bronchial hyperreactivity, 
hospitalization 
2 2 10 mg/kg Yes Yes Hepatic Other important medical event Drug-induced 
hepatotoxicity 
3 3 15 mg/kg Yes Yes Hepatic Other important medical event Drug induced 
hepatotoxicity 
4 4 20 mg/kg Yes Yes Hepatic Other important medical event Drug-induced 
hepatotoxicity 
5 4 20 mg/kg Yes No Respiratory Required hospitalization or emergency 
care 
Left pneumothorax, 
hospitalization 
6 5 20 mg/kg No No OB-GYN Other important medical event Spontaneous abortion 
7 6 20 mg/kg No No Neurological Persistent or significant incapacity or 
substantial disruption of the ability 
conduct normal life functions 
Hearing loss 
8 7 20 mg/kg Yes No Respiratory Required hospitalization or emergency 
care 
Hemoptysis, 
hospitalization 
9 8 20 mg/kg Yes Yes Hepatic Other important medical event Drug-induced 
hepatotoxicity 
Definition of abbreviations: OB-GYN = obstetric and gynecological; RIF = rifampin; SAE = serious adverse event. 
*The safety period was defined as 12 weeks after randomization or 4 weeks after the last experimental rifampin dose, whichever 
occurred later. 
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CONSORT 2010 checklist    Page E17 of E19 
CONSORT 2010 checklist of information to include when reporting a randomised trial* 
 
Section/Topic 
Item 
No Checklist item 
Reported 
on page No 
Title and abstract 
 1a Identification as a randomised trial in the title Title page 
1b Structured summary of trial design, methods, results, and conclusions (for specific guidance see CONSORT for abstracts) 1-2 
Introduction 
Background and 
objectives 
2a Scientific background and explanation of rationale 3-4 
2b Specific objectives or hypotheses 4 
Methods 
Trial design 3a Description of trial design (such as parallel, factorial) including allocation ratio 5-6; E2 
3b Important changes to methods after trial commencement (such as eligibility criteria), with reasons E4 
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STATEMENT OF COMPLIANCE 
 
This trial will be conducted with human subjects oversight from the following Institutional Review 
Boards (IRBs): 
 
Harvard Medical School 
 
Ethics Committee of the Hospital Nacional Hipólito Unanue and the University of San Martin de Porres-
Clínica Cada Mujer, Peru 
 
The study will be carried out in accordance with the following guidelines and regulations: 
 
x Compliance with the International Conference on Harmonisation (ICH) E6: Good Clinical Practice 
(GCP): Consolidated Guideline and the applicable regulatory requirements. 
x Compliance with the United States Code of Federal Regulations (CFR) applicable to clinical studies 
(Title 45 CFR Part 46 and Title 21 CFR including Parts 50 and 56 concerning informed consent and 
Institutional Review Board (IRB) regulations, 21 CFR 312). 
x NIH Clinical Terms of Award 
x Regulations of Clinical Trials in Peru. Supreme Decree No. 017-2006-SA; amendment to the 
Regulation of Clinical Trials in Peru. Supreme Decree No. 006-2007-SA. 
x Relevant regulations in the UK 
 
All key personnel (all individuals responsible for the design and conduct of this study) have completed 
Human Subjects Protection Training. 
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PROTOCOL SUMMARY 
Title: Triple Blind, Randomized, Dose-Ranging Trial of High-Dose Rifampin in Patients with New, 
Smear-Positive TB (High Dose Rifampin or HIRIF Study) 
Phase: II 
Population: New, smear-positive, pulmonary TB patients aged between 18-60 years 
Number of Sites: 2 
Site Names: Socios En Salud Sucursal Perú, Executing Institution; Research Center at Hospital Nacional 
Hipólito Unanue and Center for Research on Lung Disease at Hospital Nacional Sergio E. Bernales, Peru 
Study Sites 
Location of Sites: Lima, Peru 
Study Duration: 3 years 
Participant Duration: 12 months 
Description of Agent or Intervention: High-dose rifampin (15 and 20 mg/kg/day) 
 
Objectives: 
Across three, daily, oral doses of RIF (10, 15 and 20 mg/kg/day): 
Primary: 
1. To assess the difference in steady state pharmacokinetic exposure of RIF and 25-desacetyl-
rifampin. 
2. To assess the difference in sputum culture sterilization during the initial 8 weeks. 
3. To compare the incidence of adverse events related to study drug or regimen during the initial 8 
weeks of daily four-drug treatment, and up to four weeks later. 
Secondary: 
1. To estimate the relationship between pharmacokinetic parameters and measures of sputum culture 
sterilization. 
2. To compare 4 methods for estimating sterilizing activity: 1) decline in log colony-forming units 
(CFUs), 2) speed of culture conversion in solid & liquid media, 3) increased time to detection in 
liquid medium, and 4) proportion of patients with positive cultures at 8 weeks. 
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SCHEMATIC OF STUDY DESIGN 
 
  
Randomization: Total N=180 
N = 60 
RIF 20 mg/kg 
+ HEZ 
Intervention 2 
Enrollment: obtain informed consent; screen subjects by criteria. 
N = 60 
RIF 15 mg/kg + 
HEZ 
Intervention 1 
N = 60 
RIF 10 mg/kg + 
HEZ 
Standard dose, 
control 
Day 0 
Day 1-2 
Day 3-7 
Day 8-11 
Overnight sputum; PK & AM sputum; 
PE/AE; lab 
Day 14-16  
Day 26-30  
AM sputum; PE/AE; lab 
 
Overnight sputum; AM sputum; PK; 
PE/AE; lab 
AM sputum; PE/AE; lab 
Overnight/AM sputum; PE/AE; lab 
 
Day 54-58 AM sputum; PE/AE; lab 
Intensive phase: 
Two sputum collection groups 
1 2 
Overnight sputum 
PE/AE, lab 
Day 40-44  
Overnight sputum collection; AE 
Overnight sputum collection; AE 
Overnight sputum collection; AE 
Overnight/A.M. sputum collection; Physical exam (PE)/AE assessment; lab tests 
PE/AE, lab 
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Follow-up phase:  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Continuation phase: 
Four months daily H + RIF 10 
mg/kg three times per week 
 
AM sputum; PE/AE Day 84 (Month 3) 
AM sputum; PE/AE 
AM sputum; PE/AE 
AM sputum; PE/AE 
Day 112 (Month 4) 
Day 140 (Month 5) 
Day 168 (Month 6) 
Follow-up phase:  
AM sputum; PE/AE Month 9 
Final study visit:  
AM sputum; PE/AE 
Month 12 
“HEZ”: Standard doses of standard companion drugs, isoniazid, pyrazinamide, 
ethambutol; “PE”: Physical examination; “AE”: Assessment for adverse events; 
“Overnight sputum”: overnight pooled sputum collection as inpatient; “AM sputum”: 
early morning collection (unpooled) sample; lab: blood chemistry and hematology and 
urine testing (see schedule of events, Figure 2). 
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1.0  KEY ROLES 
Individuals:  
Co-Principal Investigator: 
Carole Mitnick, Sc.D. 
Associate Professor 
Department of Global Health and Social Medicine 
Harvard Medical School 
641 Huntington Ave., 3rd Floor 
Boston, MA 02115 
P.: (617) 432-6018 
F.: (617) 432-2565 
Email: Carole_Mitnick@hms.harvard.edu 
 
Co-Principal Investigator: 
Geraint Davies, M.B., Ph.D., MRCP, DTM&H 
Senior Lecturer in Infectious Diseases 
Honorary Consultant Physician 
School of Clinical Sciences 
University of Liverpool 
Liverpool L69 3BX 
United Kingdom 
P.: +0151-706-3036 
F.: +0151-706-5944 
Email: Gerrydavies@doctors.org.uk 
 
 
  
Page 67 of 207  AJRCCM Articles in Press. Published on 29-June-2018 as 10.1164/rccm.201712-2524OC 
 Copyright © 2018 by the American Thoracic Society 
DMID Protocol 11-0050  V7.0 September 25, 2014 
 
17 
 
 
Sponsor: 
 
National Institutes of Allergy and Infectious Diseases, 
National Institutes of Health 
 
 
Clinical Project Manager and Program Officer: 
Robin Mason 
NIAID/DMID/RDB 
6610 Rockledge Drive, #3224 
Bethesda, MD 20892 
P.:  (301) 451-3746 
F.: (301) 496-8030 
Email: rmason@niaid.nih.gov 
 
Medical Monitor: 
Mohamed Elsafy, M.D, MSc 
DMID/NIAID/OCRA 
6610 Rockledge Drive, #4409 
Bethesda, MD 20892 
P.: (301) 451-3026 
F.: (301) 480-0728 
Email: mo.elsafy@nih.gov 
 
Medical Officer: 
Alan C. Ou, MD, MPH 
Commander, US Public Health Service 
NIAID/DMID/RDB/TOMDS 
6610 Rockledge Drive, #3204 
Bethesda, MD 20892 
P: (301) 451-3346 
F: (301) 496-8030 
Email: alan.ou@nih.gov  
 
 
 
 
 
  
Page 68 of 207 AJRCCM Articles in Press. Published on 29-June-2018 as 10.1164/rccm.201712-2524OC 
 Copyright © 2018 by the American Thoracic Society 
DMID Protocol 11-0050  V7.0 September 25, 2014 
 
18 
 
 
Institutions: 
 
 
 
 
 
 
 
 
 
Executing Institution: 
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Avenida Merino. Reyna 575, Carabayllo, 
Lima 6, Perú 
Leonid Lecca, M.D. 
P.: +511-651-6512 
F.: +511-481-4478 
Email: llecca_ses@pih.org 
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Centro de Investigación del Hospital Nacional Hipólito Unanue 
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Dante Elmo Vargas Vásquez, M.D. 
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Email: dantevargasv_4@hotmail.com 
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Av. Tupac Amaru Km 14.5, Comas Lima-Perú 
Epifanio Sánchez Garavito, M.D. 
P.: +511-6377182 or -6377183 
F.: +511-5580490 
Email: epis53@yahoo.es 
 
Other Study Sites: 
 
St. George’s University of London 
Cranmer Terrace, London, SW180RE, UK 
Denis A. Mitchison, C.M.G., B.M., FRCP Path 
P.: +44-208-725-5704 
F.: +44-208-672-0234 
Email: dmitchis@sgul.ac.uk 
 
University of Florida 
Infectious Disease Pharmacokinetics Laboratory 
College of Pharmacy and Emerging Pathogens Institute 
1600 SW Archer Rd., Rm P4-33 
Gainesville, FL 32610-0486 
Charles Peloquin, Pharm. D 
 
P.: (352) 273-6266 
F.: (352) 273-6804 
Email: peloquin@cop.ufl.edu 
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2.0  BACKGROUND INFORMATION AND SCIENTIFIC RATIONALE 
2.1 Background Information 
2.1.1 Limitations of current tuberculosis treatment 
More than 9 million cases of TB occur each year; despite the availability of effective treatment, 2 million 
of these result in death.1 The standard of care for TB in most high-burden regions is a six-month, four-
drug regimen, well supported by clinical trials completed more than three decades ago.2 In particular, the 
successful introduction of rifampin (RIF) and pyrazinamide (PZA) allowed the reduction of treatment 
duration from 18 to 6 months with a risk of relapse frequency of <5%. Further reductions in treatment 
duration, however, resulted in increasing rates of relapse3 suggesting that, with standard doses of RIF 
(10mg/kg) and PZA (25mg/kg), the duration of treatment could not be less than 6 months. 
These “short-course” regimens offered vast improvements over previously used treatments in both 
delivery of care and clinical outcomes. In 1993, the 6-month regimen became the cornerstone of the 
World Health Organization (WHO) response to the TB emergency. In 2007, 5.5 million TB cases were 
treated with short-course chemotherapy. The current duration of treatment requires sustained support 
from health workers and committed adherence to the regimen from patients. Although on average 85% of 
patients treated in 2006 experienced successful outcomes, many patients cannot complete or are not cured 
by the six-month regimen.1 Subsequently, these patients may require more prolonged re-treatment with 
less chance of success and the risk of acquisition of drug resistance. Additional information on limitations 
of current treatment and work underway to address them is provided in section 17.1. 
This study will evaluate several potential surrogate endpoints for failure/relapse: culture conversion in 
solid medium at 2 months, time to culture conversion in solid medium, change in days to positivity in 
MGIT, and change in log colony forming units (CFU) in solid, selective medium. The first two semi-
quantitative measures will be performed on early morning sputum samples. The latter two will be 
conducted on pooled sputum samples collected overnight. The pooled sputum increases the heterogeneity 
of the sample, which is appropriate for these fully quantitative measures. 
2.2 Rationale 
This trial will examine the concept that an increased dose of RIF could shorten the course of standard 
therapy for TB, and improve treatment outcomes, without increased toxicity. Specifically, we hypothesize 
that steady state pharmacokinetic parameters will demonstrate greater exposure of RIF among participants 
who receive 15 and 20 mg/kg/day of RIF compared to participants who receive the standard dose of 10 
mg/kg/day. In addition, the impact of dose and concentration on the incidence of adverse events will be 
assessed. The shortening concept will be examined by evaluating surrogate measures of sterilizing 
activity—defined theoretically by Mitchison as, “the ability to kill all or virtually all of the bacilli in the 
lesions as rapidly as possible”4—of the higher doses of RIF against standard doses. Sterilizing activity is 
considered the primary determinant of length of TB treatment (additional information on sterilizing 
activity is provided in section 17.2). If sterilizing activity is enhanced in the first two months, this will be 
interpreted as proof of concept that tuberculosis treatment can be shortened. Several different methods 
will be employed to evaluate sterilizing activity. This study will compare and examine the relationships 
between these measures of sterilizing activity and pharmacokinetic parameters as well as long-term 
treatment outcomes. 
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2.2.1 High-dose rifampin for treatment shortening 
It is clear that individual anti-tuberculosis drugs make distinct contributions to the sterilizing activity of 
combination regimens. Of the four current first-line agents, RIF has the most potent and durable 
sterilizing activity and is the only drug for which available evidence suggests that an increase in dose size 
might be obtained without a substantial increase in adverse effects.5-8 There is a clear relationship 
between the duration of continuous administration of rifampin and treatment success under current dosing 
recommendations.9, 10 However, selection of the current daily dose of 600 mg appears to have been based 
on incomplete dose-finding studies and considerations of cost. Several recent reviews summarize the 
evidence that higher doses of RIF could successfully shorten TB treatment.11-15 
In vitro, animal and human data all support the concept that treatment shortening with higher RIF dose 
may be expected. This evidence is summarized below; further detail is provided in section 17.3. 
2.2.1.1 Evidence from in vitro experiments 
Rifamycins exhibit concentration-dependent killing in vitro analogous to that seen with aminoglycosides 
and fluoroquinolones.16, 17 Jayaram et al. showed that M. tuberculosis killing by RIF was influenced both 
by concentration up to the highest concentration tested (256 mcg/mL) and time up to 9 days (see Figure 5 
and Figure 6 in section 17.3.1).5 This recent data is consistent with an earlier study by Dickinson et al 
(which inferred M. tuberculosis killing from decreased uptake of uridine-14C) that showed increased 
bactericidal activity with RIF concentrations from 0.625 to 4 mcg/mL.18 
2.2.1.2 Evidence from animal experiments 
Dramatically improved sterilizing activity and survival were achieved in the mouse and the guinea pig 
with increased RIF doses.19-22 Grumbach and colleagues reported sterilization of all mice treated with 25 
mg/kg RIF and 5 mg/kg INH for 6 months, while a regimen containing only 5 mg/kg RIF had been found 
to be inadequate. Kradolfer then identified 5.6 mg/kg as the threshold for a “chemotherapeutic effect” and 
found that increasing RIF doses increased mouse survival more than did increasing INH doses. Studies by 
Verbist revealed dose-related killing of M. tuberculosis in mice given RIF 5 to 40 mg/kg: a 2-log increase 
in killing occurred when the 5 mg/kg dose was doubled (see Figure 5 in section 17.3.1). 
2.2.1.3 Evidence from human pharmacokinetics 
RIF is normally absorbed completely when taken orally, but food delays absorption. After 1.5 to 2 hours, 
a 600 mg dose yields a peak blood level of 8-24 mcg/mL.23 The half-life of RIF varies from 2 to 5 hours, 
and it is shortened by approximately 20-40% after the first week of daily treatment. 
RIF exposure is known to be dose-related and at least dose-proportional in the ranges so far examined in 
clinical studies.24 Though the extent to which metabolism of RIF is saturated at current doses has not been 
fully characterized, the available data suggest that RIF induction of hepatic microsomal enzymes may 
approach a maximum effect at doses as low as 150-300 mg.25-28 Though higher doses of RIF modestly 
shorten the time to full induction, the absolute amount of induction is not changed (see Table 10 in 
section 17.3.3).29 An EBA study revealed a near quadrupling of AUC/MIC when RIF dose was increased 
from 300 to 600 mg.7 In a recent observational study by Ruslami et al., AUC increased by a factor of 1.65 
when RIF dose was increased from 450 to 600 mg.30 Decroix et al also reported that increasing the RIF 
dose from 600 to 900 mg resulted in a near doubling of serum concentrations during the entire two 
months when concentrations were monitored.31 Acocella observed significant saturation of RIF first-pass 
metabolism as doses were increased beyond the standard 10 mg/kg dose. By doubling the RIF dose to 20 
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mg/kg, the maximum serum concentration (Cmax) was tripled.32 Thus, significant increases in exposure are 
to be expected from even modest increases in dose. 
2.2.1.4 Evidence from efficacy studies 
A series of clinical studies evaluated treatment response and toxicity over a range of increased doses of 
RIF and provided some evidence that sterilizing activity may also be accelerated. The observed increase 
in pharmacokinetic exposure with dose has been linked to improved response using markers of efficacy in 
humans. In studies of early bactericidal activity, a linear increase in the activity of RIF has been 
reproducibly demonstrated up to a dose of 1200 mg33 and the other rifamycins (rifapentine, rifabutin) 
show similar behavior. This contrasts with the dose-response curve repeatedly observed for isoniazid 
which exhibits a clear plateau of activity above 300 mg daily.34 In sum, efficacy studies reveal that RIF 
doses higher than 450 mg, 600 mg or 10 mg/kg are associated with increased the frequency of culture 
conversion at both months 1 and 2. These data, therefore, support the concept that doses greater than 600 
mg may increase culture conversion during the first two months, consistent with the results obtained in 
animal models. (For more information, see Table 10 in section 17.3.3) 
2.2.2 Substudies 
The rationale for three bacteriologic substudies is presented here. Their methods and execution are 
described in Section 4.4. 
2.2.2.1 LipTox Red Staining 
The identification of biomarkers that may replace or extend the usefulness of standard or quantitative 
bacteriology for the purpose of measuring the sterilizing activity of anti-tuberculosis regimens is a current 
research priority. An ability to more clearly identify the effect of sterilizing drugs on persister 
subpopulations of organisms in clinical specimens would be highly advantageous in the early clinical 
development phase. Such a biomarker may be better able to predict stable cure than current culture-based 
bacteriological methods. 
It is now well-documented that Mycobacterium tuberculosis, like most bacteria, exhibits a variable 
phenotype depending on environmental conditions. In particular a number of different conditions 
including hypoxia, nutrient starvation and drug pressure induce a reasonably conserved transcriptional 
response coordinated via a two-component system by the dosR regulon. This is accompanied by 
diminished or absent growth, antibiotic tolerance and a profound switch in energy metabolism in favor of 
beta-oxidation of fatty acids. Morphologically this phenotype can be identified in vitro and in vivo by 
intracellular accumulation of lipid bodies containing tri-acyl glycerol. 
A simple method for visualizing these lipid bodies has been developed using the neutral lipid stain 
LipTox Red and characterized both in vivo and in vitro. More extensive evaluation in clinical studies is 
needed to establish whether this method could be used to follow changes in persister sub-populations of 
bacilli during the course of therapy, how these changes compare with quantitative bacteriology using 
solid and liquid media and whether they can predict long-term outcome. The causal interpretation of such 
evaluation studies would be facilitated by dose-ranging designs of acknowledged sterilizing anti-
tuberculosis drugs that could in principle demonstrate a dose-response relationship on this biomarker. 
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2.2.2.2 Comparison of culture methods 
EBA studies that used decontamination prior to plating35, 36 have reported ¼-½ log less 0-2 day activity 
than studies in which decontamination was not used6, 37-40 (see Table 1 below). This may be because 
decontamination selectively kills the bacilli that would otherwise be killed in the early phase of treatment. 
Any killing due to decontamination would affect estimates of early bactericidal activity, possibly reducing 
the apparent effect of a new drug. To date, however, the effect of decontamination has not been observed 
on the bacilli that persist in the late phase; it is the bactericidal activity during the late phase that is the 
main criterion of whether treatment can be shortened. 
SSCC is a labor- and space-intensive method requiring substantial incubator space and time of laboratory 
workers to count colonies on the plates. Change in time to detection using the MGIT procedure, 
especially when performed with the machine that provides automated readouts, represents a much less 
labor intensive approach to quantifying (with greater sensitivity than with standard semi-quantitative 
culture) changes in bacterial load. 
The proposed substudy will examine the dynamic process of elimination of bacteria using three 
bacteriologic endpoints: conventional SSCC, SSCC with decontamination, and change in time to 
detection with MGIT. 
 
Table 1 Range of 0-2 day EBA by decontamination approach 
Ref Decontamination or 
digestion reported 
Baseline CFU 0-2 EBA 
Jindani et al, Nairobi6 
 
 
No Not reported 0.72 
Sirgel et al, S. Africa37 
 
No 6.32 0.50 
Chan et al, Hong Kong38 
 
No Not reported 0.43 
Hafner et al, US35 
 
 
NALC 6.69 0.27 
Kennedy et al, 
Tanzania36 
 
NAOH 6.38 0.25 (estimated from 7-
day) 
Johnson et al, Brazil39 
 
No 6.74 0.57 
Dietze et al, Brazil40 No 6.52 0.67 
2.2.2.3 Mixed strain infections 
Recent studies indicate that M. tuberculosis infections are more complex than had previously been 
appreciated: an individual can be infected with more than one strain and each strain can evolve during the 
course of infection.41, 42 Little is currently known about the prevalence of complex infections, the 
pathogen- and host-factors related to complex infections, or the effect of complex infections on the 
treatment outcomes of individuals or on the performance of strategies to control disease spread in 
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communities. The substudy proposed here will assess the pretreatment prevalence of complex infections 
and the impact of complex infection on early treatment response. 
Although DNA extraction methods from culture-negative sputum samples have been compared,43 
methods of specimen collection that will yield multiple strains, if multiple strains are present, have yet to 
be refined. Pooling of sputum samples collected from a single patient over several hours—the technique 
employed in this study at 6 time points for each participant—may optimize the ability to extract DNA 
from multiple strains. Comparing the results of strain genotyping from a pretreatment sample and from 
subsequent pooled samples (after more than 1 week of treatment) will permit assessment of selective 
killing of a subset of strains early in treatment. These results will be linked to the development of 
mathematical models designed to assess the effect of complex M. tuberculosis infection on the projected 
performance of new strategies for TB control. 
2.3 Potential Risks and Benefits of HIRIF 
Subjects in all arms will receive at least the minimum curative therapy for TB; no decrease in treatment 
efficacy, over the current standard, is expected. The four-drug, curative regimen that will be administered 
to all subjects is the standard of care for drug-susceptible TB and has been used for >30 years. In the Peru 
study site, approximately 90% of patients receiving this regimen are consistently cured (Bonilla, C., 
personal communication, 2005). Increased doses of RIF may improve the probability of cure. There are 
potential risks of the study related to the safety of using higher doses of RIF. There are other risks of the 
study related to confidentiality and study procedures. They are all discussed below. 
2.3.1 Potential Risks 
2.3.1.1 Toxicity data from animals 
Though dose-dependent toxicity of RIF has been observed in animals, RIF doses associated with such 
increases in toxicity were in the range of 100-200 mg/kg or, at least 6.67 times higher than the 15 or 20 
mg/kg doses proposed for this trial. Acute toxicity of RIF has been examined in mice, rats, guinea pigs 
and rabbits. Median lethal dose varied dramatically depending on animal and route of administration, but 
was generally at least 900 mg/kg with oral administration in all the animals. Intravenous administration 
led to mortality in half the animals at doses ranging from 260 mg/kg (in mice) to 639 mg/kg in guinea 
pigs.44-46 Additional animal toxicity data are provided in section 17.4.1.  
2.3.1.2 Toxicity data from humans: studies of tuberculosis 
Clinical safety data support the concept that serious toxicities of rifampicin are uncommon and not dose-
related. At a daily dose of 10 mg/kg (maximum 600 mg), RIF is well tolerated with <10% of patients 
experiencing significant adverse reactions. Gastrointestinal adverse effects are the most common (1-10 
percent), and include epigastric distress, anorexia, nausea, vomiting, cramps, and diarrhea. Anecdotal 
evidence suggests that GI side-effects are not dose related. In six patients not responding to standard 
doses of antituberculous therapy, RIF doses were raised from 600 mg to 900 mg, and in one patient, to 
1500 mg. Although three patients were alcoholics and one was HIV-infected, all responded to therapy and 
no adverse effects or poor outcomes were experienced.47 Kimerling and colleagues reported a similar 
experience with patients in whom RIF doses were raised in response to low serum concentrations of RIF 
on standard therapy. At least one patient ultimately received RIF at 1800 mg/day with no reported adverse 
events.48 Red-orange discoloration of tears, sweat, saliva, feces, and urine is also common and may lead 
to staining of contact lenses. 
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Serious toxicities attributed to RIF, particularly hepatotoxicity and flu-like syndrome, are not believed to 
be dose-related. RIF hepatotoxicity appears to be idiosyncratic.49 Known risk factors include advanced 
age, alcohol consumption, diabetes, and concomitant hepatotoxic agents. Although there are some 
inconclusive reports of increased incidence of hepatotoxicity with RIF and INH used in combination,49-55 
available data do not support an increase in hepatotoxicity with higher doses of RIF. Some studies have 
found increased risk of liver-function abnormality among TB patients with sub-clinical Hepatitis B or C 
(positive serology, no clinical symptoms, and transaminases within normal range) compared to those with 
negative Hepatitis B or C serology. These studies were, however, inconclusive about risk or severity of 
hepatotoxicity. And, they demonstrated that these patients can safely be treated with RIF-containing 
regimens.56-58 Moreover, there are no reports of concentration- or exposure-dependent hepatotoxicity 
among this important subpopulation. 
The flu-like syndrome is believed to be related to dosing interval and not dose size even at doses up to 
1800 mg. It is hypothesized to be immunologic in nature: an extended interval between the doses may 
induce hypersensitivity while daily dosing permits tolerance.59 The flu-like syndrome has been observed 
predominantly in situations where elevated doses are highly intermittent (once or twice weekly), either by 
design, or because of patient non-adherence to treatment.16, 60-64 Clinical studies of increased doses of RIF 
which also reported toxicity are summarized in section 17.3.3. 
Other severe adverse events, including thrombocytopenia, hemolytic anemia, and acute renal failure, also 
may occur, and these require permanent discontinuation of RIF.16, 49, 65 No evidence of increased 
frequency of these events with higher daily doses of RIF has been reported.8 Additional information is 
provided in section 17.4.2. 
2.3.1.3 Toxicity data from humans: other indications 
RIF has also been used at higher doses for other mycobacterial indications and for a wide range of non-
mycobacterial infections. These experiences support the contention that the vast majority of RIF’s adverse 
effects are idiosyncratic, and not dose related.66-72 Details are provided in section 17.4.3. 
2.3.1.4 Toxicity of companion drugs 
Information on toxicity of companion drugs is summarized below and elaborated in section 17.4.4. 
Isoniazid 
The incidence of all adverse effects from isoniazid is approximately 5%, many of which do not require 
discontinuation of the drug. Peripheral neurotoxicity is dose dependent and uncommon at conventional 
doses (<0.2%). The risk of peripheral neuropathy is increased by malnutrition or co-morbidity. 
Pyridoxine (vitamin B6) prophylaxis is recommended for these persons, and will be given to all patients in 
this trial. 
Pyrazinamide 
The most frequent pyrazinamide effects are skin rash, gastrointestinal intolerance, hepatotoxicity (1.3%), 
arthralgias (1-7%), hyperuricemia due to blockage of urate excretion (up to 66%), and rarely acute gouty 
arthritis.73, 74 These side effects are seldom dose-limiting. Asymptomatic elevations in serum uric acid are 
frequent but do not generally require treatment or discontinuation of TB therapy.75, 76 Minor arthralgias 
can usually be treated with non-steroidal anti-inflammatory agents while continuing the drug. The most 
common serious side effect of pyrazinamide is hepatotoxicity. In two randomized clinical trials the 
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addition of pyrazinamide to isoniazid and rifampin did not increase the rates of hepatotoxicity above that 
seen with the latter two drugs alone.76, 77 However, three recent retrospective cohort studies suggest that 
the incidence of pyrazinamide-induced hepatitis during active TB treatment is higher than that for other 
first-line TB drugs, and higher than previously recognized.78-80 Although PZA hepatotoxicity is clearly 
dose-related, there is no evidence that increased RIF doses, in combination with PZA, INH, and RIF, are 
likely to increase the incidence of PZA-related hepatotoxicity.81 The elevated frequency of hepatotoxicity 
with RIF/PZA appears to be idiosyncratic and has only been observed in the absence of INH (and EMB). 
 
Ethambutol 
Ethambutol is usually well-tolerated with low rates of skin rash, nausea, vomiting, or diarrhea. Fever, 
allergic reactions, abdominal pain, mental status changes, peripheral neuropathy, and increased liver 
function tests have rarely been associated with ethambutol. Adverse events occur in less than 2% of 
patients receiving ethambutol at the 15 mg/kg dose and include decreased visual acuity (0.8%), rash 
(0.5%) and asymptomatic hyperuricemia.73 The most common serious side effect of ethambutol is retinal 
toxicity, often first perceived as a decrease in color perception. Patients receiving ethambutol should be 
instructed about symptoms of ocular toxicity. If stopped promptly, permanent visual loss is rare among 
patients with ethambutol-related retinal toxicity. Rates of retinal toxicity are very low when the drug is 
given for relatively short periods of time, as is the case in this study. 
2.3.1.5 Drug-drug interactions with RIF 
Drug classes and members with reported interactions with RIF are described in Table 2. This includes 
drugs for which potential drug interactions or synergistic hepatotoxicity are a known concern, such as 
boosted protease inhibitors, non-nucleoside reverse transcriptase inhibitors, azole antifungals, statins. 
Suggestions for the management of rifampin-related drug interactions likely to be relevant in the study 
site are also presented. A prominent drug interaction of rifampin is that involving hormonal 
contraceptives. Women of childbearing potential (i.e., not surgically sterilized or postmenopausal for less 
than 1 year) will be advised to use a double-barrier contraceptive method including the following: 
condom, intravaginal spermicide (foams, jellies, sponge), and diaphragm; cervical cap; or intrauterine 
device. 
 
Table 2 Drug-drug interactions with RIF (likely in HIRIF setting) requiring change of medication 
Drug class 
 
Drugs affected by the 
rifamycins 
Comments 
Anti-infectives HIV protease inhibitors Only antiretroviral therapy containing efavirenz with 
two nucleosides or a triple-NRTI regimen should be 
used by study subjects 
 Macrolide antibiotics Azithromycin has no significant interaction with 
rifamycins. Clarithromycin and erythromycin should 
not be used 
 Doxycycline May require use of an alternate drug or drug 
combination (e.g., azithromycin) 
 Atovaquone Consider alternate form of Pneumocystis carinii 
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treatment or prophylaxis (e.g., pentamidine) 
 Chloramphenicol Consider an alternative antibiotic (e.g., 3rd-generation 
cephalosporin) 
 Mefloquine Consider alternate form of malaria treatment or 
prophylaxis (e.g., primaquine) 
Hormone therapy Ethinylestradiol, 
norethindrone 
Women of reproductive potential on oral 
contraceptives should add a double-barrier method of 
contraception 
Immuno-suppressive 
agents 
Cyclosporine, tacrolimus These drugs should not be used with rifampin. 
Consider alternate treatment (e.g., sirolimus) 
Ethanol can exacerbate the potential hepatotoxicity of isoniazid, rifampin, and pyrazinamide. Participants 
will be urged to abstain from alcohol while on study phase therapy. 
 
  
Table 3 Drugs with potential drug interactions or synergistic hepatotoxicity effect 
 
Medication Class  Names (brand name in parenthesis)  
 
 
Boosted protease inhibitors 
 
 
Saquinavir/ritonavir or any of the following 
PIs in combination (boosted) with ritonavir; 
Tipranavir (Aptivus), indinavir (Crixivan), 
saquinavir (Invirase), lopinavir+ritonavir 
(Kaletra), fosamprenavir (Lexiva), ritonavir 
(Norvir), darunavir (Prezista), atazanavir 
(Reyataz), nelfinavir (Viracept)  
Non-nucleoside reverse transcriptase inhibitors Rilpivirine (Edurant), etravirine (Intelence),  
Delavirdine (Rescriptor), efavirenz 
(Sustiva), nevirapine (Viramune)  
Systemic Azole antifungals Fluconazole (Diflucan), hexaconazole, 
itraconazole, posaconazole, voriconazole  
Statins Atorvastatin (Lipitor, Torvast), fluvastatin 
(Lescol), lovastatin (Mevacor, Altocor, 
Altoprev), pitavastatin (Livalo, Pitava), 
pravastatin (Pravachol, Selektine, Lipostat), 
soruvastatin (Crestor) and simvastatin 
(Zocor, Lipex)  
 
 
Table 4  Antibiotics contraindicated during study’s treatment 
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Abbreviation Drug Amk Amikacin Amxc Amoxicillin/Clavulanate Cfx Ciprofloxacin Cfz Clofazimine Cm Capreomicyn Clr Clarithromycin Cs Cyclocerine Eto Ethionamide Gfx Gatifloxacin Gem Gemifloxacin Km Kanamycin Lfx Levofloxacin Lzd Linezolid Mzl Metronidazole Mfx Moxifloxacin Ofx Ofloxacin Pas p-aminosalicylic acid Pto Prothionamide Rbt Rifabutin Rpt Rifapentin Spr Sparfloxacin S Streptomycin Th Thioacetazone Trd Terizidone Vi Viomycin Micobacterial drugs under investigation OPC-67683 y TMC 207  
 
2.3.1.6 Drug interactions between RIF and companion drugs 
Since INH, PZA, and EMB are metabolized via independent metabolic pathways, there do not appear to 
be any clinically significant drug interactions between RIF and the companion drugs proposed for this 
study.82-86 However, since the potential for changes in the pharmacokinetics of INH, PZA, and EMB 
when given with higher doses of RIF has not been entirely ruled out, we will also assess the effect of the 
increased RIF dose on the concentrations of the three companion TB drugs. Additional details are 
provided in section 17.4.5. 
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2.3.1.7 Potential interactions between companion medications and concomitant drugs 
The companion drugs, INH, PZA and EMB, may also result in interactions with concomitant drugs. 
Implicated classes include anti-convulsants, sedatives, neuroleptics, anticoagulants, narcotics, anti-
infectives, anti-gout, and antacids, in addition to several others. Details of the class members with 
interactions with companion drugs and suggestions for their management are listed in Section 17.4.6.  
2.3.1.8 Other Risks and Discomforts 
Home Visits 
While study participant information is completely confidential and private, there is a risk that a 
participant’s health status may become known to others through study team visits to the participant’s 
home. Everything possible will be done to prevent any type of discrimination towards the participant. If 
members of the study team are allowed by the participant to visit their home, study workers will not 
identify themselves as health workers, nor will they dress the part (such as wearing a white jacket).  
Blood Draws 
There will be several blood samples collected from the participant throughout the duration of the study. 
Risks of a blood draw may include pain or bruising where the needle is inserted, redness, fainting, or, in 
rare cases, an infection. While most sample collection requires only one puncture, more than one may be 
necessary. 
HIV/Viral Hepatitis (B & C) Testing 
HIV and Hepatitis B & C testing both incorporate risks of a blood draw. There is also the possibility of 
discrimination against individuals with HIV/Hepatitis B or C that may cause them to feel badly when they 
learn about their infection. The study team will do everything possible to reduce these risks. If diagnosed 
with Hepatitis B or C, the study team will direct the patient toward appropriate care, including facilitating 
access to the Peruvian national insurance program. If HIV infection is diagnosed, facilitated referrals will 
be made to the national STD, HIV/AIDS program. Under this program, the Ministry of Health provides 
free treatment for HIV, so the benefits of knowledge of HIV status are greater than the risks mentioned.  
Confidentiality 
There is a possibility of discrimination against individuals taking part in this study as medical information 
becomes known. Information collected from study participants during the study will be completely 
private and confidential. Precautionary measures are taken to make sure that patient confidentiality is 
upheld, including keeping patient information in private, locked files in the study office and having 
information on the computer be confidential, password protected, encrypted or protected by other security 
measures. Additionally, personal information will be kept confidential; only the study ID number will be 
used to identify the patient by the study team.  
Genetic Testing 
Genetic testing incorporates risks of a blood draw. This study will test only for specific markers that are 
associated with increased risk of adverse events; markers that are not likely to result in any discrimination 
even if they do become known. Participants will have the option to provide a blood sample for genetic 
Page 79 of 207  AJRCCM Articles in Press. Published on 29-June-2018 as 10.1164/rccm.201712-2524OC 
 Copyright © 2018 by the American Thoracic Society 
DMID Protocol 11-0050  V7.0 September 25, 2014 
 
29 
 
testing. The results of the study that uses the genetic testing data will be made available to the participant 
if they wish.  
Chest X-Ray 
Each chest x-ray will expose the patient to a low amount of radiation that is similar to the amount of 
radiation an average person is exposed to from the sun over the course of 10 days. It is also possible that 
while doing a chest x-ray, something that looks like a medical problem other than tuberculosis may be 
seen. If the radiologist thinks there may be a problem, s/he will tell the patient and help him/her receive 
follow-up care. However, if the doctor thinks the patient might have an additional medical problem, and 
s/he does not, it may cause unnecessary worry. 
2.3.2 Potential Benefits 
High-dose RIF could increase the frequency of cure, reducing transmission and morbidity and mortality 
due to TB. This intervention could also result in decreased selection for RIF-resistant mutations. 
Moreover, if inclusion of high-dose RIF results in treatment shortening, program resources can be 
extended to permit treatment of additional patients. Lastly, completion of this trial will contribute to 
strengthening scarce clinical trials capability worldwide.87 
2.3.2.1 Benefits to study participants 
All subjects enrolled will receive an anti-tuberculosis regimen of six months duration containing INH, 
PZA, EMB, and RIF, which, at standard RIF doses, is reported to cure approximately 95% of patients 
treated under trial conditions. The treatment provided in the intervention arms may or may not have 
activity that exceeds the standard treatment used in the control arm. Symptoms of TB and infectiousness 
may or may not resolve more quickly in these subjects. They may or may not be able to return to 
activities of daily life sooner as well. Subjects in all three arms will receive TB care that is of similar or 
superior quality to that received routinely through the public sector in the study site. Moreover, subjects 
will receive necessary support to facilitate completion of the study regimen. 
2.3.2.2 Potential impact on health care, policy or practice 
The proposed study will provide essential information that may support the development of a shorter, 
effective treatment regimen for the 9 million people who develop TB annually. Demonstrably increased 
sterilizing activity of an anti-TB agent, without increased adverse events, would indicate a larger study of 
a shortened regimen. Since RIF is available globally, a shortened regimen, containing RIF, could be 
integrated into national TB programs. Its expected impact on the global TB burden88 could be dramatic, 
potentially achieving one or more of the following: 1) reducing the probability of default, relapse, and/or 
resistance by shortening treatment;89, 90 2) decreasing the cost of treatment; 3) increasing the number of 
patients who could be served by TB programs, by decreasing the resources required for each patient; 4) 
reducing transmission; if the sputum of patients on high-dose RIF is sterilized more quickly than that of 
patients on conventional doses of RIF, additional transmission may be averted. 
The second broad benefit of this trial derives from its importance for other TB drug development projects. 
Subjects treated for eight weeks will be followed until the end of treatment and for six additional months. 
Consequently, we will also be able to contribute to the evaluation of bacteriologic indicators of treatment 
response for possible use as surrogate endpoints in Phase II and phase III trials of TB therapy. These trials 
have typically relied on failure/relapse as the primary endpoint. Phase III trials are long, with final results 
not available until at least one year after treatment completion. Identifying early predictors of treatment 
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failure and relapse will have substantial implications for the cost and duration of future clinical trials of 
anti-TB agents. 
The potential impact of this study is heightened by plans to coordinate efforts with a complementary trial, 
which began enrolling in 2011 in Africa (ClinicalTrials.gov identifier: NCT00760149). This study is not 
being conducted under IND. Protocols and study procedures for the proposed trial in Latin America and 
this study are being harmonized, facilitating pooling of the data. Prior to this pooling, a statistical analysis 
plan will be jointly developed. The benefits would be multiple: substantially more data would be available 
to evaluate both the safety and efficacy endpoints, adding increased certainty around effect estimates. 
Heterogeneity in efficacy or toxicity between different populations could be observed. Genotypic 
differences as well as differences in frequency of co-infection could be important between the two study 
populations.  
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3.0  STUDY OBJECTIVES & OUTCOME MEASURES 
3.1 Study Objectives 
Across three, daily, oral doses of RIF (10, 15 and 20 mg/kg/day): 
3.1.1 Primary 
1. To assess the difference in steady state pharmacokinetic exposure of RIF and 25-desacetyl-
rifampin. 
2. To assess the difference in sputum culture sterilization during the initial 8 weeks. 
3. To compare the incidence of adverse events related to the study drug or regimen during the initial 
8 weeks of daily four-drug treatment, and up to four weeks later. 
3.1.2 Secondary 
1. To estimate the relationship between pharmacokinetic parameters and measures of sputum culture 
sterilization. 
2. To compare 4 methods for estimating sterilizing activity: 1) decline in log colony-forming units 
(CFUs), 2) speed of culture conversion in solid & liquid media, 3) increased time to detection in 
liquid medium, and 4) proportion of patients with positive cultures at 8 weeks. 
3.2 Study Outcome Measures 
3.2.1 Primary 
1. AUC0-24/MIC of RIF at steady state. 
2. Serial decline in M. tuberculosis colony counts in the sputum (Log10 CFU/mL/day). 
3. Incidence of adverse events related to study drug or regimen, grade 2 or higher, during the 8-
week intensive phase, and up to four weeks after. 
3.2.2 Secondary 
1. Association between AUC0-24/MIC (and alternative measures such as AUC0-6) and bacteriologic 
endpoints (log10 CFU/mL/day, time to conversion, time to detection, negativity at 8 weeks). 
2. Association among log10 CFU/mL/day, time to sputum culture conversion on solid and liquid 
media; time to detection of M. tuberculosis in liquid medium; frequency of sputum culture 
negativity on solid medium at eight weeks. 
4.0  STUDY DESIGN 
This is a Phase II dose-ranging trial comparing 3 doses of RIF in a multidrug regimen for treatment of 
smear-positive, pulmonary TB. Patients will be randomized to 3 arms, in a 1:1:1 allocation. 
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The intervention phase of this prospective, randomized, triple-blinded trial will last 8 weeks, the duration 
of the standard “intensive” phase for short-course chemotherapy for TB. During that time, subjects will 
receive the following companion drugs (weight-based doses are specified below in Table 5): isoniazid 
(INH, 5 mg/kg/day), ethambutol (EMB, 20 mg/kg/day), and pyrazinamide (PZA, 25 mg/kg/day), 
pyridoxine (50 mg), the standard weight-based doses used in treatment. Subjects will also be randomized 
to receive one of the following weight-based doses of the study drug, rifampin (RIF): 10 mg/kg/day 
(standard dose, control), 15 mg/kg/day (intervention 1), 20 mg/kg/day (intervention 2). Placebo will be 
used to control only the additional RIF capsules provided in the intervention arms. Subjects, clinicians, 
and laboratory staff will be blinded to study arm. All patients in the same weight band will receive the 
same total number of tablets (fixed-dose combination, dosed according to package inserts plus RIF and/or 
placebo). They will also all receive 50 mg of pyridoxine three times per week to prevent peripheral 
neuropathy, a common side effect of INH. 
All participants will receive a 4-month continuation phase of thrice weekly INH (10 mg/kg) and RIF (10 
mg/kg) per WHO recommendations91 as well as pyridoxine 50 mg three times per week. 
4.1 Study Population 
The study population will comprise adults (>=18 years and <=60 years) with newly diagnosed, previously 
untreated, smear positive (>=2+) pulmonary tuberculosis presenting in metropolitan Lima. Recruitment 
will take place in the following health districts (DISA, Spanish acronym): DISA IV-Lima Este (including 
health network Lima Este Metropolitana) and DISA V-Lima Ciudad (including the health networks 
Rímac-San Martin de Porres-Los Olivos-Túpac Amaru and Lima) where the local study partner, Socios 
En Salud, has established relationships. If necessary, recruitment may be extended to additional health 
networks or facilities , located in convenient proximity to the study hospitals, with approval of local 
authorities.  
 
In 2010, the Lima Este Metropolitana health network, reported 1160 cases of smear-positive, pulmonary 
TB. Approximately 4% of TB cases were co-infected with HIV and roughly 10% also had diabetes 
mellitus.  
 
In 2011, the Rímac-San Martin de Porres-Los Olivos health network reported 785 cases of smear-positive 
pulmonary TB. Approximately 3% of those cases had HIV-coinfection. The Túpac Amaru health network 
registered 611 cases that same year; 2% of TB patients were co-infected with HIV.  
 
Patients from included facilities, who are identified as potential study participants, will be referred to 
either Hospital Nacional Hipólito Unanue or Hospital Nacional Sergio E. Bernales according to their 
jurisdiction. Both hospitals are INS-certified Research Centers. 
 
Recruiting in both Lima Este and Lima Ciudad, we estimate that we will randomize approximately 17 
patients per month.  This would result in randomization of 180 participants, the study target, in 
approximately -11 months.  
4.2 Treatment Delivery and Duration 
Study drug and companion drugs will be delivered 7 days/week during 8 weeks. However, participants 
may take as long as 9 weeks to complete the required 56 doses. If one or more of the study drugs is 
suspended for more than two weeks, the participant will be withdrawn from the study. All study 
participants will receive WHO-recommended continuation therapy (INH 10 mg/kg/day and RIF 10 
mg/kg/day) 3 days/week for 18 weeks and pyridoxine 50 mg 3 days/week. All doses in the intensive and 
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continuation phases will be directly observed.  ;. Routine, monthly bacteriologic monitoring will continue 
during this period.  
Post-treatment follow-up will be 6 months from ingestion of last dose of directly observed therapy. Total 
participation time for each subject will be 12 months. The trial will last 18 to 24 months. 
4.3 Assessment of Study Objectives & Measurement of Endpoints 
Primary and secondary outcome measures are enumerated in sections 3.2.1 & 3.2.2. 
4.3.1 Centralization of Evaluations 
All clinical evaluations, adverse event (AE)/adherence assessments, and pharmacokinetic (PK) sampling 
will all occur at one of the hospitals, Hospital Nacional Hipólito Unanue or Hospital Sergio E. Bernales. 
Each patient’s study visits will take place at the hospital most conveniently located relative the patient’s 
home. Overnight pooled sputum collection will also take place at the hospitals, or when staffing and 
infection-control conditions permit, in participants’ homes. One dedicated research microbiology 
laboratory will perform all of the study TB microbiology. Routine hematology and blood chemistry will 
be performed in a single private reference lab in Peru. For unscheduled laboratory tests, the study may 
also use the hospital laboratories. 
Site investigators will evaluate chest x-rays for inclusion criteria. One independent pulmonologist will 
read and score all chest x-rays; scores will be used as a covariate in analysis. 
4.3.2 Pharmacokinetic-Pharmacodynamic Endpoints 
Strong evidence presented in section 2.2.1.3 and section 17.3.3 supports the concept of exposure-related 
pharmacodynamics for RIF with a PK-PD index parameter of AUC/MIC. AUC0-24/MIC has therefore 
been selected as the primary PK endpoint for this study. AUC0-24, AUC0-6, Cmax, Tmax of RIF and 25-
desacetyl-RIF will be derived from measurements of RIF and 25-desacetyl-RIF in plasma samples drawn 
from participants after at least 13 days of treatment (after steady state is achieved). Plasma concentrations 
for the companion drugs will also be measured using the same sampling scheme as for RIF. This 
information will be important for adjusted analysis of the relationship between concentration and activity 
and will provide pharmacokinetic data on anti-TB drugs in South American populations. This 
complements existing data on Asian and South African populations.7, 24, 30, 92 Bioanalysis will be 
performed using a validated high-performance liquid chromatography method in Dr. Peloquin’s lab. 
Additional details are in protocol sections 8.3 and 8.4. 
RIF minimum inhibitory concentrations (MICs) will be measured in a pre-treatment sputum specimen 
collected from each study participant. The assays will be performed according to guidance from the 
Clinical Laboratory Standards Institute,93 evaluating 10 concentrations of rifampin, including the 1 
mg/liter “critical concentration” of RIF. The assay will be performed at the SES Laboratory in Peru. On a 
small sample of patient isolates (4 in each arm), MICs of 25-desacetyl-RIF will also be measured. 
4.3.3 Bacteriologic endpoints 
As outlined in section 2.1 and section 17.1 there is currently no universal agreement as to the best 
surrogate endpoint for assessment of sterilizing activity. Although there is reasonable historical support 
for the use of solid culture at two months as a surrogate for relapse, this endpoint lacks power even when 
comparing distinct regimens. It is, therefore, probably not feasible for use in dose-ranging studies. 
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Recently rate-based measures using more intensive sputum bacteriology during the first two months have 
also been used for this purpose and promise improved efficiency of early clinical evaluation.94, 95 
However, whether solid or liquid culture methods should be used and whether they should be analyzed 
using a time-to-event or non-linear regression approach remains unclear. Hence most clinical studies 
currently incorporate both bacteriological methods and more than one analysis approach with a view to 
subsequent evaluation of the utility of these different approaches. The non-linear regression approach to 
quantitative sputum culture on solid selective media has been selected as the primary endpoint for this 
study since two independent studies appear to confirm its ability to detect sterilizing activity95, 96 and 
meaningful statistical comparisons will be possible at the sample size selected for the PK study proposed. 
Nevertheless, three secondary bacteriological endpoints will also be obtained for the purposes of 
comparison with the non-linear regression results and as a contribution towards evaluation of their 
relative support. 
The decline in log colony forming units will be calculated based on measurements from pooled sputum 
samples collected at specified time points during the first 2 months of treatment. (The details of the 
sampling scheme are specified in section 7.2.1.3 and in the schedule of events, Figure 2). Each patient 
will provide samples on day 0 and on 5 other days. This sampling scheme represents the best balance 
among burden on study participants, power to detect a difference, and accuracy of the estimate. Samples 
will be cultured on selective, solid 7H11 (Middlebrook) medium. 
Time to culture conversion will be calculated as the interval between the start of treatment and the date of 
collection of sputum, which, when cultured in LJ medium, results in the first observed negative sputum 
culture in a profile terminating in negative cultures. A culture can be read as negative only after 60 days. 
Change in time to positivity will be measured as the rate at which the difference between date of 
inoculation and date of observed growth for specimens cultured in the MGIT (liquid) system changes 
with time. 
Frequency of culture conversion at two months will be measured as a count of study participants whose 
sputum culture (grown in solid LJ medium), collected after 2 months of treatment, is negative after 60 
days of incubation. 
4.3.4 Safety endpoints 
Section 2.3.1 (and section 17.4) describes the known toxicities associated with RIF and their attribution to 
higher doses of RIF. Of particular interest for ultimate implementation of a TB regimen with higher doses 
of RIF are toxicities so severe or dangerous as to result in discontinuation of treatment, in particular 
hepatitis and hematologic disorders.  
The primary endpoint for the analysis of safety and tolerability will be the incidence of adverse events 
grade 2 or higher, related to the study drug or regimen, occurring during the 8-week intensive phase.  
Secondary safety and tolerability endpoints include the frequency and timing of Grade 3 and 4 toxicities 
that are determined by the investigators to be related to study drug or regimen.  
The frequency and timing of permanent discontinuation for any reason other than being found to be 
ineligible for continuing in the study (because of drug-resistance, or lack of growth of M. tuberculosis 
from the initial sputum culture) will also be recorded for secondary analyses.  
Adverse events will be measured through clinical and laboratory evaluations at intervals specified in 
section 7.0. Please see Table 9 for modified study-related toxicity criteria. The adverse events will be 
graded according to Table 9, which is derived from the DMID Adult Toxicity Tables (Draft November 
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2007) (see Figure 8 in section 17.6). The interval from treatment start until the event is first observed will 
be recorded.  
4.3.5 Safety monitoring committee (SMC) 
An SMC will be formed and will function according to DMID guidelines 
(http://www3.niaid.nih.gov/LabsAndResources/resources/DMIDClinRsrch/safetyoversight.htm). The 
SMC will comprise one clinical TB expert, one internationally recognized clinical trialist, and one clinical 
researcher with expertise in a topic of relevance to the study (e.g., hepatotoxicity), none of whom will be 
otherwise involved in the study. A statistician may also participate, either as a full voting member or as a 
consultant to the SMC at open session meetings. S/he will not otherwise be involved in the study.  
Additional expertise may be added for open or closed meetings, as needed, on an ad hoc basis. Open 
meetings will be held after 60 patients have completed 4 weeks of study treatment and then again after 
120 patients have completed 4 weeks of study treatment or as needed for SAEs and unexpected AEs. If 
the committee determines that access to unblinded data is required, the meeting(s) will be closed 
executive session(s). Please see section 9.6 for more detail regarding safety oversight.  
4.3.6 Interim analysis plans 
An early safety evaluation will be performed when the first 60 patients (approximately 20 per arm) have 
completed 4 weeks of study treatment. Safety data will be reviewed by the SMC. The SMC will provide 
recommendations for further action, including continuation of all three arms, discontinuation of one arm 
(with rollover to standard dose of RIF or lower intervention dose), or termination of the trial. In addition, 
the SMC will review trial progress after 120 participants have completed 4 weeks of study treatment.  
An interim, blinded PK analysis will be performed by Dr. Davies when PK data are available for half the 
patients. 
No interim efficacy analysis is planned for this Phase II trial. 
4.4 Substudies 
Substudies will contribute to the knowledge base of the microbiology and molecular biology of M. 
tuberculosis. Our understanding of several microbiologic endpoints will be refined through this trial. 
Through three substudies, we will examine: 1) the value of lipid-body content in sputum samples as a 
potential surrogate marker for clinical endpoints; 2) the effect of decontamination on early- and late-phase 
quantitative culture results, and the agreement between days to positivity (DTP) in MGIT and SSCC in 
both early and late phases; and, 3) questions of emerging importance about mixed strain (or super) 
infection: what is the frequency of mixed strain infections detectable in pooled sputum collections? What 
is the contribution of mixed strain infections on interim and clinical endpoints? 
4.4.1 LipTox Red Staining Study design 
4.4.1.1 Aim 
To evaluate the utility of LipTox Red staining as a measure of response of persister sub-populations to 
therapy and as a predictor of treatment success. 
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4.4.1.2 Objectives 
1) To describe the proportion and estimated absolute number of LipTox Red-positive organisms 
in sputum at baseline 
2) To estimate changes in the proportion and estimated absolute number of LipTox Red-positive 
organisms during the course of therapy  
3) To relate measures of LipTox Red positivity at baseline to late phase decline in colony counts 
derived from non-linear mixed effects analysis of quantitative culture on solid media 
4) To relate measures of LipTox Red positivity at baseline to changes in DTP in automated liquid 
culture  
4.4.1.3 Participants 
Participants in the study will already have been recruited to the HIRIF study. The three sputum samples 
for this substudy are all samples that will already be collected during the HIRIF study and are already 
described in the HIRIF study protocol.  
4.4.1.4 Procedures 
The early-morning sputum samples collected for the study at baseline, at study visit 5 or 6 (see Figure 2. 
Schedule of Events) and at visit 7 will be used for smear microscopy on site and for assessment of lipid 
body content in Liverpool. Frozen sputum samples will be sent to University of Liverpool for processing, 
reading, and analysis.  
4.4.1.5 Analysis 
The proportion and number of LipTox Red-positive cells will be summarized graphically and expressed 
as mean or median with appropriate confidence or interquartile intervals and ranges. Exploratory data 
analysis will relate these findings to other covariates obtained in the study such as baseline colony count, 
DTP, and radiological extent of disease. 
The analysis of colony counting and liquid culture data from the HIRIF study will employ a multivariate 
mixed effects approach with a bi-exponential or non-parametric structure as appropriate. The proportion 
of LipTox Red-positive cells will be evaluated as a covariate in these models using Wald tests of the 
coefficients and the likelihood ratio test to assess overall model fit. Other relevant covariates to be 
included in the model will be HIV status, radiological extent of disease, and dose size of rifampin. 
The profiles of estimated absolute numbers of LipTox Red-positive cells will also be modeled using a 
mixed effects approach with an appropriate structural model to be determined from the data since no 
longitudinal data yet exists. A linear contrast for treatment effect will be fitted to the final model. 
4.4.2 Variability in early- and late-phase activity by microbiological procedures 
4.4.2.1 Aim 
To estimate whether the effect of sputum decontamination on colony counts obtained on selective solid 
medium is the same at all stages of treatment. 
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4.4.2.2 Objectives 
1) To compare the colony counts determined on selective solid medium to those determined on 
decontaminated, selective solid medium at each sputum sampling point. 
2) To compare colony counts on selective solid medium determined using both methods (with 
decontamination and without decontamination) with DTP at each sputum sampling point. 
3) To estimate rates of contamination of cultures on selective solid medium according to method 
of sputum processing. 
4.4.2.3 Participants 
Participants in the study will already have been recruited to the HIRIF study. No additional samples or 
clinical study procedures will be required in addition to those specified by the HIRIF protocol. 
4.4.2.4 Procedures 
In the Lima study lab, each of the pooled sputum samples (of sufficient volume), collected at 6 time 
points during study treatment, will be cultured in three different ways: (1) 1/3 of the specimen will be 
digested with dithiothreitol (DTT), but not decontaminated, and plated out from serial dilutions on 
selective 7H11 plates for colony counting; this is considered the “standard” method; (2) 1/3 of the 
specimen will be decontaminated with the NALC procedure followed by plating out from serial dilutions 
on selective 7H11 plates for colony counting; (3) 1/3 will be decontaminated with the NALC procedure 
and cultured in MGIT liquid medium bottles.  
4.4.2.5 Analysis 
The mean profiles of colony counts and the confidence intervals obtained using both methods of sputum 
processing will be plotted over all the sampling points. Summary statistics representing the slope of the 
decline of colony counts in the time intervals 0-2, 2-14 and 14-56 days will also be computed and the 
effect of decontamination assessed using analysis of variance for each time period. A linear or 
generalized additive model will also be used to relate the DTP results in liquid culture to colony counts 
on solid medium and to examine the effect of the covariates, day of sample, and sputum processing 
method on the regression coefficients of this model.  
4.4.3 Complex infection in pooled sputum samples 
4.4.3.1 Aim 
To evaluate the use of pooled sputum samples to identify complex infections and understand the impact 
of such infections on treatment response. 
4.4.3.2 Objectives 
1) To assess the pre-treatment prevalence of complex infections identifiable in pooled sputum 
specimens and  
2) To measure the impact of complex infection measured from pooled sputum on early treatment 
response. 
Page 88 of 207 AJRCCM Articles in Press. Published on 29-June-2018 as 10.1164/rccm.201712-2524OC 
 Copyright © 2018 by the American Thoracic Society 
DMID Protocol 11-0050  V7.0 September 25, 2014 
 
38 
 
4.4.3.3 Participants 
Participants in this substudy will be accrued from the study population recruited for the HIRIF study. No 
additional samples or clinical study procedures will be required in addition to those specified by the 
HIRIF protocol. 
4.4.3.4 Procedures 
Genotyping will be performed to determine if, within each specimen collected, more than one molecularly 
distinct strain (representing either multiple strain infection or with-in host diversification of a single 
infecting strain) can be identified. 
4.4.3.5 Analysis 
The proportion of infections with evidence of clonal heterogeneity or multiple strains will be measured at 
each sampling point (stratified by treatment arm). Genotyping will also permit identification of strain 
lineage.  
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5.0  STUDY ENROLLMENT AND WITHDRAWAL 
5.1 Study Population 
HIV-infected and -uninfected individuals 18 to 60 years with newly diagnosed, previously untreated, 
smear-positive (>= 2+), pulmonary TB may be evaluated for eligibility. 
We will randomize 180 subjects. Sufficient statistical power for the primary endpoint will be retained as 
long as no more than 30 patients are lost to follow up. Therefore, we expect at least 150 subjects, 50 in 
each arm, to complete the study treatment and follow up.  
Approximately 40% of subjects will be female, while 60% will be male. This reflects the relative 
frequency of case notification between men and women in the study site (57% of cases notified in Peru in 
2007 were male).1 
 
Patients will be recruited from ambulatory facilities in the Peruvian public health system in the DISA IV-
Lima Este and in the DISA V-Lima Ciudad. These health centers function as part of a network of centers 
with personnel dedicated to TB screening, diagnosis, and treatment. Patients with a single positive sputum 
smear (>=2+) will be invited to participate by health center staff and then recommended for screening. 
Interested patients will be referred to study staff at the two Hospital Research Centers. 
5.2 Recruitment and Retention 
Recruitment will occur over an 11-month period. In light of the enrollment targets relative to the number 
of incident cases of TB, the investigators do not expect difficulties enrolling subjects through the routine 
passive case detection services in operation at the study sites. Recruitment progress will be continually 
reevaluated to determine if additional sites or intensified case-finding will be necessary to meet 
recruitment goals. 
Retention will be assured through a system of DOT supervisors and enablers. All treatment will be 
ambulatory, and delivered by dedicated DOT supervisors in health centers or in a location of each 
subject’s choosing (e.g., workplace, home). During the intensive phase of the study, treatment adherence 
will be confirmed through bi-weekly medication review visits. In the continuation phase, treatment 
adherence will be confirmed through monthly visits. Transport costs for study visits, as well as for 
collection of PK and sputum samples, will be covered by the study. Participants will receive food 
vouchers monthly during the intensive and continuation phases, and quarterly during follow-up. Meals 
will also be provided during inpatient stays for pooled sputum collection and PK sampling. 
5.3 Subject Inclusion Criteria 
Inclusion criteria for the trial are:  
1. Newly diagnosed pulmonary TB with acid-fast bacilli (>=2+) in a stained sputum smear. 
2. Susceptibility of isolate to INH and RIF by HAIN test.  
3. Willingness to undergo HIV testing according to the National Health Guidelines for TB control 
in Peru. The study will also consider patients who have had negative HIV serostatus 
documented within six months prior to enrollment or if verifiable positive serostatus was 
documented using a validated test any time previously.  
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4. Age ≥ 18 years and <61 years.  
5. Signed informed consent.  
6. Negative serum pregnancy test (women of childbearing potential). 
7. Women of child-bearing potential must agree to practice a double-barrier method of birth 
control during treatment. Adequate contraceptives (condoms and spermicide) will be provided 
by the study to avoid pregnancy among female subjects. 
8. Karnofsky score of at least 50 (requires considerable assistance and frequent medical care). 
9. Intends to remain in jurisdiction of health center during study and follow up. 
5.4 Subject Exclusion Criteria 
Subjects will be excluded from the trial for any of the following:  
1. Body weight <30 kg. 
2. Prior treatment with multidrug anti-TB therapy for more than one month.  
3. Resistance on HAIN to INH and/or RIF. These patients will be treated according to local 
programmatic guidelines. 
4. Central nervous system or miliary TB. 
5. Clinical or radiological signs suggestive of pericardial or pleural involvement. 
6. Presence of significant hemoptysis. Patients who cough up frank blood (more than blood-streaked 
sputum) will not be eligible for enrollment. 
7. Known intolerance to any of the study drugs. Use of concomitant drugs that interfere with the 
pharmacokinetics of anti-TB drugs (see Table 2); use of concomitant hepatotoxic drugs (other 
than companion study drugs) for which potential drug interactions or synergistic toxicity are 
known: boosted protease inhibitors, non-nucleoside reverse transcriptase inhibitors, azole 
antifungals and statins (see Table 3); use of antibiotics that are contraindicated during the study’s 
TB therapy (see Table 4).  Current daily use of acetaminophen or paracetamol for two weeks or 
more.   
8. History of liver disease.  
9. Uncontrolled condition that might interfere with drug absorption, distribution, metabolism or 
excretion (i.e. chronic gastro-intestinal disease, renal insufficiency defined by creatinine 
clearance <60mL/min). 
10. Uncontrolled diabetes mellitus (HbA1c>7.5%). 
11. Refusal to be tested for HIV infection; HIV infection with contraindication for treatment with 
efavirenz (including resistance). 
12. Pulmonary silicosis. 
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13. Breastfeeding. 
14. Rifampin contraindications such as hypersensitivity or jaundice. 
15. Likely difficulty adhering to the study protocol, as assessed by the investigator. 
16. Laboratory results in the 14 days preceding enrollment showing: 
a. Serum amino alanine transferase (ALT) >2 times upper limit of normal 
b. Serum total bilirubin concentration >2.5 times upper limit of normal 
c. Serum creatinine concentration > 2 times upper limit of normal and/or creatinine clearance 
<60 mL/min 
d. Hemoglobin concentration < 7.0 g/dL 
e. Platelet count < 150,000/mm3 
f. White blood count <4500 cells/μL. 
17.  Having a serological test positive for HBVsAg (hepatitis B virus surface antigen) or for HCVAb 
(hepatitis C virus antibody) test. 
5.5 Treatment Assignment Procedures 
This will be a triple-blinded (participants, clinical staff, and laboratory staff) randomized trial. Treatment 
assignment will be randomized by the study statistician. 
5.6 Randomization Procedures 
Eligible patients will be randomized to 3 arms, in a 1:1:1 allocation. Randomization to RIF dose will be 
implemented by the pharmacist at the study site using a predetermined randomization scheme created by 
the study statistician at the study data and coordinating center (DCC) at Harvard University. 
Randomization will be blocked. Randomization will not be stratified.97 
5.7 Blinding Procedures 
Participants, clinicians, and laboratory staff will be blinded to treatment assignment. Blinding of 
clinicians and laboratory staff is essential to reduce the probability of biased reporting of adverse events 
and laboratory endpoints, respectively. To protect blinding, block size will not be available to 
investigators. Pharmacy staff will not be blinded to assignment. Pharmacy staff will receive 
randomization assignment from the DCC and prepare medication boxes according to patient weight and 
treatment-arm assignment. Pharmacy staff will have no contact with participants and will not 
communicate treatment assignment information to clinical or laboratory staff. Subjects across all 3 arms 
within a single weight band will receive identical numbers of capsules (RIF and/or placebo) and FDCs 
(see Table 5). 
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5.8 Withdrawal 
5.8.1 Reasons for withdrawal 
Subjects may withdraw voluntarily from participation in the study at any time upon request. Subjects may 
also withdraw voluntarily from receiving the study intervention for any reason. 
In addition to voluntary withdrawal, study drugs may be discontinued by trial staff for the following 
reasons: 
x Any clinical AE or laboratory abnormality that, depending on its nature and severity, requires 
temporary suspension of the study drugs until the toxicity resolves as indicated in the subsequent 
section describing adverse event management (Section 9.2.3).  If one or more of the study drugs 
is suspended for more than two weeks, the participant will be withdrawn from the study. 
x An intercurrent illness, other medical condition or situation occurs such that continued 
administration of study drugs and/or participation in the study would not be in the best interest of 
the subject. 
x Development of any exclusion criteria may be cause for study withdrawal. 
x Any patient without culture confirmation of M. tuberculosis, or whose isolate is found to be 
resistant to any of the study drugs after study treatment is initiated, will be discontinued from the 
study, but followed for 14 days to detect late toxicities from study therapy. If a participant’s 
isolate tests resistant to ethambutol or pyrazinamide, in the absence of resistance to isoniazid or 
rifampin, confirmation of the resistant result will be required prior to termination from the study. 
The subject will continue to be followed for 14 days with the subject’s permission if withdrawal occurs. If 
a subject becomes pregnant while receiving therapy and study drugs are discontinued, the newborn will 
be followed for six months. 
In the event of study closure by the sponsor or regulatory agency, study subjects on intensive phase TB 
treatment will be discontinued from their assigned study regimen. Subjects will be treated with a standard 
regimen for TB according to local guidelines.  
5.8.2 Handling of Withdrawals 
Attempts to contact participants who do not complete study follow-up will include at least 3 home visits 
and 1 telephone call, if appropriate. Interviews with patients who withdraw from the study will focus on 
the reason for discontinuation and whether it was related to development of adverse reactions. If 
withdrawal occurs, the subject will be asked to continue scheduled evaluations. 
5.8.2.1 Procedures/Evaluations in case of withdrawal 
If withdrawal occurs, and we have the participant’s permission, subjects will be given appropriate care 
under medical supervision until the symptoms of any AE resolve or stabilize. Subjects still receiving TB 
treatment will be referred to the local TB clinic or hospital outpatient TB program for care.  
If a participant withdraws prior to completion of two weeks of study drug, the patient will be included 
only in analysis of safety. Since blood samples will not have been collected for PK, participants 
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withdrawing before two weeks will not be included in PK analysis. And, an insufficient number of 
sputum samples will have been collected for inclusion in the efficacy analysis. 
If a participant withdraws after completion of two—but before completion of eight—weeks of study 
therapy, s/he will be included in the safety and PK analyses; available SSCC data will also be used in the 
efficacy analysis.  
If a participant withdraws after completion of eight weeks of study therapy, s/he will be included in 
safety, efficacy, and PK analyses.  
If the subject is willing, a termination visit will be performed. 
5.9 Termination of Study 
The study may be terminated by DMID, the PIs, one of the IRBs, the FDA or another regulatory agency. 
Termination could occur after the development of unacceptable toxicities or as a recommended outcome 
of an SMC review. 
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6.0  INVESTIGATIONAL PRODUCT 
6.1 Study Product Description 
RIFADIN (rifampin capsules USP) for oral administration contain 150 mg rifampin per capsule. The 
capsules also contain, as inactive ingredients: corn starch, D&C Red No. 28, FD&C Blue No. 1, FD&C 
Red No. 40, gelatin, magnesium stearate, and titanium dioxide. 
Rifampin is a semisynthetic antibiotic derivative of the natural product rifamycin SV. Rifampin is a red-
brown crystalline powder very slightly soluble in water at neutral pH, freely soluble in chloroform, 
soluble in ethyl acetate and in methanol. Its molecular weight is 822.95 and its chemical formula is 
C43H58N4O12. The chemical name for rifampin is either: 
3-[[(4-Methyl-1-piperazinyl)imino]methyl]rifamycin 
Or 
5,6,9,17,19,21-hexahydroxy-23-methoxy-2,4,12,16,20,22– 
heptamethyl-8-[N-(4-methyl-1-piperazinyl)formimidoyl]-2,7-
(epoxypentadeca[1,11,13]trienimino)naphtho[2,1-b]furan-1,11(2H)-dione 21-acetate. 
Its structural formula is: 
Figure 1. Chemical structure of rifampin 
 
6.2 Companion drugs 
6.2.1 Ethambutol 
Ethambutol (EMB) is an ethylenediimino derivative of butanol that interferes with cell wall synthesis in 
mycobacteria; other bacteria are uniformly resistant to EMB. EMB’s primary contribution to anti-TB 
Page 95 of 207  AJRCCM Articles in Press. Published on 29-June-2018 as 10.1164/rccm.201712-2524OC 
 Copyright © 2018 by the American Thoracic Society 
DMID Protocol 11-0050  V7.0 September 25, 2014 
 
45 
 
treatment is to prevent the emergence of drug resistant strains. EMB has no sterilizing activity at 
clinically-tolerated doses.98 
6.2.2 Isoniazid 
Isoniazid (INH) is the hydrazide of isonicotinic acid and is one of the primary drugs for tuberculosis 
treatment. Its spectrum of activity is limited to the mycobacteria of the M. tuberculosis complex; it is 
bactericidal for rapidly replicating organisms and bacteriostatic for dormant bacilli. INH is thought to act 
by inhibiting biosynthesis of mycolic acids, which are a component of the mycobacterial cell wall.  
6.2.3 Pyrazinamide 
Pyrazinamide (PZA) is an analog of nicotinamide and has unique activity against M. tuberculosis. In 
liquid culture media, PZA has little activity except at low pH. However, in animal models and in the 
treatment of human tuberculosis PZA has unique sterilizing activity; its addition to the multidrug regimen 
permitted treatment duration to be decreased from 9 months to 6 months, when used in conjunction with 
RIF. The mechanism of action of pyrazinamide remains unknown. 
6.2.4 Placebo 
The scarlet 150 mg placebo capsules contains, as inactive ingredients: corn starch, D&C Red No. 28, 
FD&C Blue No. 1, FD&C Red No. 40, gelatin, magnesium stearate, and titanium dioxide. 
6.3 Adjunctive therapies 
6.3.1 Pyridoxine 
Pyridoxine is a member of the water soluble B vitamin group. Vitamin B6, or pyridoxine, is active in the 
metabolism of proteins, carbohydrates and fats. It is also a necessary part of hemoglobin synthesis. B6 
deficiency results in retarded growth and a peripheral neuropathy. All patients will receive 50 mg of 
pyridoxine three times per week during the study’s intensive and continuation phase.  
6.4 Acquisition of Study Drugs 
Study drug and placebo will be donated by Sanofi aventis, 82 Ave Raspail, 94256 Gentilly Cedex, 
FRANCE. Companion drugs (FDCs) and pyridoxine  will be purchased from MacLeod pharmaceuticals.  
6.4.1 Quality Assurance of Study Drugs 
The study will be performed under US FDA IND (#106635). The study drug is approved by a stringent 
regulatory authority (EMA). MacLeod, the company from which companion FDC tablets will be 
procured, has been pre-qualified by the World Health Organization’s Global Drug Facility.  
6.4.2 Formulation, Packaging, and Labeling 
In the intensive phase of treatment, Rifadin and placebo will be supplied in blister packs of 14 150-mg 
blue and scarlet capsules. Standard Rifadin doses and companion drugs will be supplied in FDCs. 
Pyridoxine will be supplied in bottles containing 6 50-mg tablets.  
In the continuation phase of treatment, Rifadin will be supplied in blister packs of 12 150-mg blue and 
scarlet capsules. Isoniazid will be supplied in bottles containing 100 mg tablets, the number of tablets in 
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each bottle will be according to patient’s weight band. Pyridoxine will be supplied in bottles containing 
12 50-mg tablets.  
 Package inserts for Rifadin, FDCs, and pyridoxine are included in section 17.5. 
6.4.3 Product Storage and Stability 
Rifadin and companion drugs should be kept tightly closed, in a dry place, away from excessive heat 
according to the manufacturer’. The storage facility will be kept locked. Access to the storage facility will 
be limited to the study pharmacy team. Visitors to the facility will be recorded in a study log. Lastly, 
inventory will be controlled and logged by pharmacy staff. 
6.5 Dosage, Preparation and Administration of Investigational Product 
To simplify treatment administration, companion drugs will be administered in FDCs. Since all FDCs 
contain RIF, participants will receive standard weight-based dosing of FDCs, including RIF at 
approximately 10 mg/kg (maximum of 750 mg in >70 kg participants, per FDC package). In the 
intervention groups, this will be supplemented by loose capsules of 150 mg each to reach doses of 
approximately 15 (maximum of 1200 mg in >70 kg participants) or 20 mg/kg (maximum of 1500 mg in 
>70 kg participants). Participants in the control group will receive placebos in numbers to match the 
active capsules received by intervention subjects in the same weight band (see Table 5). All 
administration will be oral and directly observed, once daily, seven days/week, for eight weeks. 
 
  
Table 5 Dosing of RIF by treatment arm and baseline weight 
r=150 mg RIF 
p=150 mg placebo 
Control group Intervention 1 Intervention 2 
Weight 
bands 
# of 
FDCs 
RIF from 
FDCs 
# RIF & 
placebo 
Total 
RIF 
# RIF & 
placebo 
Total 
RIF 
# RIF & 
placebo 
Total 
RIF 
30-37 2 300 0r + 2p 300 1r + 1p 450 2r + 0p 600 
38-54 3 450 0r + 2p 450 1r + 1p 600 2r + 0p 750 
55-70 4 600 0r + 4p 600 2r + 2p 900 4r + 0p 1200 
>70                                                                                          5 750 0r + 5p 750 3r + 2p 1200 5r + 0p 1500 
6.5.1 Modification of Investigational Product for a Participant 
Certain events or conditions may necessitate modification or temporary or permanent discontinuation of 
the study medication. Patients who experience such events or conditions, however, will still be "on study" 
and will be followed until study completion. Any patient for whom the study medication is temporarily 
discontinued will be restarted on study medication as soon as possible as their clinical condition dictates. 
Study regimens will be discontinued and non-study regimens will be used with continued study follow-up 
for patients in whom treatment-emergent drug toxicity warrants discontinuation of study therapy and for 
patients who become pregnant. If study drugs are permanently discontinued, further antituberculosis 
therapy may be administered at the local clinical investigator's discretion in coordination with the local 
TB program. These patients will be followed in the study for a maximum of 6 months of TB treatment, 
according to the guidelines and time-points established in the protocol, starting from the date of initiation 
of HIRIF intensive phase treatment.  
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6.5.1.1 Criteria for temporary discontinuation of study drugs 
x Any clinical AE or laboratory abnormality that, depending on its nature and severity, requires 
temporary discontinuation of the study drugs until the toxicity resolves as indicated in the 
subsequent section describing adverse event management (Section 9.2.3). 
x An intercurrent illness, other medical condition or situation occurs such that continued 
administration of study drugs and/or participation in the study would not be in the best interest of 
the subject. 
x Development of any exclusion criteria may be cause for discontinuation. 
6.5.1.2 Criteria for permanent discontinuation of study therapy 
x Development of a toxicity that warrants permanent discontinuation of any study drug (refer to 
section 9.2.3). 
x The patient refuses further therapy or withdraws for any reason. 
x It is the investigator's judgment that it is no longer in the best interest of the patient to continue 
study therapy. 
x Termination of the study. 
If a patient refuses further therapy or withdraws consent for treatment under the protocol, the patient will 
be treated with a non-study regimen. If the patient has withdrawn consent, all follow-up will stop. 
6.6 Accountability Procedures for the Investigational Product 
The investigator will acknowledge receipt of the study drug, companion drugs, and matching placebos. 
The study pharmacist will maintain inventory of the study drug, companion drugs and matching placebos. 
Study staff has the responsibility to assure that study drugs are dispensed to patients in compliance with 
the protocol.  
6.7 Assessment of Subject Compliance with Investigational Product 
Administration of all doses of study and companion drugs will be supervised by study staff during the 
intensive and continuation phases. . Delivery of study medications may occur in the health center, 
hospital, or a place convenient to the subject (home, place of work). The decision will be made jointly 
between subjects and treatment supervisors. Adherence to study drug and companion drugs will be 
assessed and captured on a case report form (CRF) at visits where used drug supply is returned and new 
drug supply is dispensed. 
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6.8 Concomitant Medications/Treatments 
Companion drugs will also be administered orally in FDC once daily, seven days/week for eight weeks. 
Standard weight-based dosing will be used (as illustrated in Table 6).  Additionally, all patients will 
receive 50 mg of Pyridoxine three times per week.    
Table 6  Doses of companion medications during the intensive phase 
Drug Dose for daily therapy 
Isoniazid  
 30-37 kg 150 mg 
 38-54 kg 225 mg 
 55-70 kg 300 mg 
 > 70 kg 375 mg 
Pyrazinamide  
 30-37 kg 800 mg 
 38-54 kg 1200 mg 
 55-70 kg 1600 mg 
 > 70 kg 2000 mg 
Ethambutol  
 30-37 kg 550 mg 
 38-54 kg 825 mg 
 55-70 kg 1100 mg 
 > 70 kg 1375 mg 
 
In the continuation phase, all patients will receive 4 months (18 weeks) of RIF 10 mg/kg/day and INH 10 
mg/kg/day thrice weekly according to WHO guidelines. For RIF, patients weighing 30-37 kg will receive 
no more than 300 mg/day. Patients weighing 38-49 kg will receive a maximum of 450 mg/day, and 
patients weighing >=50 kg are not to exceed 600 mg/day.  
 
For INH, patients weighing 30-39 kg will receive no more than 300 mg/day. Patients weighing 40-49 kg 
will receive a maximum of 400 mg/day, patients weighing 50-59 kg will receive a maximum of 500 
mg/day, patients weighing 60-69 kg will receive a maximum of 600 mg/day, and patients weighing =>70 
kg are not to exceed 700 mg/day. 
 
In the continuation phase, patients will also receive 50 mg of Pyridoxine three times per week.  
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7.0  STUDY SCHEDULE 
This is summarized in the Schedule of Events (Figure 2) and detailed below. 
7.1 Screening/Enrollment 
7.1.1 Screening for eligibility, day -3 to 0 
Any patient presenting to a participating health center with at least one positive sputum smear (>=2+) will 
be asked by health center staff about their interest in participating. Study personnel will then explain the 
study, including the screening process. The patient will receive a consent form and be encouraged to 
consider participation in consultation with family. No more than 48 hours after study staff becomes aware 
of a positive sputum smear result (>=2+), study personnel will regain contact with the prospective 
participant. Those willing to participate will be consented by a study physician. If the patient consents, the 
following screening procedures will be implemented beginning on screening day-3. 
1. Record demographics including age (Confirm 60>= age >=18 years), gender, and race. 
2. Complete physical exam including neurologic assessment, weight, vitals, Karnofsky assessment; 
rule out extrapulmonary TB through clinical screening. 
3. Complete medical history and concomitant medication review per checklist. 
4. HIV screening according to the National Health Guidelines for the TB control in Peru.  Potential 
participants found to be HIV positive will receive a facilitated referral to the National STD 
HIV/AIDS program for confirmatory testing and treatment.  
 
5. Collect 1 sputum sample for smear, and if positive (>1+) HAIN test, and culture. Results of 
HAIN test must be available before initiation of study therapy. The strain isolated from this 
specimen will also be used for MIC measurement. 
6. Perform posterior-anterior chest x-ray; rule out miliary TB, pleural or pericardial involvement. If 
a chest x-ray has been performed and documented within 2 weeks prior to enrollment, and is 
made available by the patient to the study, and is of quality judged to be adequate by a site PI or 
Sub-I, it will be used in lieu of a new x-ray. This will reduce participant exposure to radiation. 
7. Draw blood samples (approximately 10 ml) for hematology (CBC with differential), biochemistry 
(LFTs, albumin, alkaline phosphatase), creatinine, HbA1c, Hepatitis B & C serology and serum 
pregnancy tests (if female). Results must be available before initiation of study therapy. Any 
abnormal results, which do not meet the threshold for exclusion, will be recorded as baseline 
findings. A portion of the blood sample collected on day -3 will be saved for pharmacogenetic 
testing, which will be performed only on samples from patients who meet all inclusion criteria.
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Figure 2. Schedule of Events 
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Notes:  
 
‘1’ indicates procedures in which only sputum collection Group 1 will take part. 
‘2’ indicates procedures in which only sputum collection Group 2 will take part.  
‘X’ indicates procedures in which all study participants will take part. 
                                                          
1The elements listed here are for early termination during the continuation phase. If early termination occurs during the intensive phase, the visit should include the procedures 
listed as well as chest x-ray; complete blood count, blood chemistry; visual acuity and color vision testing; and urinalysis. 
2 All participants will also receive integrated care, according to National TB Guidelines, including a psychological, nutritional and social work evaluation. Patients with diabetes 
will also have an evaluation with an endocrinologist who will determine diabetes management and follow-up. 
3 Visit 4 can take place anytime between Day 3 and Day 7. However, Visit 4 sputum collection should not fall on the night immediately succeeding the sputum collection for Visit 
3, i.e., for a given participant, there should be at least one night with no collection between Visit 3 and Visit 4 overnight collections 
4 Can take place between days 8-10. 
5 Can take place between days 9-11. 
6 Patients who had one or more of the study drugs suspended and then returned to full dose, may have until treatment day 72 to complete the intensive phase of the study. 
7 MGIT culture and quantitative culture will be performed on all overnight, pooled samples. 
8 In addition to quantitative culture, samples will be used for MIC. 
9 Overnight pooled sputum collections for groups 1 and 2 at Visit 3 can take place on either Day 1 or Day 2.  
10 Can take place between days 14-16. 
11 Can take place between days 26-30. 
12 Can take place between days 40-44. 
13 Can take place between days 54-66. 
14 One sample is collected. HAIN test will be performed on positive smears. Specimens with M. tuberculosis sensitive to RIF and INH on HAIN will be cultured on L.J. medium. 
A subculture will be plated in Middlebrook and used to measure minimum inhibitory concentrations. 
15 Store samples to be used for LipTox 
16 Two samples should be collected for smear microscopy 
17 DST will be performed only if sensitive to H and R on HAIN test; DST to be performed in MGIT 
18 DST will be performed only on the first culture that is positive, at or after Month 4 and continuing through Month 12. 
19 PK visit will take place the morning following the fifth overnight sputum collection visit, on day 15th or 29th  
20 These procedures will only be done, in addition to those listed, if early termination occurs during the intensive phase 
21 AST, ALT, ALP, bilirubin, albumin. 
22 Repeated in case of reported loss of visual acuity or color vision. 
23 Pharmacogenetic testing will be performed on blood collected at study visit 1, only among those who meet all study inclusion criteria after screening is completed.  
24 Includes review of concomitant medications, signs and symptoms that might have appeared since last visit, according to body organ and system.   
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7.1.2 Pre-Dosing/treatment initiation 
The initiation visit should begin no more than 3 days after pre-screening, among those established as 
eligible.  
Pre-dosing, day 0 (visit 2): 
Procedures or activities not completed during the screening visit will be completed on this day.  
One overnight, pooled sputum sample collection begins at the pre-dosing visit and ends the next day, on 
study treatment initiation day.  
Conventional susceptibility testing to confirm rapid INH & RIF sensitivity, as well as to test susceptibility 
to PZA & EMB, will be performed in MGIT on the strain isolated from this first overnight sputum 
sample. In case this sample is not adequate we will use the morning sputum sample.  
Treatment initiation, day 1 (visit 3): 
The following activities will take place:  
1. Measurement of vital signs: heart rate, blood pressure, respiratory rate, and weight, and height.  
2. Complete Snellen visual acuity examination & Ishihara color test. 
3. Urinalysis (proteinuria). 
4. Toxicity counseling and counseling on potential failure of hormonal contraception and alternative 
methods. The study will provide subjects with condoms and spermicide to avoid pregnancy 
among female participants.  
5. All participants will receive standard integrated care, according to National TB Guidelines, 
including a psychological, nutritional, and social work evaluation. Patients with diabetes will also 
have an evaluation with an endocrinologist who will determine the patients’ corresponding 
diabetes management and follow-up.  
6. Review of inclusion and exclusion criteria.  
7. Randomization assignments will be made to: treatment group (1:1:1); PK group (sparse or 
intensive sampling, 2:1); and pooled sputum sample collection schedule (1:1).  
8. First dose of treatment 
9. 2-week supply of study medication and companion drugs will be provided at treatment initiation. 
A log will be maintained of persons who are eligible but do not initiate study treatment. 
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7.2 On-treatment 
7.2.1 Intensive Phase 
7.2.1.1 Treatment support 
Study DOT supervisors will be trained nursing assistants or lay workers with commensurate experience. 
They will be trained in GCP, including for the administration of anti-TB medication and in triage for 
signs or symptoms of adverse events. They will observe administration of treatment daily, in the patient’s 
home, health center, or other elected location. DOT supervisors will record dose administration in the 
Treatment Supervision Card. Supervisors will be in daily contact with study nurses and will report any 
signs or symptoms of toxicity to study nurses, who will determine if an unscheduled visit is necessary. 
7.2.1.2 Clinical and laboratory follow-up 
1. Visit at week 1 will include an interval medical history as well as Adverse Event & Treatment 
adherence assessment. Participants will be asked about what medications they have been taking 
and if they have had any illnesses since the last visit. 
2. Visits at weeks 2, 4, & 6 will comprise an interval medical history, physical and neurological 
exam, including vital signs and weight. Study participants will also receive a new supply of 
medications for the subsequent 2 weeks, according to weight band and treatment assignment. All 
doses will be supervised by DOT supervisors. Participants will be asked about what medications 
they have been taking and if they have had any illnesses since the last visit. Adherence to study 
medications since the previous visit will be documented.  
3. Additionally, visits at weeks 2 & 4 will comprise of the drawing of blood samples for CBC with 
differential and chemistry (AST, ALT, ALP, bilirubin, albumin). Creatinine will be measured at 
week 4. Any new abnormal findings, or changes from baseline, will be considered AEs: they will 
be graded, assessed for relation to study drug, determined as expected or unexpected, and 
reported according to regulatory requirements. 
4. Week 6 visit will comprise a complete physical and neurological exam, including weight, vital 
signs and interval medical history. Participants will be asked about what medications they have 
been taking and if they have had any illnesses since the last visit. Blood draw for chemistry will 
be performed. 
These visits should occur within 2 days (before or after) the actual week’s end. 
7.2.1.3 Bacteriologic follow-up 
As noted above, participants will be assigned randomly to one of two pooled sputum collection schedules. 
Dividing the participants into two groups, each providing ½ the required samples, permits optimization of 
the number of time points at which bacteriologic specimens will be available, while reducing the burden 
on study participants. Half the participants in each study arm will be assigned to each sample schedule. 
This is illustrated in Table 7, where an “X” denotes that participants in the specified sputum collection 
group will provide an overnight pooled sputum sample beginning on the specified day at one of the 
inpatient clinical research facilities (the TB ward at either Hospital Nacional Hipólito Unanue or Hospital 
Sergio E. Bernales in Lima) or at the participant’s home. All overnight sample collections will be 
supervised by a DOT supervisor or study nurse. The sample will be used for assessment of microbiologic 
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endpoints. On certain days, as noted in the Schedule of Events (Figure 2) an additional early-morning 
sputum sample will be required for smear microscopy and LJ culture.  
Sputum will not be induced in cases when spontaneous expectoration is not successful. This is not 
standard practice in the study site, nor has induction been used in published SSCC studies. Moreover, the 
accuracy of calculation of CFU decline is unlikely to be compromised by a few, inevitable missing 
results. Information from all pooled sputum samples from all participants will be used to calculate decline 
in colony forming units. Plans for missing bacteriologic data are detailed in the analysis section. 
Table 7  Overnight, pooled sputum collection suggested schedule by assigned group 
Treatment Day1 0 1 2 3 7 82 92 142 283 423 563 
Visit Number 2 3 4 5 6 7 8 9 
Sample # 1 2 3 4 5 6 
Group 1 x x  x  x  x  x  
Group 2 x  x  x  x  x  x 
 
7.2.1.4 Pharmacokinetics, [d13-56] 
After no fewer than 13 and no more than 56 (including 3 consecutive daily) doses of RIF and companion 
drugs administered by DOT, patients will be admitted to a study research center for PK sampling. The 
preference is to draw the PK blood samples at the 5th overnight sputum sample collection in order to 
minimize the number of patient visits. PK sampling, however, may occur anytime between treatment days 
14 and 56. 
 
Participants will arrive at the clinical research center the night before the scheduled draw. Participants 
will be weighed; urine and sputum samples will be collected, and vital signs measured. In the morning, a 
standard breakfast will be provided for all subjects no less than 4 hours prior to or 2 hours after treatment 
administration (details will be provided in the PK procedures).  
Study treatment will be administered and observed in the clinical research center with time of dosing 
recorded on the patient’s medical record. Subjects will abstain from eating (may drink water) for 2 hours 
after the time of treatment administration. 
Similar to the bacteriology scheme, efficiencies in sampling are being achieved by randomly assigning 
participants within arms to two groups, 2:1 sparse to intensive sampling. Subjects randomized to the 
sparse sampling scheme (2/3 of participants) will have blood samples drawn for PK at the following fixed 
time points: 0, 120, and 360 minutes after dosing (10 ml at each time point). 
Subjects randomized to the intensive sampling scheme will have blood samples drawn for PK at any time 
during the following sampling windows 0, 15-45 mins, 45-75 mins, 75-105 mins, 105-135 mins, 345-375 
mins, and 825-855 mins after dosing (10 ml at each time point). 
Further details about PK sampling can be found in section 8.3.1. 
                                                          
1 Sputum collection will be completed on the day specified in the table, having started the night before.  
2 Window: Up to 2 days after. 
3 Window: Up to 2 days before or 2 days after. 
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7.2.2 End of intensive phase study visit 
The end of the intensive phase of therapy is defined by number of doses (56) and should be completed no 
later than treatment day 64. Patients who had one or more of the study drugs suspended and then 
returned to full dose, may have until treatment day 72 to complete the intensive phase of the study. The 
end of intensive phase study visit will comprise a physical exam, including weight, vital signs, Karnofsky 
assessment. A neurological exam will be performed to monitor for peripheral neuropathy. Chest 
radiograph will be performed. Blood samples will be drawn for HIV testing, CBC with differential, blood 
chemistry, and creatinine, visual acuity and color vision testing will be repeated, as will urinalysis. 
Patients will be asked as part of the interval medical history about what medications they have been 
taking and if they have had any illnesses since the last visit. Any new abnormal findings, or changes from 
baseline, will be considered AEs: they will be graded, assessed for relation to study drug, determined as 
expected or unexpected, and reported according to regulatory requirements. Adherence to study 
medications since the previous visit will be documented. A new 1-month supply of study medication will 
also be given.  
In addition, two sputum specimens will be obtained to assess sputum-culture and -smear conversion. 
These specimens must be obtained on the day of completing the intensive phase of therapy or up to one 
week after completion, but before more than one dose of continuation therapy has been given. The two 
sputum specimens can be obtained on the same day; at least one should be early morning. 
7.2.3 Continuation Phase 
7.2.3.1 Clinical and laboratory follow-up 
Patients will have study visits 3, 4, 5, and 6 months after treatment initiation (these should occur within 
one week of the target date). They will comprise a physical exam, including weight and vital signs, and 
interval medical history. At each study visit during the continuation phase of therapy, patients will be 
asked what medications they have been taking and if they have had any illnesses since the last visit. At 
each of these visits, participants will have their adherence to study medications since the previous visit 
documented. At months 3, 4, and 5, participants will receive a new supply of medication. 
Patients will be assessed for delayed toxicity from the intensive phase of therapy. This will consist of a 
symptom-driven examination. Laboratory testing will be at the discretion of the lead study clinician. At 
the 3-month visit, any new abnormal findings, or changes from baseline, will be considered AEs: they 
will be graded, assessed for relation to study drug, determined as expected or unexpected, and reported 
according to regulatory requirements. 
7.2.3.2 Bacteriology 
An early morning sputum sample will be obtained at 3, 4, 5, and 6 months for smear microscopy and LJ 
culture (samples must be taken no less than 26 days and no more than 35 days after the previous sample). 
A sputum sample will be defined as unobtainable (and negative for analytic purposes of the binary 
endpoints) if no sputum can be obtained. 
Repeat DST will be done only on the first positive culture occurring at or after the 4- month visit. Patients 
with resistant isolates will be referred for alternative treatment according to local protocol. These patients 
will be included in PK, efficacy, & safety analyses. All patients with positive bacteriology at month 5 or 6 
will be assigned outcomes of treatment failure.  
Page 108 of 207 AJRCCM Articles in Press. Published on 29-June-2018 as 10.1164/rccm.201712-2524OC 
 Copyright © 2018 by the American Thoracic Society 
DMID Protocol 11-0050  V7.0 September 25, 2014 
 
58 
 
The continuation phase will end after 54 doses of continuation-phase therapy have been administered. 
The final on-treatment bacteriology and clinical visits will occur no later than one week after treatment 
has been completed.  
7.2.4 Follow-up period 
At months 9 & 12 (visits to occur not less than 12 weeks or more than 16 weeks after the prior visit) 
follow-up visits will be made. Visits will comprise a physical exam, including weight, vital signs, and 
medical history. 
Patients will have an assessment for delayed toxicity from the intensive phase of therapy. This will 
consist of a symptom-driven examination. Laboratory testing will be at the discretion of the clinical 
investigators. Patients will be screened for active tuberculosis, based on signs and symptoms. Early 
morning sputum samples will be collected for sputum smear microscopy and culture in solid medium. 
Repeat DST will be done only on the first positive culture occurring during follow up. Patients with 
resistant isolates will be referred for alternative treatment according to local protocol. Positive 
bacteriology in the follow-up period will result in classification of treatment outcome as recurrence. 
Molecular fingerprinting will be performed on the recurrent isolate to compare to the baseline isolate. 
Patients will be asked about what medications they have been taking and if they have had any illnesses 
since the last visit. 
7.3 Final Study Visit 
The visit at month 12, or no more than 30 weeks after treatment completion, will represent the final study 
visit. This will comprise physical exam with: weight, vital signs, Karnofsky assessment, and interval 
medical history. Two early-morning sputum samples will also be collected and tested by smear 
microscopy and culture in solid medium. Repeat DST will be done on any culture, newly positive for M. 
tuberculosis (i.e., negative throughout the follow-up period, but positive at final visit). Patients with 
resistant isolates will be referred for alternative treatment according to local protocol. Positive 
bacteriology at the final study visit will result in classification of treatment outcome as recurrence. 
Molecular fingerprinting will be performed on the recurrent isolate to compare to the baseline isolate. 
7.4 Early Termination Visit 
If termination occurs during the continuation phase, then the early termination visit will include the 
following: 
Physical exam, weight, vital signs, Karnofsky assessment, assessment of adverse events, and interval 
medical history (inquiry about what medications they have been taking and if they have had any illnesses 
since the previous visit) will be performed. Two early-morning sputum samples will also be collected for 
smear microscopy and culture on LJ. Repeat DST will be done on any culture, newly positive for M. 
tuberculosis (i.e., negative throughout the continuation period, but positive at early termination visit). 
Patients with resistant isolates will be referred for alternative treatment according to local protocol. 
Positive bacteriology at the final study visit will result in classification of treatment outcome as 
recurrence. Molecular fingerprinting will be performed on the recurrent isolate to compare to the baseline 
isolate. 
If termination occurs during the intensive phase, then the visit will include the elements described above 
as well as: chest x-ray, complete blood count, blood chemistry; visual acuity and color vision testing; and 
urinalysis.  
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7.5 Unscheduled Visit 
Unscheduled visits in patient homes, health centers, or research centers may occur for the following 
reasons, among others: adverse events occurring between scheduled study visits, patient perception of 
non-response to study medication, difficulty with adherence. Follow up AE/SAE management procedures 
are detailed in sections 9.2.3 and 9.5.  
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8.0 STUDY PROCEDURES/EVALUATIONS 
8.1 Clinical Evaluations 
Study DOT supervisors will accompany study participants at all study visits.  
Medical history will be obtained from patient interview with research center staff at initial screening. 
History will involve establishing occurrence and timing of any prior TB disease. Questioning will 
ascertain history of all medications taken, including anti-TB drugs. Prospective participants will be asked 
if they are currently taking any of the drugs in Table 2 (list of contraindicated medications) or if they have 
previously taken any treatments that would indicate underlying disease, which precludes participation. 
Interview will inquire about HIV testing/status, pregnancy, breastfeeding, and other conditions that could 
result in ineligibility (i.e., pulmonary silicosis, chronic gastro-intestinal disease, liver disease, 
uncontrolled Diabetes Mellitus or renal disease), alcohol or drug abuse. Karnofsky evaluation will also be 
performed. 
Physical examination will comprise: vital signs (measurement of blood pressure, respiratory rate, 
temperature, peripheral pulse), height (only at treatment initiation visit) and weight and review of organ 
systems (respiratory, cardiovascular, gastro-intestinal, musculoskeletal, neurologic).  
Interval histories will ascertain history of medications taken since last history, including anti-TB drugs, 
and any adverse events experienced. Where possible, identification of the causative agent will be 
attempted. Participants will be asked if they are currently taking any of the drugs in Table 2 (list of 
contraindicated medications). Interview will inquire about pregnancy, breastfeeding, and other conditions 
that would result in ineligibility, as well as about alcohol or drug abuse. 
Counseling procedures. Study participants will be advised by study nurses of the importance of 
completing all doses of treatment, in spite of mild discomforts. They will be informed by study nurses of 
possible adverse events (dizziness, somnolence, joint pain, pruritis, erythema, discoloration of urine, 
tears, perspiration; increased appetite, anorexia/hyporexia, nausea/vomiting, abdominal pain, jaundice). 
Symptoms reported at the time of supervised treatment will be recorded and managed according to 
protocol section 9.2.3. 
8.2 Laboratory Evaluations 
8.2.1 Hematology and chemistry 
Hematology will include complete blood count with differential, including platelets. Chemistry tests will 
comprise a full liver profile including AST, ALT, ALP, bilirubin, and albumin. These will provide lab 
values to assess the development of important adverse events--hepatotoxicity, thrombocytopenia, 
leucopenia--which may be associated with high-dose RIF. 
At baseline, samples will be taken also for HbA1c, ß-HCG, and creatinine; potential participants with 
uncontrolled diabetes (HbA1c>7.5), creatinine clearance <60mL/min, or who are pregnant will be 
excluded. Hepatitis B&C serology will be performed on a blood sample collected at the screening visit. 
Those patients with positive HBVsAg or HCVAb will be excluded from study participation. 
During the whole study, we will collect approximately 80 to 120 mL of blood from study participants. 
Biochemistry and hematology assays will be performed at a private, clinical research lab in Lima, Peru. 
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8.2.2 Bacteriology 
Bacteriology procedures are summarized here. All study microbiology procedures will conform to 
standards specified by the Clinical Laboratory Standards Institute. 
8.2.2.1 Serial sputum colony counts and days to positivity 
Pooled sputum samples will be collected from all patients at 6 time points during the intensive phase of 
treatment (as specified in Table 7). Patients will be in a hospital research center or supervised in their 
home overnight for approximately 12 hours, assisted by a study nurse or nursing assistant, to provide 
continuous sputum samples in sterile wide-mouthed plastic container (honey jar approximately 200-250 
ml volume container) and stored on ice for the duration of the collection. Although attention will be paid 
to assure the quality and quantity of samples (as described in lab procedures), there will be no minimum 
sample volume requirement.  
Samples will be transported by study staff to the bacteriology lab. Transport will require maintenance of 
the cold chain with an insulated pack and ice, which are separated from the specimen by a divider.  
Processing and testing will be performed in the BSL 3 lab, using at least BSL 2 practices and procedures. 
Samples will be divided into three parts for “standard” & decontaminated plating in 7H11 medium and 
for MGIT culture. There is no minimum sputum sample size required for processing. After the 1st part is 
taken, there may be smaller quantities left for the 2nd & 3rd methods (especially later in treatment, when 
sputum production is often low). To assure that the smallest amounts are not always used for the same 
method, the order of assignment of parts to each microbiologic assay will be randomized according to the 
sputum sample distribution procedure. 
A sample of sputum specimens will be sent to SGUL on not more than 4 occasions to check SSCC 
enumerations of viable colony counts. No more than 50 specimens of 1 ml each—from sputum samples 
of at least 3 ml volume—will be shipped for this purpose. The technique used at SGUL will be the same 
as is used in the Lima study lab. 
8.2.2.2 Smear, culture, sensitivity tests, and RIF MICs 
Smear, culture, and sensitivity testing will be performed at the intervals specified in the schedule of 
events, Figure 2 and section 7.0. All of these assays will be performed at the dedicated study lab in Lima. 
i. Direct smear examination (DSE) 
 
At each sampling point, participants will provide an early-morning sputum sample. Direct smear 
examination (DSE) will be performed on all sputum specimens. These include use of new slides; with 
approximately 10μl-30μl of sputum spread over an area of 2 cm by 1cm. Sputum will be dried and 
fixed (avoiding excessive heat). Staining will be either Ziehl Neelsen or Auramine and examined as 
quickly as possible after staining, rinsing, and air-drying. Auramine-stained slides will be read first by 
fluorescence examination with a 25X objective. Situations may require confirmation by Ziehl-
Neelsen (100X objective) or a second reader. Semi-quantitative results will be recorded. 
ii. Mycobacterial culture in solid medium 
 
Samples will be cultured on LJ slopes in the BSL 3 lab, using at least BSL 2 practices and procedures. 
Sputum will be digested and decontaminated using NALC-NaOH, with exposure to decontaminant 
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limited to avoid killing mycobacteria. The specimen will be centrifuged, the supernatant decanted, 
and the sediment neutralized prior to inoculation on the medium. All cultures will be examined 72 
hours after inoculation to detect contaminants; thereafter, cultures will be examined weekly for 8 
weeks. Growth rate determination and colony morphology will be used as well as the niacin test for 
identification of mycobacteria. Semi-quantitative results will be reported. 
iii. RIF MICs 
RIF MICs will be measured in positive cultures grown on 7H11 medium from the pre-treatment 
sputum specimen. This will be performed at the SES microbiology lab either immediately after 
collection or in batches, after storage at -70 Celsius. The 7H11 medium has been selected for SSCC 
and MICs as it contains enzymatic casein hydrolysate, which promotes the growth of a few strains of 
M. tuberculosis that grow with difficulty or not at all on 7H10.99 Performing the assay on two samples 
permits distinction between intra- and inter-patient variability in RIF MICs. MIC will be measured by 
inoculating each strain of M. tuberculosis onto sectors of 7H11 agar medium in a series of 10 plates, 
containing the concentrations of RIF specified in Table 8. 
Table 8  Concentrations of rifampin in plates with their log values 
Plate 
No 
RIF 
µg/ml 
Log 
RIF 
1 0.000  
2 0.088 -1.054 
3 0.125 -0.903 
4 0.177 -0.753 
5 0.250 -0.602 
6 0.354 -0.452 
7 0.500 -0.301 
8 0.707 -0.151 
9 1.000 0.000 
10 1.414 0.151 
 
The plates will be divided into sections (8 or fewer) to permit testing of multiple specimens on a single 
day. Plates will be incubated for 4 weeks in the incubator and classified as growth or no growth. Plates 
will be reviewed from highest to lowest RIF concentrations and the concentration of the last slope with no 
growth will be the minimum inhibitory concentration. 
8.2.3 Drug susceptibility testing (DST) 
HAIN GenoType MTBDR assay (line-probe assay) will be used for rapid detection of MDR-TB at 
baseline (according to the directions of the manufacturer). Indirect DST methods will be used to confirm 
results of the HAIN test and evaluate resistance to ethambutol and pyrazinamide. Testing will be 
performed in the BACTEC960 MGIT system with the SIRE kit (one each lyophilized vials of 
streptomycin, isoniazid, rifampin and ethambutol and eight vials of SIRE supplement and the PZA kit). 
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Using aseptic techniques and specified quantities, each drug will be reconstituted into stock solution. 
Inocula will be prepared from pure cultures of M. tuberculosis and suspended in Middlebrook 7H9 
medium. The suspension will be vortexed and adjusted, ultimately, to ≥0.5 McFarland Standard for 
turbidity and then diluted (1:5). All MGIT DSTs will be performed with a growth control. Check for 
bacterial contamination will be performed at 48 hours; testing will be repeated if growth on blood agar is 
detected. The BACTEC 960 MGIT will monitor the tests until a result is determined.  
A sample of 15% of pretreatment cultures will be sent to SGUL for quality control of DST. Samples will 
be stored at the SES study lab until a sufficient number has accumulated to fill a biohazard shipping box. 
Shipments will be sent with cold bags at -70°C to SGUL until 15% (27 cultures) have been evaluated. If 
quality problems are detected, improvements will be implemented and the process will be repeated. 
At SGUL, DSTs in liquid medium will be set up in the BactAlert system using a single bottle for each 
drug known in this system to be the optimal break point and growth will be monitored in this bottle as an 
indication of resistance. This program will require bottles containing the critical concentration for 
isoniazid, rifampin and ethambutol together with a drug-free control bottle.  
DSTs in Middlebrook 7H11 will also be set up on each culture using the standard British Medical 
Research Council method. In addition pyrazinamide susceptibility will be tested by the Brander method at 
pH 7.0 on slopes containing 500, 1000 and 2000 µg/ml nicotinamide.100 Additional tests for pyrazinamide 
will be carried out on acid LJ medium. Amidase activity will be tested with an ammonium ion electrode. 
8.3 Special Assays or Procedures 
8.3.1 PK Sampling 
After no fewer than 13 days of RIF and companion drugs administered by DOT, patients will be admitted 
to one of the study research centers. The preference is to draw the PK blood sample at the 5th overnight 
sputum sample collection in order minimize the number of patient visits. PK sampling may be scheduled, 
however, on any single day between treatment day 14 and day 56, with > 3 prior doses administered on 
consecutive days prior to sampling.  
At the study research center, participants will be interviewed to obtain additional information about recent 
weight loss or weight gain, concomitant medications on the day prior to and the days of PK sampling, and 
gastrointestinal symptoms. Each participant will be weighed and their vital signs recorded. Urinalysis will 
be performed (proteinuria) and sputum samples will be collected for the LipTox Red substudy. 
Participants will be observed to abstain from food for four hours prior to and for two hours after drug 
administration on the day of PK sampling. Water will be allowed, as desired. A small bore intravenous 
cannula will be inserted aseptically into a forearm vein, secured and its patency maintained using heparin 
or saline flushes. Baseline blood samples will be collected for PK (10 mL total). Scheduled study 
medication will then be administered according to the participants’ assigned dose.  
120 participants will be randomly selected during the pre-dosing visit for sparse PK sampling. They will 
have two further PK samples, 10 mL at each time point, drawn at 2 and 6 hours after drug administration.  
60 participants will be randomly selected for participation in the intensive PK study. They will have 6 
further samples, 10 mL at each time point, according to an optimized sampling scheme determined from 
existing and pilot data in Peruvian tuberculosis patients. Their baseline sample will be followed by 
samples collected during six sampling windows (15-45 mins, 45-75 mins, 75-105 mins, 105-135 mins 
345-375 mins and 825-855 mins after dosing). 
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8.3.2 Pharmacogenetic testing 
One baseline blood sample will be collected for pharmacogenetic analyses. These specimens will be 
tested for polymorphisms in SLCO1B1 and NAT2, which have been linked to variability in absorption.  If 
different rates of hepatotoxicity are observed among the treatment arms, specimens will be analyzed for 
polymorphisms in NAT1, CYP2E1, and GSTM1, which have been linked to hepatotoxicity in patients 
receiving anti-TB therapy. 
8.3.3 Genotyping 
Baseline M. tuberculosis isolates will be stored frozen at -70°C, labeled with the study identifier number 
and the date of sputum collection. Stored M. tuberculosis isolates will be tested by genotyping methods 
(MIRU-VNTR) in case of recurrent disease among a study participant during the follow-up period.  
8.4 Specimen Preparation, Handling, and Shipping 
We will follow standard procedures for the preparation, handling, and shipping of blood (for PK 
analysis), raw sputum, and frozen sputum and cultures.  
Procedures are summarized here. 
8.4.1 Instructions for Specimen Preparation, Handling and Storage 
8.4.1.1 Bacteriology 
Quality of sputum, as a diagnostic specimen, is dependent on the composition (saliva vs. sputum), degree 
of contamination, and cold chain maintenance. Failure to maintain a cold chain will result in a lower 
culture positivity rate and increased contamination rate. Quality of samples also degrades over time so all 
sputum samples will be used within 72 hours (3 days) of collection. Efforts will be in place to ensure cold 
chain maintenance and biosafety with handling of sputum cups, since mycobacteria are often found on the 
outside of sputum cups. 
Procedures: 
1. After specimen collection, labeling and recording, the specimen will be stored in a refrigerator 
(between 2q and 8qC) as soon as possible.  
2. Measures for quality control will be implemented.  
3. Specimens will be transported in a closed container with ice packs, to maintain the cold chain, 
and transport temperature should be quality controlled.  
4. Specimen tracking forms will accompany specimens, but will be stored separately (to prevent 
contamination). They will be used to assure complete transfer of specimens. 
5. Sputum specimens will be delivered on working days to the microbiology lab, before midday 
when possible. All specimens will be processed, stained, and read as soon as possible, preferably 
within 24 hours of collection. 
6. Cultures (LJ, MGIT, & Middlebrook) and DST will be inoculated as soon as possible, preferably 
within 48 hours of sputum specimen collection. 
7. Isolation of DNA for line-probe assay (HAIN test) will be achieved as soon as possible, 
preferably within 24 hours of collection. 
8. The 15% of pre-treatment cultures to be sent for QA of DST will be frozen at -70C in cryovials 
labeled with patient and specimen IDs in the freezer in the microbiology lab. 
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The microbiology samples that will be stored for potential later or long-term use are: 1) isolated DNA 
from 1 pre-treatment culture used both for molecular typing in case of recurrent disease and for the 
complex infection substudy, and 2) isolated DNA from, and all cultures performed on, 2 on-treatment 
pooled sputum samples for the complex infection substudy. Study participants will be asked to provide 
informed consent specific to storage and use of each of these specimens. 
8.4.1.2 Pharmacokinetics and Pharmacogenomics 
 Procedures: 
1. All PK samples are venous blood drawn into a heparinized collection tubes.  
2. PK samples, after being drawn into 10 ml heparinized tubes and centrifuged, will be placed in ice 
slurry (packed ice & water).  
3. Plasma for each patient at each sampling time point will be pipetted into cryovials and frozen at -
20°C as soon as possible (preferably within 1 hour of the blood draw so that degradation of the 
drug does not occur). The cryovials will then be transported to the SES laboratory where they will 
be stored at a temperature of -70°C.  
4. Labeled plastic EDTA tubes with 2 mL blood sample for pharmacogenetic analysis will be stored 
(unprocessed) in the -70°C freezer with the plasma samples. 
5. Times of specimen collection, processing, and freezing will all be recorded.  
6. Freezers temperature will be monitored and documented. 
 
8.4.2 Specimen Shipment 
Susceptibility testing, SSCC, and other solid and liquid culture bacteriology will be performed at the SES 
microbiology lab; local transport will be effected according to the procedures outlined above.  
For international shipment of specimens, HIRIF will contract with an experienced shipper of 
biohazardous materials. A small number of cultures and sputum specimens will be sent to St George’s, 
University of London; frozen sputum will be sent to Liverpool for the LipTox Red substudy. We will 
have export permits for shipping sputum specimens out of Peru and import permits for receiving them in 
the UK. These specimens are considered biological materials, which require a permit for importation. 
Shipments will contain proper documentation (printed on official letterhead) for the appropriate 
authorities in the UK. Specifically, St. George’s will do the following. 
 
1. A sequential sample of 15% of the patients will have a pretreatment culture tested by a standard 
DST method as a check on the DST methodology. Packages containing not more than 60 ml of 
infective material may be sent as accumulated. They will be sent packed in dry ice to maintain 
temperature, via an experienced shipper of biohazardous materials. 
2. Quality control of CFU counting will be performed on a small (50), non-random sample of 
overnight, pooled sputum specimens at SGUL. Samples containing at least 3 ml of sputum will be 
eligible for use in this quality control. One ml of sputum will be separated and sent with cold bags 
to maintain temperatures between 2 and 8 degrees Celsius, via a commercial, authorized 
biohazard carrier, at four different times during the study. Specimens to be contained in these 
shipments may be refrigerated in a temperature-controlled refrigerator at the microbiology lab for 
up to 1 week prior to shipment. There will be no more than 60 ml of infective material per 
shipment and no more than four shipments. These will be set up by the standard method for 
comparison with the results from the SES microbiology lab. Timing of shipping of PK specimens 
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will be arranged with the Lima site, based on pace of enrollment and sample volumes.  Samples 
will remain frozen at -70C until assayed.  
Divided PK samples (no two samples from a single patient at a single time point will be sent in the 
same package) will be batch shipped to Dr. Charles Peloquin (Infectious Disease Pharmacokinetics 
Laboratory, College of Pharmacy, and Emerging Pathogens Institute University of Florida, 1600 
SW Archer Rd., Rm P4-33, Gainesville, FL 32610-0486) in compliance with relevant Federal and 
International regulations. Shipping labels with the universal biohazard symbol, the address of the 
importer (Dr. Peloquin), the permit number, and the expiration date, are also issued to the importer 
with the permit. The importer must send the labels and one or more copies of the permit to the 
HIRIF site investigators. The permit and labels inform the U.S. Customs Service and U.S. Division 
of Quarantine Personnel of the package contents 
8.4.3 PK Assays: Rifampin, Isoniazid, Pyrazinamide, and Ethambutol 
Validated techniques that have been inspected and approved by the College of American Pathologists 
(CAP) will be used to determine the plasma drug concentrations of the 4 drugs, as previously described in 
publications by Dr. Peloquin.101-103 In prior studies, the absolute recovery of rifampin from serum was 
95.5%. The within-day precision (%CV) of validation quality control samples was 2.4 to 4.6%, and the 
overall validation precision was 6.3 to 7.1%. Comparable specifications are recorded for the other 3 drugs 
in the validation reports. The standard curves for the rifampin concentration in plasma covered a range 
from 0.5 to 50 ug/ml.  
Because these assays will be identical to those used in previous clinical studies, the results should be 
directly comparable. Rifampin and isoniazid will be assayed using high performance liquid 
chromatography (HPLC); pyrazinamide and ethambutol will be measured using gas chromatography/mas 
spectrometry (GC/MS).  
The specimens stored for the complex infection sub study will not be transferred out of Peru under this 
protocol.  
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9.0  ASSESSMENT OF SAFETY 
9.1 Specification of Safety Endpoints 
Safety endpoints are listed in Section 4.3.4.  
9.2 Methods and Timing for Assessing, Recording, and Analyzing Safety 
Parameters 
9.2.1 Adverse Events 
ICH E6 defines an adverse event (AE) is any untoward medical occurrence in a patient or clinical 
investigation subject administered a pharmaceutical product regardless of its causal relationship to the 
study treatment. The FDA defines an AE as any untoward medical occurrence associated with the use of a 
drug in humans, whether or not considered drug related. An AE can therefore be any unfavorable and 
unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated 
with the use of a medicinal (investigational) product.  The occurrence of an AE may come to the attention 
of study personnel during study visits and interviews of a study recipient presenting for medical care, or 
upon review by a study monitor. The determination of seriousness, severity, and causality will be made 
by an on-site investigator who is qualified (licensed) to diagnose AE information, provide a medical 
evaluation of AEs, and classify AEs based upon medical judgment. 
All AEs must be graded for relationship to study product. 
9.2.1.1 Assessing AEs 
Study participants will be monitored and assessed clinically for AEs at study visits at weeks 1, 2, 4, 6, 8 
according to procedures specified in section 7. Daily visits for supervised treatment will provide 
additional opportunities for symptomatic screening and referral for unscheduled visits for potential AEs. 
Lab screening for hematologic and biochemical abnormalities will be conducted at study visits at weeks 
2, 4, (6 for biochemistry only) and 8. Clinical visits during the continuation and follow-up phase will also 
assess delayed AEs at weeks 12, 16, 20, 24, 36, and 48. AEs of grade two or higher during the intensive 
phase, and up to four weeks after, are toxicity endpoints in this study.  
9.2.1.2 Severity of Event 
All clinical and laboratory findings (solicited and unsolicited) will be graded by clinical investigators 
according to severity using the modified DMID Adult Toxicity Tables (see Figure 8 in section 17.6). 
Please see Table 9 for modified study-related toxicity criteria. The following serves as a general guideline 
to quantify intensity. 
 
x Grade 1 Mild asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention 
not indicated. Events require minimal or no treatment and do not interfere with the patient’s daily 
activities. 
Page 118 of 207 AJRCCM Articles in Press. Published on 29-June-2018 as 10.1164/rccm.201712-2524OC 
 Copyright © 2018 by the American Thoracic Society 
DMID Protocol 11-0050  V7.0 September 25, 2014 
 
68 
 
x Grade 2 Moderate minimal, local or noninvasive intervention indicated; limits age-appropriate 
instrumental ADL.4 Events result in a low level of inconvenience or concern with the therapeutic 
measures. May cause some interference with functioning. 
x Grade 3 Severe or medically significant but not immediately life-threatening; hospitalization or 
prolongation of hospitalization indicated; disabling; limits self-care ADL.5 Events interrupt a patient’s 
usual daily activity and may require systemic drug therapy or other treatment. Severe events are 
usually incapacitating. 
x Grade 4 Life-threatening consequences; urgent intervention indicated. Any adverse drug experience 
that places the patient or subject, in the view of the investigator, at immediate risk of death from the 
reaction as it occurred. Events that are considered life-threatening meet SAE criteria and will be 
reported to the sponsor by the site within 24 hours of awareness of the event. 
x Grade 5 Death related to AE. Death is an event outcome that meets SAE criteria and will be reported 
to the sponsor by the site within 24 hours of awareness of the event. 
9.2.1.3 Relationship to Study Regimen 
All AEs must have their relationship to study product assessed Peruvian standards, relationship will be 
assigned by local investigators using the following terms: not related, definitely related, probably related, 
possibly related, and probably not related. For the purpose of reporting to DMID, tracking events towards 
the halting rules, or any other safety oversight activities, only the terms related or not related will be used. 
They are defined as follows: 
x Related – The event is temporally related to the administration of the study product and no other 
etiology explains the event. This will include all events assessed by investigators to be definitely 
related, probably related, possibly related, or probably not related. 
x Not Related – The event is temporally independent of study product and/or the event appears to be 
explained by another etiology. 
9.2.2 Serious Adverse Events 
A serious adverse event is defined as an AE meeting one of the following conditions: 
x Death during the period of protocol defined surveillance 
x Life threatening event (defined as a subject at immediate risk of death at the time of the event) 
x An event requiring inpatient hospitalization or prolongation of existing hospitalization during the 
period of protocol defined surveillance  
x Results in congenital anomaly or birth defect 
x Results in a persistent or significant incapacity or substantial disruption of the ability to conduct 
normal life functions. 
                                                          
4Instrumental ADL refer to preparing meals, shopping for groceries or clothes, using the telephone, managing money, etc. 
5 Self care ADL refer to bathing, dressing and undressing, feeding self, using the toilet, taking medications, and not bedridden. 
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x Any other important medical event that may not result in death, be life threatening, or require 
hospitalization, may be considered a serious adverse experience when, based upon appropriate 
medical judgment, the event may jeopardize the subject and may require medical or surgical 
intervention to prevent one of the outcomes listed above. Examples of such medical events include 
allergic bronchospasm requiring intensive treatment in an emergency room or at home, blood 
dyscrasias or convulsions that do not result in inpatient hospitalization, or the development of drug 
dependency or drug abuse. 
All serious adverse events will be: 
x Recorded in a timely and proper manner, and reported to the relevant entities.  
x Followed through resolution by a study clinician 
x Reviewed and evaluated by a study clinician 
9.2.3 Procedures to be Followed in the Event of Abnormal Laboratory Test Values 
or Abnormal Clinical Findings 
In this section, lab values for grading of AEs/SAEs are specified. Management procedures are also 
detailed, including continuation or suspension of study medication, additional evaluations, and clinical 
management of adverse events. 
Grading according to lab values 
All adverse events will be graded, and their severity and relationship to study drugs will be established 
according to criteria established in section 9.2.1. Laboratory values will be used for grading as specified 
in Table 9. Values in Table 9 have been derived mostly from the DMID Adult Toxicity Table (November 
2007 draft), completed with criteria from the NCI CTCAE version 4.0, and modified to reflect normal lab 
values in the clinical lab in Peru. This includes only values for laboratory tests carried out routinely 
during HIRIF:  
x Hematology: CBC with differential, platelet count 
x Biochemistry: AST/ALT/ALP, bilirubin, albumin  
Any other unexpected AEs or SAEs will be graded according to the DMID Adult Toxicity Table 
(November 2007 draft, Figure 8).  
Management 
In general, for all toxicities that are treatment-emergent and that require the study therapy to be 
temporarily or permanently discontinued, relevant clinical and laboratory tests will be obtained as 
clinically indicated and repeated as needed until final resolution or stabilization of the toxicity. 
For grade 1 toxicities, the participant will be followed more frequently by clinical study staff than 
specified in the schedule of visits; study drugs will be continued.  
For grade 2 toxicities, the participant will be followed more frequently, with additional laboratory and 
clinic visits as necessary. The study drugs may be continued or temporarily held at the investigator’s 
and/or independent safety monitor’s discretion. For Grade 2 thrombocytopenia (platelet count <75,000/cu 
mm) attributed to RIF, RIF should generally not be restarted. 
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For any grade 3 toxicity, which, in the clinical site PI’s judgment is NOT related to study drug(s), the 
participant will be followed more frequently, with additional laboratory and/or clinic visits as necessary. 
When possible, concomitant medications should be held first, at the discretion of the investigator, if 
he/she suspects they are contributing to toxicity. The study drugs may be continued or temporarily held at 
the investigator’s and/or independent safety monitor’s discretion, or if they are suspected to contribute to 
toxicities due to concomitant medications. 
For any grade 3 toxicity, which, in the clinical site PI’s judgment is related to study drug(s), the causative 
study drug(s) should be held. At clinical site PI’s discretion and guided by local standard practice, it 
would also be acceptable to continue treatment, in conjunction with additional clinical and laboratory 
monitoring, and suspend treatment if the participant’s condition or test result worsens. The clinical site PI 
should exclude other possible causes of the event before suspending study drug(s). When possible, 
concomitant medications should be held first at the discretion of the investigator if he/she suspects they 
are contributing to toxicity. Depending on the nature and severity of the toxicity, the degree to which it 
resolves, and/or the emergence of alternative explanations for the toxicity or the subject’s deterioration, 
the study drug(s) may be restarted at the discretion of the investigator. In the case of Grade 3 hepatoxicity, 
ALT>3 x ULN with symptoms, >5x ULN without symptoms, per the guidelines of the American 
Thoracic Society—the drug can be restarted only if the subject's ALT returns to baseline level, <2 x 
ULN.49 
Any participant with grade 4 toxicity will have study therapy immediately suspended. The laboratory test 
or clinical finding in question will be reassessed as soon as possible. The repeat test will guide 
management of the event as follows: 
 
x If the repeat test shows grade 4 toxicity, then the patient will be permanently discontinued from 
study medications. Further treatment of TB will be directed by the investigator on an 
individualized basis, according to local standard of care. The patient will continue to be followed 
in the study. 
x If the repeat assessment shows toxicity of grade 3 or lower, and if the patient has received study 
drugs between the two testing dates, then the patient will be managed according to the toxicity 
level of the repeat test. If the repeat test shows toxicity of grade 3 or lower, and if the patient has 
not received study drugs between the two testing dates, then the re-introduction of study drugs is 
at the discretion of the investigator with input from the ISM, DMID and SMC. 
For any recurring grade 3 or grade 4 toxicity the study drugs should be temporarily held and may be 
permanently stopped at the discretion of the investigator and/or the ISM, DMID and SMC. 
If a patient develops hepatic toxicity requiring study drug discontinuation, the following evaluation will 
be undertaken: assessment for history of injection or non-injection drug use, alcohol ingestion, and use of 
other hepatotoxic drugs. 
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Table 9  Toxicity Criteria-Routine Lab Testing and Temperature Measurement During HIRIF Study 
Adverse Event  
Grade 
 
 1 2 3 4 5 Source 
Hematology       
Hemoglobin 9.5-10.5 
mg/dL 
8.0-9.4 gm/dL 6.5-7.9 gm/dL <6.5 gm/dL - DMID, 2007, draft 
Platelets 75,000-
99,999/mm3 
50,000-
74,999/mm3 
20,000-
49,999/mm3 
<20,000/mm3 - DMID, 2007, draft 
WBC-high >11,000-
13,000/mm3 
>13,000-
15,000/mm3 
>15,000-
30,000/mm3 
>30,000/mm3 - DMID, 2007, draft 
WBC-low <LLN–
3000/mm3 
<3000-
2000/mm3 
<2000-
1000/mm3 
<1000/mm3 - NCI, 2010, 
CTCAE version 
4.0; adapted for 
Peru clinical lab 
Biochemistry       
Creatinine 1.1-1.5x ULN 1.6-3.0x ULN 3.1-6x ULN >6x ULN or 
dialysis 
required 
- DMID, 2007, draft 
AST (SGOT) <2.0x ULN 2.0- <3.0x ULN 3.0-8.0x ULN >8x ULN - DMID, 2007, draft 
ALT (SGPT) <2.0x ULN 2.0- <3.0x ULN 3.0-8.0x ULN >8x ULN - DMID, 2007, draft 
ALP <2.0x ULN 2.0- <3.0x ULN 3.0-8.0x ULN >8x ULN - DMID, 2007, draft 
Bilirubin (when 
accompanied by 
increase in 
other liver 
function test) 
1.1- <1.25x 
ULN 
1.25- <1.5x 
ULN 
1.5- 1.75x ULN >1.75x ULN - DMID, 2007, draft 
Bilirubin (when 
other liver 
function tests 
are in normal 
range) 
1.1- <1.5x 
ULN 
1.5- <2.0x ULN 2.1 - 3.0x ULN >3.0x ULN - DMID, 2007, draft 
Albumin <LLN-3 g/dL <3-2 g/dL <2 g/dL -- - NCI, 2010 CTC 
AE Version 4.0; 
adapted for Peru 
clinic lab 
Systemic       
Fever, oral 37.7 – 38.5C 
or 100.0 – 
101.5F 
38.6 – 39.5C or 
101.6 – 102.9F 
39.6 – 40.5C or 
103 – 105F 
>40.5C or 
>105F 
- DMID, 2007, 
draft, overlap 
corrected 
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9.3 Reporting Procedures 
This reporting system has been developed to ensure timely and accurate reporting of adverse events in 
order to monitor patient safety. It also assures compliance with Department of Health and Human 
Services (HHS) and Food and Drug Administration (FDA) regulations, in-country regulations, as well as 
dissemination of information to investigators working with the study drugs. In accordance with the FDA’s 
Code of Federal Regulations, the sponsor of this clinical trial and the participating investigators are 
responsible for reviewing all information relevant to the safety of the study drugs. Reporting and 
monitoring of SAEs are required to alert the FDA, sponsor, institutional review boards, and the 
investigators of real and potential safety issues. 
The study drugs are ethambutol, isoniazid, rifampin, and pyrazinamide. The most common adverse 
effects associated with the study drugs are specified in section 2.3. The investigator is responsible for 
monitoring all adverse events that are observed or reported during the study, regardless of whether they 
are related to study drugs. 
9.3.1 Adverse Events 
x Document AEs from the first study intervention, Study Day 1, through Study Day 365 (end of follow-
up).  
 
Adverse events including local and systemic reactions not meeting the criteria for “serious adverse 
events,” should be captured on the appropriate case report form. Information to be collected includes 
event description, time of onset, investigator assessment of severity, relationship to study product, time of 
resolution of the event, seriousness, and outcome. All adverse events occurring during the first three 
months of treatment must be documented appropriately regardless of relationship. All AEs will be 
followed to adequate resolution.  
Any medical condition that is present at the time that the patient is screened should be considered as 
baseline and not reported as an AE. However, if it deteriorates at any time during the study it should be 
recorded as an AE. The maximum level of toxicity reached will be clearly indicated. 
 
AEs will be followed until resolution even if this extends beyond the study-reporting period. Resolution 
of an AE is defined as the return to pretreatment status or stabilization of the condition with the 
expectation that it will remain chronic.  
9.3.2 Serious Adverse Events 
x Document SAEs from the first study intervention, Study Day 1, through Study Day 365 (end of 
follow-up).  
 
SAEs will be followed until resolution even if this extends beyond the study-reporting period. Resolution 
of an SAE is defined as the return to pretreatment status or stabilization of the condition with the 
expectation that it will remain chronic. 
Any AE that meets a protocol-defined serious criterion must be submitted within 24 hours of site 
awareness on an SAE form to the DMID Pharmacovigilance Group, at the following address:  
 
 
DMID Pharmacovigilance Group 
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Clinical Research Operations and Management Support (CROMS)  
6500 Rock Spring Dr. Suite 650 
Bethesda, MD 20814, USA 
SAE Hot Line: 1-800-537-9979 (US) or 1-301-897-1709 (outside US) 
SAE FAX Phone Number: 1-800-275-7619 (US) or 1-301-897-1710 (outside US) 
SAE Email Address: PVG@dmidcroms.com 
 
Other supporting documentation of the event may be requested by the DMID Pharmacovigilance Group 
and should be provided as soon as possible.  
The DMID medical monitor and clinical protocol manager will be notified of the SAE by the DMID 
Pharmacovigilance Group. The DMID medical monitor will review and assess the SAE for potential 
impact on study subject safety and protocol conduct.  
At any time after completion of the study, if the investigator becomes aware of an SAE that is suspected 
to be related to study product, the investigator will report the event to the DMID Pharmacovigilance 
Group.  
Any AE that meets a protocol-defined serious criterion must be submitted within 24 hours of site 
awareness on an SAE form to the IND holder. If the IND holder deems regulatory reporting of the SAE 
necessary, an IND safety report will be submitted to the FDA. Submission will be realized within 15 
calendar days of the date on which reporting was determined to be necessary.  
9.4 Reporting of Pregnancy 
For the purposes of this study, pregnancy will be reported as an adverse event. All pregnant patients will 
be taken off study therapy and treated according to local TB program guidelines for tuberculosis 
treatment during pregnancy. Women who become pregnant while on study treatment will, with their 
permission, receive follow up for 14 days after discharge from the study; newborn will be followed for 6 
months. Pregnancy will be reported to the local IRB and Partners IRB as an unanticipated problem 
involving risks to subjects or others. 
9.5 Type and Duration of Follow-up of Subjects after Adverse Events 
Adverse event follow-up will be reported on a designated form as soon as possible after the resolution or 
stabilization of the AE, but no later than 45 days after the AE was reported. An SAE will be reported by 
the study site to the sponsor within 24 hours of awareness of the event. AEs and SAEs will be followed, 
until resolved or considered stable, per the study schedule of evaluations, or more often at the discretion 
of the investigator. The investigator will submit any information regarding follow-up on the SAE as soon 
as possible after the information becomes available to the study site. A copy of the completed AE report 
and any FDA-related communications to DMID will be reported within 7 days of becoming available. 
9.5.1 Halting Rules 
The Chairman of the SMC or his/her designee will review each SAE deemed to be related to rifampin 
within 48 hours of report. The Chair or his/her designee will determine whether the SAE requires halting 
of the trial pending consideration by the full SMC. In addition, the SMC will be notified if any of the 
following events occur and the trial will be halted pending SMC review and recommendations: 
a) 3 or more SAEs of the same type, assessed by the PI, ISM, and MM to be related to rifampin. 
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b) 6 or more grade 3 or higher AEs related to rifampin, excluding elevated biochemical 
transaminases.  
c) 3 grade 3 or higher elevated biochemical transaminases accompanied by clinical symptoms 
consistent with hepatotoxicity, related to rifampin.  
d) 1 or more systemic hypersensitivity reaction (anaphylaxis) within 24 hours after receiving 
rifampin and related to rifampin. 
If, in accordance with the above halting rules, the study is temporarily halted and then restarted, the count 
of events that invoked the rule will restart at “0”. 
The SMC, PI, and DMID retain discretion to halt the study for other safety concerns (or based on interim 
safety results) until a safety evaluation is performed by the SMC, if warranted by frequency, nature, or 
severity of recorded events. The SMC will review all of the safety data and recommend whether 
enrollment and dosing should resume. Subsequent review of serious, unexpected, and related AEs by the 
SMC, IEC/IRB, the Sponsor, or the FDA or relevant local regulatory authorities may also result in 
suspension of further trial interventions/administration of study product at a site. 
The Sponsor will notify the FDA if the study is halted. A decision to reinitiate the study will be made 
based on the recommendation of the SMC and the sponsor. 
 
In the event of a study safety halt, subjects will be treated with a standard regimen for TB according to 
local guidelines. When and if it is determined that the study may continue, participants in the intensive 
phase of treatment will reinitiate their assigned study regimen.  
9.6 Contingency Plan for Unblinding 
 
The site principal investigator will not have access to the randomization code indicating the 
investigational treatment arm assigned to a participant except in the case of an emergency and when 
knowledge of treatment arm assignment is essential to ensure the immediate safety and clinical 
management of the participant.  
The site principal investigator is the only member of the study team who has the authority to unblind the 
study, and only in the interest of ensuring study participant safety. Afterwards, s/he will report the 
unblinding promptly (within no more than 72 hours after unblinding) to the study sponsor and the DMID 
Medical Monitor. The Safety Monitoring Committee may request unblinded data in order to ensure the 
safety of study participants. 
The documentation regarding unblinding must be registered in the participant's clinical history and must 
be captured in the study data base, including the date and time in which the change took place, and the 
names of all the staff involved. Additionally, the AEs that lead to the unblinding must be recorded in the 
appropriate study CRF. Once a study participant’s treatment assignment is unblinded, that participant will 
not be able to restart study treatment. 
9.7 Safety Oversight 
An Independent Safety Monitor (ISM) and a Safety Monitoring Committee (SMC) will provide safety 
oversight.  
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The ISM will be a physician with expertise in TB treatment and clinical research. The ISM will not be 
under the direct supervision of the PI, nor will s/he be considered a member of the SMC. He/she will be 
responsible for providing independent safety monitoring in a timely fashion. Participation is for the 
duration of the study. The ISM will review any SAEs and unexpected AEs of concern, immediately after 
they occur, and follow-up through resolution. The ISM will have ready access to participant records and 
will be provided a copy of the SAE at the time the SAE report is submitted to the DMID 
pharmacovigilance group. He/she will independently review all SAEs and thoroughly investigate those 
events considered unexpected. Clinical and laboratory data, clinical records, and other study-related 
records will be made available for ISM review, by local investigators and/or coordinators. The clinical PI 
will ensure that the ISM is apprised of all new safety information relevant to RIF and companion drugs.  
The ISM will review all protocol revisions and may receive other documents related to the study. The 
ISM may transiently or permanently halt enrollment at any time for any safety related issue. The ISM will 
contact the PI at the enrollment site and the medical monitor at the DMID for any event that needs further 
evaluation. The ISM will provide a written assessment about all SAEs to the DMID. The DMID will 
communicate with the SMC chair. 
The SMC will comprise one clinical TB expert, one internationally recognized clinical trialist, and one 
clinical researcher with expertise in a topic of relevance to the study (e.g., hepatotoxicity), none of whom 
will be otherwise involved in the study. A statistician may also participate, either as a full voting member 
or as a consultant to the SMC at open session meetings. S/he will not otherwise be involved in the study.  
Additional expertise may be added for open or closed meetings, as needed, on an ad hoc basis. A simple 
majority will be considered a SMC quorum. The SMC will meet after approximately three months, or 
after 1/3 of patients are enrolled to assess safety for each arm of the study. See sections 4.3.5 and 4.3.6 of 
protocol for details regarding SMC review and data to be reviewed for the interim analysis plan. If halting 
rules are invoked, more frequent meetings may be held. The SMC will operate under the rules of a 
DMID-approved charter that will be written at the organizational meeting of the SMC. At this time, each 
data element that the SMC needs to assess will be clearly defined. The SMC will assess 
interim/cumulative data for evidence of study-related adverse events, data quality, completeness and 
timeliness, demographic information on study participants, factors that might affect the study outcome or 
compromise the confidentiality of the trials (such as protocol deviations) and factors external to the study 
such as scientific or therapeutic developments that may impact participant safety or the ethics of the 
study. The ISM or SMC may temporarily or permanently halt enrollment at any time for any safety 
related issue. The SMC should conclude each review with its recommendations to the study sponsor as to 
whether the study should continue without change, be modified, or terminated. 
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10.0 CLINICAL MONITORING 
10.1 Site Monitoring Plan 
Under the U01 mechanism, site monitoring is the responsibility of the investigators. To ensure that human 
subject protection, study procedures, bacteriology procedures, study intervention administration, and data 
collection processes are of high quality and meet sponsor, GCP/ICH, and regulatory guidelines, and that 
the study is conducted in accordance with the protocol and sponsor SOPs, the study will contract with an 
external monitor who will comply with the requirements laid out in the ICH GCP Guidelines E6, Section 
5.18. This is detailed in the Clinical Monitoring Plan. 
Study monitors will meet with investigators to discuss any problems and actions to be taken and 
document visit findings and discussions in a formal report as specified in section 5.18.6 of ICH GCP 
Guidelines E6. 
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11.0  STATISTICAL CONSIDERATIONS 
11.1 Study Hypotheses 
Primary: 
H1: The distribution of AUC0-24 of RIF will be different among the three dosing groups. 
H2: Sputum culture sterilization will occur more quickly in the intervention groups than in the control 
group. 
H3: Adverse event (grade 2 and higher) incidence will be independent of dose size, AUC and Cmax of RIF. 
Secondary:  
H4: Sputum culture sterilization will occur more quickly in study participants with higher RIF AUC/MIC. 
H5: A relationship among four different methods of measuring sterilizing activity can be characterized. 
H6: Participants with accelerated sputum culture sterilization will have a lower probability of failure and 
relapse. 
11.2 Sample Size Considerations 
11.2.1 Pharmacokinetics 
Existing unpublished data suggest a minimum increase in AUC of 12 mcg/mL*hr across dose groups. 
Assuming a standard deviation of AUC of 24 mcg/mL*hr and α=0.05, a linear contrast test across the 
three treatment groups has 90% power to detect a total effect size of 14 mcg/mL*hr between the top and 
bottom dose levels at a sample size of 50 evaluable subjects per arm. We propose to recruit 60 subjects 
per arm which will allow up to 17% loss to follow up. With 50 evaluable patients/arm, the study has 90% 
power to detect a total effect size as small as 12.8. 
11.2.2 Efficacy 
Estimation of the sample size for the serial sputum colony counting endpoint is based on computation of 
the population Fisher's Information matrix derived from linearization of a non-linear mixed effects model 
for the data. The parameter θ4 in this model represents the late phase decay in colony counts, a surrogate 
measure of sterilizing activity. Under conventional assumptions of α=0.05 and ß=0.20 with a coefficient 
of variation on this parameter of 20% a sample size of 48 per arm is sufficient to detect a difference 
between the highest and lowest dose arms of 0.025 log10 CFU/ml, comparable in magnitude to those 
observed in previous SSCC studies. A sample size of 60 per arm allows for a rate of patient withdrawals 
of up to 25%. 
11.2.3 Safety 
Hepatotoxicity has been observed to occur in between 0 and 27% of patients receiving RIF-containing 
regimens for TB, with the summary frequency from one meta-analysis estimated at 2.7%. Other serious 
toxicities, such as hematologic disorders and flu-like syndrome are estimated to occur in between 1 and 
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5% of patients on standard doses of RIF. In a pivotal trial of rifapentine (compared to standard doses of 
RIF) 5% of subjects receiving standard doses of RIF permanently discontinued treatment.104 We expect 
5% of patients in the control arm to experience adverse events requiring treatment discontinuation; we 
expect at least twice this many, or 10%, to experience a grade 2 or higher event. 
We have 62% power (1-sided α=0.1) to detect adverse events occurring twice as frequently in the 
intervention arms combined, and greater than 95% power to detect a relative risk of >3. We have greater 
than 70% power to rule out that there is  a tripling of risk in one of the intervention arms, compared to the 
control arm. If we assume the frequency of any adverse event (greater than grade 2) is higher, 10% in the 
control arm, we have 68% power (1-sided α=0.1) to detect adverse events occurring twice as frequently in 
the intervention arms. Since we will be comparing incidence of adverse events, a continuous variable, the 
statistical power afforded by the study sample is size is actually slightly higher. 
11.3 Final Analysis Plan 
More details will be available in a full statistical analysis plan completed prior to initiation of any 
analyses. 
All initial analyses will be intent to treat. All analyses will examine the effect on specified endpoints of 
increased doses of RIF. Distribution of potentially important covariates among treatment arms will be 
assessed. These include: age, gender, cavitation, HIV, RIF MICs, and baseline bacillary load. Any 
imbalance will result in adjustment in multivariable analyses for covariates that are not evenly distributed 
among the treatment arms. Study participants who are lost to follow up will contribute information until 
their loss to follow up. Informative missingness will be assessed for any missing endpoints and 
covariates.105 Results of these assessments will inform handling of missing data in subsequent analyses.106 
Plans include full case analysis and imputation for PK, efficacy, and safety; and integration of separate 
likelihoods (PK). An analogous approach will be applied to informative censoring in the time-to-event 
models. General approaches are outlined below. 
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11.3.1 Pharmacokinetic-Pharmacodynamic analysis 
These analyses will address the primary question of whether AUC0-24 varies by treatment arm. 
11.3.1.1 Data cleaning, transformation and missing data 
Plasma RIF concentrations (μg/mL) divided by RIF MIC will be used as the primary endpoint. Missing 
concentration values for protocol or technical reasons will be assigned NA. Values below the Limit of 
Detection (LOD) of the assay will be handled by creating two datasets: one in which these values are also 
assigned NA and another in which a value half the LOD is assigned. Analysis with the imputed values 
will serve as an assessment of the degree to which these LOD observations may be informative. The 
dataset will also be prepared in NONMEM format and values below the limit of detection coded as 
MDV=1. 
We anticipate that parametric methods will be appropriate since, based on prior reports, we do not expect 
the distribution of RIF plasma concentrations to violate the normality assumption. We will, however, 
evaluate this assumption and adopt non-parametric analytic approaches if the distribution of RIF plasma 
concentrations is non-normal.107 
11.3.1.2 Data summaries and descriptive statistics 
Plasma RIF concentrations will be plotted raw and grouped by subject on the original scale to detect 
outliers. MICs will also be plotted. Summary statistics (mean, median, quartiles and standard deviation) 
will be computed for PK at each individual time point and for RIF MICs to evaluate the distribution of the 
data. Outliers will be retained in the dataset but any extreme cases may be queried with the laboratory, re-
analysed and potentially removed by consent of the study team. Standard summary pharmacokinetic 
parameters (Cmax, tmax, AUC0-24, AUC0-6, AUC0-∞ and total clearance) will be obtained using non-
compartmental analysis and summarised graphically and numerically as described above by dose group. 
Percent extrapolation for AUC0-24 will also be recorded for each subject. Ratios of AUC0-24/MIC will also 
be calculated for each patient. 
11.3.1.3 Prespecified analyses 
The primary analysis will be a two-sided linear contrast test of dose-response of AUC0-24/MIC across the 
three dose groups with a significance level of 5%.  
Secondary analyses of the summary parameters will include similar tests of dose-response for AUCo-∞ and 
Cmax. If departure from linearity is evident from plots of the PK parameters, alternative contrasts (concave 
or convex) or polynomial terms will also be fitted to obtain better estimates of the dose-response 
relationship. Exploratory analyses of additional determinants of the exposure parameters (AUC0-24 , 
AUCo-∞ and Cmax) and of clearance will include the covariates study site, body mass, sex, and plasma 
concentration of companion drugs. 
Population PK modelling of the parent compound and its major metabolite, 25-desacetylrifampicin, using 
the rich and the complete datasets will also be carried out. A one compartment model for the parent 
compound alone and a simultaneous parent-metabolite model will be fitted. Similar dose-response 
contrasts and covariates will also be examined in this model. 
We will use data from the small number of MICs of 25-desacetylrifampicin for exploratory analyses of 
the possibility that the metabolite adds to RIF’s activity.  
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11.3.1.4 Statistical methods 
Non-compartmental analysis (NCA) will be carried out using WinNonLin 5.0 (Pharsight Co, USA). Tlast 
will be selected automatically or confirmed by the analyst for profiles with more than two data points. 
The trapezoidal rule with the log up-linear down option will be used to fit the profiles. The summary PK 
parameters will be analysed using analysis of variance in (SAS version 9.1, The SAS Institute, Cary, NC). 
Population PK modelling will be carried out in NONMEM VI (ICON) via R and the packages NMFuns 
and Mifuns (Metrum Institute). The Laplacian and/or First Order Conditional Estimation method with ε-η 
interaction will be used. Covariate selection will be done using graphical screening methods, univariate 
fitting of candidates with a conservative level of α=0.10 and backwards elimination from the final model 
with α =0.05. Model comparison will be based on changes in the NONMEM objective 
function/Likelihood ratio test, examination of weighted and conditionally weighted residual plots and 
posterior predictive checks. Missing observations will be handled in three ways: first by ignoring the 
missing observations, secondly by imputing a value of half the LOD and thirdly by separately integrating 
the likelihood for these missing observations using a purpose written subroutine. Covariate selection will 
be done using graphical screening methods, univariate fitting of candidates with a conservative level of 
α=0.10 and backwards elimination from the final model with α=0.05. 
11.3.2 Efficacy analyses 
These analyses will answer the secondary question of whether observed sterilizing activity, particularly in 
the latter part of the intensive phase, varies by treatment arm. 
11.3.2.1 Data cleaning, transformation and missing data 
Replicate sputum colony counts will be averaged and transformed to the log10 scale. Since the counts are 
performed on cultures grown from homogenized sputum samples, they will not be normalized by sputum 
volume; previous work reveals that such normalization does not decrease variability in colony counts in 
most populations.108 Counts not available will be distinguished as to the reason for being missing: not 
collected vs. no sputum produced vs. contaminated vs. below LOD. The first three will be coded NA. The 
point of culture conversion will be defined as the first value below the LOD in an individual subject's 
profile ending in at least two such values. Two distinct datasets will then be created: one in which the 
below LOD observations are all coded NA and a second which the value at the point of culture 
conversion is imputed a value of half the LOD and all successive values coded NA. 
Liquid culture results will be recorded as DTP and all bottles will be declared negative at 42 days of 
incubation. For the survival analysis dataset this time point will represent culture conversion, the event of 
interest, and all profiles not achieving this endpoint will be censored at last SSCC/DTP sputum collection 
time point. For the regression analysis of the DTP data, DTP will ideally be analysed on the original scale 
but may be transformed to stabilize the variance. A similar approach to missing data will be adopted as 
above but with a value of 42 days imputed at the point of culture conversion. 
11.3.2.2 Data summaries and descriptive statistics 
Both SSCC and DTP data will be plotted and basic descriptive statistics computed at all time-points in 
order to assess heteroscedasticity and detection of outliers. Kaplan-Meier plots will also be created 
according to dose level. 
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11.3.2.3 Prespecified analyses 
The co-primary efficacy comparisons will be based on a two sided linear contrast test of the three dose 
levels on the parameter θ4 (late-phase sterilizing slope) derived from non-linear mixed effects modelling 
and the hazard ratio of culture conversion derived from the Cox proportional hazards model at a 
significance level of 5%. 
11.3.2.4 Statistical methods 
SSCC data will be analyzed using a non-linear mixed effects (NLME) model employing maximum 
likelihood estimation in the package NLME in R. The basic structural model will be a four parameter 
biexponential decline with random effects for all the parameters and a variance function to account for 
heteroscedasticity. The following covariates will be examined for inclusion in the adjusted model: HIV 
status, sex, age and extent of disease (radiography), RIF AUC/MIC. Model comparison will be based on 
the Likelihood Ratio Test for models estimated by maximum likelihood and on examination of residual 
plots. The final model will also be checked for residual serial correlation and stability of variance 
components under REML estimation. The analysis will be repeated for the imputed dataset to check 
robustness of the conclusions of the analysis to missing data. 
We will assess whether the assumption of proportionality necessary for Cox proportional hazards models 
is met, examining plots of the natural logarithm of the negative natural logarithm of the survival curve. If 
so, Cox proportional hazards regression will be carried out using the survival package in R. The exact 
partial likelihood method will be used to resolve ties and comparison of models will be on the basis of the 
likelihood ratio test and examination of martingale residuals. If not, a non-parametric survival model will 
be used. 
DTP data will also be analysed using NLME in R. Linear, monoexponential and spline structural models 
will be tested with a variance function if necessary. The same set of covariates will also be examined and 
incorporated according to the same selection criteria. 
11.3.3 Toxicity 
To evaluate the effect of dose size on adverse events (grade 2 or higher), the primary analysis will be a 
comparison of time to adverse events occurring in the first 12 weeks of treatment and determined to be 
related to the study drug or regimen in the intervention groups to the time to adverse events in the control 
group.  
Secondary analyses will examine differences in time to all SAEs—and specifically in time to 
hepatotoxicity—requiring treatment discontinuation. 
11.3.3.1 Data cleaning, transformation and missing data 
The time to an adverse event will be recorded as the interval between the treatment initiation date and the 
midpoint between the last study visit without an event and the first study visit (scheduled or not) at which 
the AE was diagnosed. For participants lost to follow up after at least one study visit post treatment 
initiation, data will be censored at the midpoint between the last recorded study visit and the date of loss 
to follow up. Data from participants for whom no study visits occurred will be excluded from this 
analysis. 
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11.3.3.2 Data summaries and descriptive statistics 
Incidence rates of predefined and unexpected AEs and SAEs will be calculated. Kaplan-Meier plots will 
also be created according to dose level and stratified by severity grade (1-4). 
11.3.3.3 Prespecified analyses 
The incidence rate of grade 2 AEs, determined to be related to the study drug or regimen and occurring in 
the first 12 weeks, in the 2 intervention groups combined will be compared to the control group. Further 
the rate of discontinuation due to hepatotoxicity will be compared between the intervention and control 
groups. If a significant difference is detected, comparison will be made between the 15 mg/kg 
intervention group and the control as well as between the 20 mg/kg intervention group and the control. 
RIF AUC and other covariates including age, sex, reported alcohol consumption and baseline LFT will be 
considered as covariates in multivariable regression of time to event, time to discontinuation (due to all 
SAEs), and time to discontinuation due to hepatotoxicity. 
11.3.3.4 Statistical methods 
The proportionality assumption will be assessed as described above. If met, Cox proportional hazards 
models will also be run to assess differences in time to AE between the intervention groups and the 
control group. If not, a non-parametric survival model will be used. 
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12.0  SOURCE DOCUMENTS AND ACCESS TO SOURCE 
DATA/DOCUMENTS 
12.1 Source Documents and Access to Source Data/Documents 
Appropriate medical and research records will be maintained for this trial, in compliance with ICH E6 
GCP, Section 4.9 and regulatory and institutional requirements for the protection of confidentiality of 
subjects.  
The following individuals and groups will have access to study records: 
x Members of the study team 
x IRBs that review the study (including IRB members, staff, and legal counsel) 
x  Office of Human Research Protections 
x FDA 
x DMID/NIAID/NIH 
x Regulatory Agencies in Peru  
x Study Monitor 
Authorized representatives of the sponsor(s), DMID, and regulatory agencies indicated above will be 
permitted to examine (and when required by applicable law, to copy) clinical records for the purposes of 
quality assurance reviews, audits and evaluation of the study safety and progress. 
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13.0  QUALITY CONTROL AND QUALITY ASSURANCE 
Standard operating procedures for quality management will be developed and detailed in a separate 
Quality Management Plan.  
The executing institution is responsible for conducting routine quality assurance (QA) and quality control 
(QC) activities to internally monitor study progress and protocol compliance. The Principal Investigator 
will provide direct access to all trial-related sites, source data/documents, and reports for the purpose of 
monitoring and auditing by the sponsor, and inspection by local and regulatory authorities. The Principal 
Investigator will ensure all study personnel are appropriately trained and applicable documentations are 
maintained on site.  
Clinical site monitors will verify that the clinical trial is conducted and data are generated, documented 
(recorded), and reported in compliance with the protocol, GCP, and the applicable regulatory 
requirements. Clinical monitoring reports will be submitted to DMID. 
The Data Centers at each site (DC) will implement quality control procedures beginning with the data 
entry system and generate data quality control checks that will be run on the database. Any missing data 
or data anomalies will be communicated to the clinical site(s) for clarification and resolution. 
All key study staff will be trained and certified in good clinical practices. 
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14.0  ETHICS/PROTECTION OF HUMAN SUBJECTS 
The protection of human research subjects will be assured throughout the study execution and reporting.  
14.1 Ethical Standard 
The investigator will ensure that this study is conducted in full conformity with the principles set forth in 
The Belmont Report: Ethical Principles and Guidelines for the Protection of Human Subjects of Research 
of the US National Commission for the Protection of Human Subjects of Biomedical and Behavioral 
Research (April 18, 1979) and codified in 45 CFR Part 46 and/or the ICH E6; 62 Federal Regulations 
25691 (1997). In addition, the investigator will ensure that this study is conducted in full conformity with 
the current revision of the Declaration of Helsinki, or with the International Conference for 
Harmonisation Good Clinical Practice (ICH-GCP) regulations and guidelines, whichever affords the 
greater protection to the subject. It will also be conducted in full compliance with 21 CFR 50 and 56. In 
addition, this study will be conducted in accordance with Peruvian standards. 
14.2 Institutional Review Board 
Before they are placed into use, the study protocol and informed consent documents will be reviewed and 
approved by IRBs supervising all involved institutions (Harvard, St. Georges, University of Liverpool, 
University of Florida, Peru). Any amendments to the protocol or consent materials will be reviewed and 
approved by the IRBs before they are placed into use. 
14.3 Informed Consent Process 
Informed consent is a process that will be initiated prior to the individual’s agreeing to participate in the 
study and will continue throughout the individual’s study participation. Extensive discussion of risks and 
possible benefits of this therapy will be provided by study staff to potential subjects (and, with permission 
from potential subjects, their families). Potential subjects will receive counseling about study objectives 
and procedures, potential toxicities, and the informed consent process. Consent forms describing in detail 
the study interventions & products, study procedures and risks will be given to the subject and written 
documentation of informed consent will be required prior to starting intervention/administering study 
product. Consent forms will be IRB approved, will contain all the elements required by the ICH E6 
Guidelines for Good Clinical Practice and any additional elements required by local regulations, and 
written in Spanish; English versions will be available for IRB and sponsor review. The subject will be 
asked to read and review the document. Upon reviewing the document, the person obtaining consent will 
explain the research study to the subject and answer any questions that may arise. For subjects who speak 
and understand the language used in the consent document, but are unable to read or write, all of the 
information in the consent form will be communicated verbally, in the presence of an adult witness who is 
not a member of the study team; informed consent requires the signature or mark of the subject. The 
subject will sign or mark the informed consent document prior to any procedures being done specifically 
for the study. The subjects will have the opportunity to discuss the study with their surrogates or think 
about it prior to agreeing to participate. The subjects may withdraw consent at any time throughout the 
course of the trial. A copy of the signed and dated informed consent document will be given to the 
subjects for their records. The rights and welfare of the subjects will be protected by emphasizing, to 
subjects, that the quality of their medical care will not be adversely affected if they decline to participate 
in this study. The informed consent process will be recorded in the subject’s clinical chart. 
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During the informed consent process, the subject will receive information about compensation for study 
participation. Specifically, subjects will not be paid for study participation. Study subjects will be 
reimbursed for transportation expenses to the research center they are assigned to and monthly food 
vouchers for the duration of time they are in the study. They will also receive meals while in the research 
center for PK and overnight pooled sputum collection. Study drugs will be provided free of charge. 
14.4 Informed Consent/Assent Process (in Case of a Minor) 
Not applicable. All study subjects will be ≥ 18 years of age. 
14.5 Exclusion of Women, Minorities, and Children (Special Populations) 
Children will be excluded from this Phase II study because, unlike in adults, there is limited information 
on the safety and tolerability of high-dose RIF among children. Pregnant and breast-feeding women will 
be excluded from this study because of the lack of evidence on the safety and tolerability of high-dose 
RIF among infants and fetuses. If its safety and tolerability among adults is confirmed with this study, 
research examining safety and tolerability among children will be planned. 
14.6 Subject Confidentiality 
This study will be performed in accordance with U.S., and Peruvian standards for protection of privacy of 
identifiable health information. 
All study records will be managed in a secure and confidential fashion. Study records will be maintained 
in locked cabinets, and computer records will be password protected. Access to study records will be 
restricted to specified team members. Methods for secure data handling are detailed below in Section 
15.0. 
The study monitor, other authorized representatives of the sponsor, and U.S. and/or local regulatory 
authorities may inspect all documents and records required to be maintained by the investigators, 
including but not limited to, case report forms and pharmacy records for the subjects in this study. The 
clinical study sites will permit access to such records. 
14.7 Study Discontinuation 
In the event that the study is discontinued (e.g. by the investigator, the sponsor, the SMC, and/or 
regulatory groups), subjects on study phase treatment will continue to receive TB treatment in accordance 
with national guidelines. Treatment will be offered free of charge, as guaranteed through the public health 
system in Peru. 
14.8 Future Use of Stored Specimens 
Pharmacogenetic samples will be stored for up to 5 years. This is to permit testing for newly identified 
polymorphisms related to TB drug metabolism. Cultured organisms and mycobacterial DNA, which will 
be isolated from patient specimens at baseline and twice during the intensive phase, will be stored for 
analysis for complex infections.  
Subjects will be asked to provide written informed consent allowing their blood samples and TB strains to 
be stored and analyzed for these studies. A section about the future use of specimens is included in the 
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consent forms. If a subject does not agree to consent to the future use of stored specimens, this does not 
preclude him or her from participating in the present study. Relevant institutional review boards will 
oversee any future research using these samples. 
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15.0  DATA HANDLING AND RECORD KEEPING 
The following types of forms will be used in this trial to ensure appropriate data handling and record 
keeping is performed: 
 Informed consent forms for enrollment, in English and translated into Spanish. 
 Eligibility screening forms 
 Medical records and case report forms that document enrollment, follow-up visits, adherence, and 
specimen collection 
 Administrative forms that document participant deaths, termination from study drugs, and work up 
and treatment of AEs and treatment failure 
A participant’s name will be collected only one time, and this information will be kept on a form that does 
not contain any test results, and that is filed separately from forms that do contain test results. Each 
participant will be assigned a unique study ID number. This number will be recorded on each data 
collection form and clinical specimen to facilitate linkage of data. The study ID number will be used on 
data collection forms; names and other obvious identifiers will not be used on data collection forms.  
All data collection forms will be stored in locked files in a secure area. Access to study records and data 
files will be limited to study personnel, the NIH and its designees, the FDA, and local regulatory 
authorities. 
All forms will be reviewed prior to data entry for accuracy, consistency, and completeness by designated 
study staff. 
For banked specimens, the study ID number, date of collection, specimen volume, and freezer location 
will be recorded on the laboratory requisition forms and entered into the computer. 
15.1 Data Management Responsibilities 
The on-site principal investigator and the data manager will be responsible for the accuracy, 
completeness, and storage of source records and study data collection forms. The study team, monitor and 
data entry staff will review source documents and laboratory reports to ensure accuracy and completeness 
as appropriate. The site staff will maintain logs to record dates of completed and upcoming clinic visits 
and specimen collections. 
15.2 Data Capture Methods 
All information needed for the study will be entered into the electronic data capture (EDC) system and 
then verified. 
15.3 Types of Data 
Data for this study will include safety, laboratory (microbiology), and clinical data. All of these elements 
will be recorded in the EDC system. 
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15.4 Timing/Reports 
Safety/tolerability data will be reviewed by the SMC after enrollment of each 60 (1/3 of) study subjects; 
reports for the SMC will be prepared for the SMC according to a schedule determined at the first 
convened SMC meeting. Data coding will occur at the time of data collection; ongoing logical data 
queries will be performed. 
15.5 Study Records Retention 
Within 2 years of completion of the study, identifiers excluding the study ID number will be deleted from 
computerized and paper data files. Study records will be maintained by the investigator for a minimum of 
5 years following discontinuation of the study. The IND sponsor and DMID will approve study record 
destruction. 
15.6 Protocol Deviations 
A protocol deviation is any noncompliance with the clinical trial protocol, Good Clinical Practice (GCP), 
or Manual of Procedures requirements. The noncompliance may be either on the part of the subject, the 
investigator, or the study site staff. As a result of deviations, corrective actions are to be developed by the 
sites and implemented promptly.  
It is the responsibility of the sites to use continuous vigilance to identify and report deviations according 
to the guidelines of the IND sponsor. All deviations from the protocol must be addressed in study subject 
source documents. Protocol deviations must be sent to DMID and the local IRB in accordance with 
standard procedures. 
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16.0  PUBLICATION POLICY 
Following completion of the study, the investigator will plan to publish the results of this research in a 
scientific journal. The International Committee of Medical Journal Editors (ICMJE) member journals 
have adopted a trials-registration policy as a condition for publication. This trial has been registered in 
ClinicalTrials.gov (NCT01408914). It is anticipated that the results of this study will be submitted for 
publication in a peer-reviewed scientific journal. The study PI(s) will retain primary responsibility for the 
preparation of publications. An NIAID Project Scientist will also have substantial involvement in 
providing scientific/programmatic support in the preparation of publications. Publications and oral 
presentations of work performed under this agreement will receive appropriate acknowledgment of 
support by the NIAID/NIH.  
Authorship will be extended to the following individuals: study investigators, site PIs, and other 
individuals having major contribution to the study design, implementation, data analysis, and preparation 
of the written manuscript.  
Prior to submission for presentation or publication, any materials derived wholly or in part from this study 
must be submitted to the study PI(s), site PI, and all co-authors for review. 
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17.0 PROTOCOL APPENDIX 
17.1 Current Drug Development in Tuberculosis 
The limitations of the current TB control strategy have resulted in renewed focus on development of 
effective “ultra-short-course” regimens. It has been estimated that successful introduction of an effective, 
inexpensive, two-month regimen could prevent 13 million infections and 6 million deaths in the 18 years 
following its introduction.109 
Several such efforts, which could result in incremental progress towards this goal, are underway. The 
most advanced are Phase III trials designed to demonstrate the efficacy and regimen-shortening potential 
of the 8-methoxyfluoroquinolones moxifloxacin and gatifloxacin for first-line therapy. Preliminary results 
of the gatifloxacin-containing regimen do not support shortening with this regimen. Results from the 
study with the moxifloxacin-containing regimen are expected in 2014. Moreover, a number of chemically 
novel compounds are in pre-clinical testing or early clinical development, among them two 
nitroimidazoles (PA-824 and delamanid), a diarylquinoline (bedaquiline) and an ethambutol derivative 
(SQ-109). Clinical development of some of these compounds is at present focused on improving 
treatment of MDR-TB.110 Phase III trials for first-line therapy with these compounds have recently begun. 
One of these drugs, bedaquiline, was conditionally approved for MDR-TB by the US FDA in December 
2012 and by the EMA in 2013; delamanid also received conditional approval by the EMA in 2013. 
The need for improved outcomes, however, is urgent: nearly 90 million new cases of TB and 20 million 
TB deaths can be expected over the next ten years. Moreover, the Global Plan to Stop TB: 2006-2015 
projected an estimated 11.7 million cases of TB/HIV coinfection and 3.4 million cases of multidrug-
resistant TB (MDR-TB) by 2015.111 
17.2 Measuring the Sterilizing Activity of Combination Regimens 
Short-course regimens effectively reduce bacillary burden in the early phase of treatment, preventing 
death, bacteriological failure during treatment and the emergence of resistance. However, their inability to 
prevent relapse as the duration of therapy is reduced, despite favourable results during and at the end of 
treatment, led to the concept of “sterilizing activity”. As noted, this has been defined theoretically by 
Mitchison as, “the ability to kill all or virtually all of the bacilli in the lesions as rapidly as possible”4 in 
the context of the hypothesis of heterogeneous bacillary subpopulations in vivo. In particular, the 
phenomenon of “persistence” during therapy attributed to one or more subpopulations of metabolically 
inactive and antibiotic-tolerant organisms is now widely acknowledged to be a major limitation to 
shortening the length of current regimens.112 In pre-clinical development this idea has led to the 
refinement of in vitro models differentiating drug activity between logarithmic and stationary growth 
phase bacilli and to improved animal models of chronic disease where sterilizing activity can be defined 
as the ability to render organs (lung, spleen) culture negative. 
Recent advances using transcriptomics and imaging to examine clinical specimens have also confirmed 
the existence of the persister phenotype in clinical specimens.113, 114 Quantitative studies of bacillary load 
in humans during short-course chemotherapy reveal that the rate of elimination of organisms slows 
dramatically as early as the second week of treatment with HREZ across populations (See Figure 3 and 
Figure 4). Activity during this slow pharmacodynamics phase has been adopted as the operational 
definition of sterilizing activity by Jindani and colleagues.115 Sterilizing activity is considered to be the 
key determinant of the length of the regimen: the greater the sterilizing activity, the shorter the regimen 
may be without substantial risk of relapse.2 Since the relapse rate, the definitive measure of sterilizing 
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activity, is not a feasible endpoint for early clinical trials, a number of different bacteriological measures 
during the first two months of therapy have been proposed as surrogate endpoints. Recent re-evaluation of 
the historical series of short-course trials shows that such endpoints do have significant trial-level 
surrogacy for relapse. Across trials, however, a single bacteriological method, time point and form of 
analysis that best represent sterilizing activity has yet to be determined.116 This is currently an area of 
research critical to the success of early clinical development efforts since boosting sterilizing activity is 
clearly the key to ultra-short treatment regimens for tuberculosis. However, providing reliable proof-of-
concept for individual agents and effectively screening combination regimens for progress into Phase III 
trials can only be done with better surrogate endpoints for sterilizing activity.  
Figure 3: Log10 CFU During Treatment with HRZE from 3 studies: Nairobi (red), Oflotub study (blue), Thailand 
(green) (Davies G, unpublished data) 
Figure 4: Association Between the Treatment Effect on a Positive Culture and the Treatment Effect on a Poor 
Outcome (across studies comparing regimens containing RIF throughout) 
Figure 3:       Figure 4: 
 
 
 
 
 
 
17.3 Additional Evidence on RIF’s Potential for Treatment Shortening 
17.3.1 Evidence from In Vitro Experiments 
Since RIF’s discovery as an orally bioavailable rifamycin,117 much effort has been invested in identifying 
in vitro experimental conditions that predict in vivo efficacy. The minimum inhibitory concentration 
(MIC) of RIF for M. tuberculosis is 0.005 to 1.0 mcg/mL depending on the specific experimental 
conditions and the strain (including both wild-type M. tuberculosis and laboratory strains (i.e. H37Rv or 
H37Ra).118-120 MICs on egg-based media (including Lowenstein-Jensen) are higher at 2.5-10 mcg/mL.120, 
121 The concentrations in non-egg based media are significantly lower than concentrations known to be 
effective in vivo and this large disparity may partially be explained by RIF’s significant protein binding. 
Jayaram et al. reported that the MIC of RIF in M. tuberculosis strain H37Rv in broth (BACTEC 7H12B) 
alone was 0.1 mcg/mL. The authors attribute the higher MIC in the presence of serum to protein binding 
as the mean level of protein binding by RIF in these experiments (by equilibrium dialysis) was found to 
be 83.8%.5 In light of the high level of protein binding found in humans (84-91%),122 in vitro 
measurements derived in the absence of serum may significantly underestimate concentrations necessary 
for treatment in humans. 
Higher concentrations of RIF may have favourable properties in addition to improved bactericidal 
activity, including prevention of resistance acquisition. Although the mutant prevention concentration of 
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RIF in vitro has been estimated at 2.2 mcg/mL,123 Verbist et al reported that of 154 clinical isolates, 132 
were susceptible to RIF at 2.5 mcg/mL, while all 154 were susceptible to RIF at 5 mcg/mL. And when M. 
tuberculosis H37Rv was exposed to RIF at concentrations from 2.5 to 80 mcg/mL, only the highest 
concentration suppressed all growth.124 
Increasing the duration of exposure results in prolonged post-antibiotic effect (PAE).18 Gumbo et al 
recently showed that the development of resistance and the length of the PAE may be related to the peak 
concentration of RIF in vitro. The emergence of resistance to RIF decreased over the range of Cmax/MIC 
tested (from 0 to 250) and a 20-minute exposure to 14 mcg/mL yielded a longer PAE than longer 
incubations with lower concentrations of RIF.98 
Ex vivo macrophage models suggest that elimination of intracellular infection may require higher 
concentrations of RIF than extracellular models.125-127 In peritoneal macrophages isolated from BALB/c 
mice using M. microti as a model organism for M. tuberculosis, Dhillon and Mitchison found a 5-fold 
increase in MIC for RIF in mouse peritoneal macrophages as compared to cell-free media (0.05 mcg/mL 
versus 0.01 mcg/mL).125 Furthermore, higher concentrations of RIF appear to yield better outcomes in 
intracellular models as well: using J774A.1 mouse macrophages, both time and concentration were shown 
to influence killing with a maximum reduction (of 2.3 log10 CFU) on day 4 with the maximum 
concentration of rifampin studied (50 mcg/mL).5 
 
Figure 5: Effect of increasing Cmax/MIC ratios on the bactericidal activity of rifampin on days 1, 7, and 9 after the 
addition of drug (Jayaram et al)5 
Figure 6: Growth of M. tuberculosis in BACTEC 7H12B broth following exposure to increasing concentrations of 
rifampin (Jayaram et al)5 
17.3.2 Evidence from Animal Experiments 
Work by Dickinson and Mitchison demonstrated the role of PZA and RIF in sterilizing activity in murine 
tuberculosis.128 This was distinct from the contribution made by other drugs, such as INH and SM, to 
early killing. Grosset later affirmed these findings129, illustrating that RIF acts both on rapidly multiplying 
organisms, and those persisters thought to be responsible for relapse.  
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 Figure 7: Sterilizing activity of RIF in mice (adapted from Verbist)22 
 
17.3.3 Evidence from Human Pharmacokinetics 
RIF is a potent ligand for the orphan nuclear receptor PXR130 resulting in potent induction of metabolism 
for many drugs.131, 132 However, since RIF is not a substrate for CYP and its autoinduction does not 
appear to be mediated by these enzymes, the precise mechanism for autoinduction remains unknown. The 
half-life is unaffected by renal impairment but is increased by liver disease or biliary obstruction. RIF is 
deacetylated to the enterohepatically recirculated active metabolite 25-desacetyl rifampicin, and 50% to 
60% is excreted in the feces. Up to 30% of a dose is excreted in the urine. Approximately 85% of 
circulating RIF is bound to plasma proteins, and is widely distributed throughout the body.5, 122  
Table 10  Limited change in time to full induction (and absolute amount of induction) with doubling of 
RIF dose29 
RIF dose # of days Timing Antipyrine 
Clearance 
% change Antipyrine 
t1/2 
% change 
600 mg 
 
7 days Before 43.3  13.7  
  
 
After 69.1 60 9.2 -33 
1200 mg 7 days 
 
Before 43.2  15.0  
  
 
After 85.7 98 7.9 -47 
  
 
     
600 mg  14 days 
 
Before 37.4  11.2  
  
 
After 79.7 113 6.1 -46 
co
lo
ny
 fo
rm
in
g 
un
its
 (l
og
 
sc
al
e)
 
Duration of treatment with Rifampin 
5 mg/kg
10 mg/kg
20 mg/kg
40 mg/kg
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1200 mg 14 days 
 
Before 49.6  11.3  
  
 
After 101.1 104 6.0 -47 
Substantial inter-patient variability in plasma concentrations of RIF (and rifapentine) has been 
documented repeatedly and low concentrations have been associated with decreased effectiveness of 
treatment.31, 133-136 A suggested minimal target peak serum concentration for RIF is 8 mcg/mL and even 
this achieves a mean AUC/MIC of only 32.16 Because only 15% of RIF plasma concentration is 
unbound,5, 122 and because oral bioavailability is variable, higher doses increase serum concentrations24, 30, 
31 and are thought to produce more favourable penetration into all tissues, including large caseous or 
purulent lesions.92, 135, 137, 138 This improved penetration and higher RIF concentrations at the site of 
infection may explain the observed enhanced sterilizing activity in animal models, and could improve 
outcomes in humans.47 
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 Table 11  Summary of safety, tolerability, and efficacy findings from clinical studies of high-dose RIF 
Authors, year 
(reference) 
Summary of Design N* % Convert 
1 month 
% 
Convert 2 
months 
% failure 
&/or 
relapse 
Adverse Events 
 
 
Decroix, Kreis, 
Sors et al, 196931 
 
RIF (900 mg) + H (750 mg) 
twice weekly 
 
32 44 75 NA None 
RIF (600 mg) + H (450 mg) 
twice weekly 
 
38 39 70 NA 2 elevated LFT; 1 erythema 
 
 
Kreis, Pretet, 
Birenbaum et al, 
19761391 
 
 
 
H (900mg) + SM (1 g) + 
     
          RIF 1200 mg (daily) 
 
44 72.3 93.6 11.4  
NA 
          RIF 1200 mg (every 2 
days) 
47 70.4 93.2 14.9 
 
Long, Snider, 
Farer et al 
(USPHS), 197982,3 
 
I: H (300 mg) daily + 
    Leucopenia, hepatoxicity, arthritis, 
anemia (no significant different among 
groups) 
          RIF (450 mg) daily, 20 
weeks 
167 24 60 22.4/3.1 6.2% 
          RIF (600 mg) daily, 20 
weeks 
324 35 70 9.1/0.6 6.8% 
          RIF (750 mg) daily, 20 
weeks 
331 33 75 9.4/0 5.7% 
 C: H (300 mg) + EMB (15 
mg/kg) 
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E. Africa/BMRC, 
19721404 
     4% had drugs interrupted/terminated; 3 
(0.05%) had RIF interrupted/terminated 
Daily SM (1 g) + H (300 mg), 6 
months + 
80 20 49 10/15 4% 
          RIF (10mg/kg), 6 
months 
82 29 73 9/1 6% 
          PZA (2 g), 6 months 73 29 64 10/6 9% 
          THZ (150 mg), 6 months 66 17 46 8/16 8% 
SM, 8 weeks; THZ (150 mg), 
18 months, daily 
68 18 56 8/0 13% 
 
 
Verbist & Rollier, 
1971135  
RIF 30 mg/kg (1200, 1500, 
1800 mg) + 
     
Transient increases in bilirubin only; 
renal monitoring, no AEs           H (15 mg/kg) 53 NA NA NA 
          EMB (100 mg/kg) 43 NA NA NA  
 
Decroix, Kreis, 
Sors et al, 1971525 
RIF (600 mg) + H (450 mg) 
daily 
47 37 71 0 2% changed due to AEs 
RIF (900 mg) + H (750 mg) 
twice weekly 
50 44 74 0 1% changed due to AEs 
 
Cooperative TB 
Chemotherapy 
Study, Poland, 
19751416 
I: RIF (600 mg) + EMB (25 
mg/kg) daily 12 weeks 
247 25 60  Overall 12%: self-limiting increase in 
LFTs, asymptomatic. No permanent drug 
withdrawals. 
C: RIF (1200 mg) + EMB (50 
mg/kg) 
     
          Once weekly, 12 months 123 NA NA 2/6.7 29% systemic, 3% hepatic; rx withdrawn 
in 10% 
          Twice weekly, 12 months 124 NA NA 4/0.6 24% systemic, 2% hepatic; rx withdrawn 
in 10% 
  
Page 148 of 207 AJRCCM Articles in Press. Published on 29-June-2018 as 10.1164/rccm.201712-2524OC 
 Copyright © 2018 by the American Thoracic Society 
DMID Protocol 11-0050  V7.0 September 25, 2014 
 
98 
 
 
Cooperative TB 
Chemotherapy 
Study, Poland, 
19761426,7 
I: RIF (600 mg) + EMB (25 
mg/kg) daily, 12 weeks 
     
C: RIF (600mg) + EMB  
(50 mg/kg) 
   NA/6.7  
Once weekly, 12 months 38 NA NA 5/8 10% AEs; 2% treatment changed 
Twice weekly, 12 
months 
40 NA NA 5/5 3% AEs; 0% treatment changed 
C: RIF (1200 mg) + EMB 
(50 mg/kg) 
 NA NA 2.9/0.6  
Once weekly, 12 months 35 NA NA  
4.6/0 
 
33% AEs; 9% treatment changed Twice weekly, 12 
months 
30 NA NA 
Once weekly, 18 months  
70 
NA NA  
3.4/4 
 
27% AEs; 19% treatment changed Twice weekly, 18 
months 
NA NA 
Once weekly, 24 months  
68 
NA NA  
2/0 
 
26% AEs; 20% treatment changed Twice weekly, 24 
months 
NA NA 
 
 
Hong Kong TB 
Treatment 
Services, 1975143 
H-Resistant, 
previously treated 
w/H, SM and/or 
PAS; adverse 
reactions 
evaluated up to 18 
months8 
I: EMB (15 mg/kg) + RIF (450 
mg), daily, 2 months 
     
C: EMB (25 mg/kg) + RIF 
(450 mg), daily, 16 months 
42 NA NA 2/0 11% of 47 (0 flu-like) 
C: EMB (25 mg/kg) + RIF 
(450 mg), daily, 10 months 
39 NA NA 3/0 Excluded (not followed for 18 months) 
C: RIF (>20 mg/kg) + 
EMB (90 mg/kg) once 
weekly, 16 months 
62 NA NA 13 48% of 77 (40% flu-like) 
RIF (>20 mg/kg) + EMB (45 
mg/kg) twice weekly, 18 
months 
84 NA NA 21 32% of 68 (22% flu-like) 
RIF (>20 mg/kg) + EMB (90 
mg/kg) once weekly, 18 months 
53 NA NA 19 61% of 72 (50% flu-like) 
I: Ethio (>10 mg/kg) + PZA 
(>30 mg/kg) + CS (0.5 g) daily, 
68 NA NA  54% of 57 (0 flu-like) 
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6 months 
C: Ethio (>10 mg/kg) + 
PZA (>30 mg/kg), daily, 12 
months 
   19/0  
 
 
Dutt, Moers, 
Stead, 1983619, 
elderly patients 
     Mean age of those experiencing AEs 
older than treatment population 
I: RIF (600 mg) + H (300 mg), 
daily, 1 month 
586 NA  
 
71 
 
 
2.9/1.7 
6% major (hepatitis, blood disorders); 0 
flu-syndrome 
C: RIF (600 mg) + H (900 mg) 
twice weekly (8 months) 
  4.7% major (hepatitis, blood disorders); 
1.5% flu-syndrome 
 
 
 
Ruslami, 
Nijland, 
Alisjahbana et 
al, 200714410 
I: H (300 mg) daily + PZA 
(1500 mg) + EMB (750 mg) + 
 NA NA   
C: H (900 mg) thrice weekly, 3 
months + 
     
RIF (450 mg, 9.5 [1.4] mg/kg) 24   8 Hepatoxicity, grades 1 & 2: 20%; grade 
3: 12% 
RIF (600 mg, 12.9 [1.7] 
mg/kg) 
23   4 Hepatoxicity, grades 1 & 2: 46%; grade 
3: 4% 
 
Poole, Stradling, 
Worlledge, 197162 
I: SM (0.75 g) + H (300 mg) + 
RIF (600 mg), daily, 3 months 
37 NA 89  22% discontinued RIF: flu-like (16%); 
thrombocytopenia (6%) 
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 C: H (900 mg) + RIF (1200 
mg), twice weekly, 15 
months 
   NA Transient renal failure (1 patient) 
 
 
Agarwal, 1983145 
RIF (450-2400 mg) + SM (1 g) 
daily 1 month, RIF (600-900 
mg) + H (15 mg) + SM weekly 
2 months, H + SM weekly 2 
months 
30 33.3% 70.37% NA Jaundice, severe giddiness, flu-like 
symptoms 
Footnotes: 
NA= not reported or available. * Different numbers of subjects were used across analyses within studies. When 
possible, the N reported is the number of participants included in the analysis of the 
first endpoint. 
  1 Failure= reappearance of bacilli and radiologic shadiness 
Phase of Treatment 2 Failure= not culture converted on HR before 20 weeks. Also, after 20 weeks, while 
on HE: culture-positive, clinical non response, or prolongation of HE 
I=Intensive SM= streptomycin 3 Includes AEs in HE continuation phase 
C=Continuation THZ= thiacetazone 4 Failure= > 1 positive culture in last 3 months of treatment 
 RIF= rifampin/rifampicin 5 Failure= > 1 positive (>+) culture in the last 6 months of treatment 
H=isoniazid 6 Failure= > 2 positive cultures (>6 results) at 44, 48, & 52 weeks, or in final 3 
months of treatment 
EMB=ethambutol 7 This paper was the second report of the same study described in ref. 36. The design 
& results, specifically the randomization groups, were presented differently in the 2 
reports. Moreover, although the 18-month and 24-month groups were split for 
dosing frequency (once or twice weekly), because no difference was detected, all 
results were aggregated by the study authors. 
Ethio=ethionamide 8 Failure= > 2 positive cultures (among 6) at 16, 17, & 18 months 
CS=cycloserine 9 Failure= no bacteriologic conversion after 5-6 months of treatment 
 10 Failure= Smear-positive at month 5 or later 
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17.3.3.1 Pharmacogenomics Relevant to RIF Concentrations 
Recent unpublished work has revealed variability in RIF concentrations by polymorphisms in the 
SLCO1B1 gene, up to 35% decrease in AUC0-24. The frequency of these polymorphisms varies by race.146 
Other preliminary work has suggested an association between other polymorphisms and hepatotoxicity 
induced by TB treatment [Davies GR, personal communication, 2009]. The ability to evaluate the effect 
of such polymorphisms on distribution of RIF concentrations will be important for interpretation of 
results.  
17.3.4 Evidence from Efficacy Studies 
Dozens of studies were undertaken during the 1960s-80s to evaluate RIF efficacy, toxicity, or tolerability, 
within a multidrug regimen. These are summarized in Table 11. Differences in design, dosing, and 
endpoints measured make formal comparison among the studies difficult, but certain patterns can be 
observed. We highlight the following findings. Decroix et al compared doses of 600 and 900 mg in 
combination with isoniazid. After two months, 75% of the 600 mg group and 30% of the 900 mg group 
had negative cultures. Earlier, the difference was larger: 19% at two weeks.31 Another study compared 
two groups of patients that received 1200 mg RIF in combination with INH and streptomycin; in one arm 
dosage was daily, in the other intermittent.139 The probability of culture conversion at one month was 
greater than 70% in both groups; at two months, the percent converted exceeded 93%. By comparison, in 
USPHS Study 19, only 60% of those receiving 450 mg of RIF, but approximately 70% of those receiving 
600 mg/day and 75% of patients receiving 750 mg of RIF/day, had culture converted by 2 months.8 In an 
East African/British MRC trial using approximately 10 mg/kg/day or RIF (450 mg in patients under 50 kg 
and 600 mg RIF in patients over 50 kg), results were similar to those found in the lower-dose arm in the 
USPHS study: at months one and two, 29% and 73% of patients respectively had negative cultures.140 
Looking informally across studies, the highest dose (1200 daily or intermittent) achieved 2-month 
conversion in approximately 20% more patients than did the middle doses (10mg/kg, 600 mg, or 750 mg) 
and 30% more than the lowest (450 mg). In sum, we observe that RIF doses higher than 10 mg/kg are 
associated with the frequency of culture conversion at both months 1 and 2.  
17.4 Potential Risks: Additional Toxicity Evidence 
17.4.1 Toxicity Data from Animals 
Furesz et al reported evaluation of long-term toxicity (6 months) in rats, dogs, monkeys, and rabbits. In 
rats, doses up to 100 mg/kg revealed no toxicity, while doses of 200 mg/kg yielded some indications of 
hepatotoxicity. Mortality occurred in 1 dog at 25 mg/kg, with necrotic hemorrhagic enteritis. At 50 
mg/kg, dogs showed some weight loss and hematologic changes. One dog died with severe renal and 
hepatic damage. There were weak indications of dose response in liver toxicity.44 In monkeys, doses up to 
75 mg/kg resulted in no toxicity. Vomiting and deterioration occurred among some of the animals at 
doses in excess of 105 mg/kg. Rabbits treated daily for 4 weeks tolerated 100 mg/kg with no symptoms. 
At 400 mg/kg, 3 of 5 rabbits died. 
No evidence of ototoxicity or vestibular toxicity was found in mice or rabbits studied while receiving 
doses of 50 mg/kg or 150 mg/kg for 31 days.147, 148 Although doses of 50 mg/kg and 100 mg/kg were not 
toxic to rat embryos, beginning at 200 mg/kg fetal death and abnormalities began to occur. All foetuses 
died at 300 mg/kg. Similar results were found among rabbits, though slight elevations in fetal 
abnormalities occurred at doses of 50 and 100 mg/kg. In teratogenicity studies, deformities occurred 
beginning at 150 mg/kg in mice and rats, but not in rabbits. Limited drug interaction studies were 
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performed in animals. In rats, 14-day studies of RIF (15 mg/kg or 30 mg/kg) with INH at 5 mg/kg 
revealed steatosis and liver cell damage in 7 of 31 rats. No fatty liver degeneration, however, was 
observed.149   
17.4.2 Toxicity Data from Humans: Studies of Tuberculosis 
Even non-linear increases in peak serum concentration (more than doubling for dose increase of 50%) do 
not appear to be associated with increased adverse event frequency.31, 52 Although Verbist and Rollier 
observed transient increases in total and direct bilirubin in African patients receiving 30 mg/kg RIF (1200, 
1500, 1800 mg doses) over 10 weeks, these increases did not persist and there were no additional signs or 
symptoms of liver toxicity in the trial, even among patients with baseline liver function abnormalities.135 
In one possible exception, Ruslami et al reported recently that grades 1 and 2 hepatotoxicity occurred 
more frequently in patients exposed to higher-dose RIF (p=0.054) while grade 3 hepatotoxicity occurred 
in 12% of the lower-dose and 4% of the higher-dose arm (p=0.32).144  
Martinez and colleagues suggest that the increased frequency of flu-like syndrome in intermittent 
treatment is due to “an antibody excess relative to the antigen level in the drug-free days.”150 In at least 
one study, frequency of “flu-like” syndrome was higher in patients who received RIF (900-1800 mg) only 
once weekly when compared to patients who received it twice weekly.143 Even then, these reactions may 
not warrant regimen changes141 and typically do not occur until after three months of treatment. It is likely 
that any sterilizing and shortening effect of high-dose RIF would be realized in 8 weeks or less.7, 8, 11, 12, 122 
If higher doses of RIF were only used during the 8-week intensive phase, then existing data do not 
support increased frequency of these reactions. 
Occasional thrombocytopenia, haemolytic anemia, and acute renal failure are associated with the presence 
of RIF-dependent IgM or IgG antibodies. RIF has variable effects on cellular and humoral immunity. 
Suppression of in vitro lymphocyte responses in cells collected from TB patients has been reported, but 
clinically evident immunosuppression has not been demonstrated.16, 151 See Table 11 for summaries of 
additional studies. 
17.4.3 Toxicity Data from Humans: Other Indications 
With intermittent treatment for leprosy (usually at 900 mg) flu-like syndrome may be reported66, but 
generally resolves spontaneously. RIF is also used commonly at 900 mg for 45-60 days to treat 
brucellosis. In combination with doxycycline, ROF has the “most favourable efficacy/safety ratio” among 
the recommended regiments67 and was not associated with more adverse events than two other regiments 
in a multicentre trial.68 RIF (20 mg/kg/day for 7 days) was used in an outbreak of resistant Streptococcus 
pneumonia at a day care in the US without any reports of adverse events.69 In staphylococcal infections of 
orthopaedic implants, daily RIF (900 mg) was used in combination for 6 months with no treatment-
related side effects reported in 46 patients.70 RIF (1200 mg) was administered for 21 days in a patient with 
Legionella jordanis without any reported problem.71 Lastly, in a randomized placebo-controlled trial, RIF 
was used at 1200 mg daily for 4 weeks to treat cutaneous leishmaniasis. The authors report that there 
were no elevations in liver function tests “or other side effects” during therapy.72 
17.4.4 Toxicity of Companion Drugs 
Isoniazid 
Other nervous system reactions are rare at normal doses, and they include convulsions, encephalopathy, 
optic neuritis, memory impairment, and psychosis. Gastrointestinal adverse effects include nausea, 
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vomiting, and epigastric distress. Asymptomatic elevation of aminotransferases is common (10-20%). 
Idiosyncratic severe hepatitis is uncommon but more likely with increasing age (up to 2.3% incidence in 
persons more than 50 years old), and may be life threatening. The risk of isoniazid-associated 
hepatotoxicity is also increased by daily consumption of alcohol and in the postpartum period.  
Pyrazinamide 
In initial randomized clinical trials of a 2-month regimen of rifampin plus pyrazinamide (RZ) treatment 
for latent tuberculosis in HIV-infected persons, the incidence of severe liver injury was low and similar to 
that of daily isoniazid.152-154 However, subsequent reports described severe liver injury in patients treated 
for latent tuberculosis infection with RZ, and on the basis of these reports, CDC collected data from 
cohorts of patients in the United States who received RZ for the treatment of LTBI during the period of 
January 2000 to June 2002. Of the 7.737 patients started on RZ, 77% received daily doses and 23% twice-
weekly doses. A total of 204 patients (2.6%) discontinued treatment with RZ because of AST 
concentrations higher than five times the upper limit of normal. An additional 146 patients (1.9%) 
discontinued using RZ because of symptoms of hepatitis. Of the 30 patients (0.4%) with severe liver 
injury, 23 recovered and 7 died (0.09%). As a consequence, ATS and CDC recommends against routine 
use of RZ for treatment of latent TB infection. Several additional latent TB treatment studies confirm a 
relatively high frequency of hepatitis among RZ recipients—combined data from five recent studies 
include 1,311 patients showed a rate of Grade 3 or 4 liver injury of 5.8%, which is higher than that 
reported previously with isoniazid therapy.155-159 In a randomized trial of two short-course regimens to 
prevent TB in high risk contacts of active TB cases in Rio de Janeiro, Brazil, Grade 3 or 4 liver injury 
developed in 17 of 163 (10%) participants receiving twice weekly RZ and <1% of participants receiving 
isoniazid plus rifapentine (RE Chaisson, unpublished data). The mechanism of RZ-associated 
hepatotoxicity remains unknown. Similarly, it is unclear why rates of hepatotoxicity with RZ for LTBI 
are higher than those observed among patients with active TB treated with isoniazid in addition to 
rifampin and pyrazinamide for 2 months. Possible explanations include impaired inflammatory response 
(resulting in impaired liver inflammation) in patients with active TB, or a mitigating effect of isoniazid on 
RZ-associated hepatotoxicity. 
17.4.5 Drug Interactions between RIF and Companion Drugs 
INH is largely cleared by N-acetyltransferase 2 (NAT2), which has not been shown to be induced by 
RIF.160 Concurrent administration of larger doses of RPNT (cyclopentyl-RIF) did not alter the INH 
pharmacokinetics in USPHS Study 25.85,161 PZA is metabolized to pyrazinoic acid and hydroxyl 
pyrazinoic acid by non-P450 pathways, and the metabolites are cleared renally.25,162 EMB is partially 
cleared renally and partially cleared hepatically.85,163 The precise enzymes involved in EMB metabolism 
have not been determined. Available data do not reveal differences in the pharmacokinetics of EMB when 
delivered alone compared to PK results for EMB in the presence of RIF.25,164 
 
17.4.6 Potential interactions between companion medications and concomitant drugs 
The companion drugs, INH, PZA and EMB, may also result in interactions with concomitant drugs. 
Implicated classes include anti-convulsants, sedatives, neuroleptics, anticoagulants, narcotics, anti-
infectives, anti-gout, and antacids, in addition to several others. Details of the class members with 
interactions with companion drugs and suggestions for their management are listed below in Tables 12, 
13 and 14. These drugs should be avoided in HIRIF patients, or management strategies should be 
followed. 
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Table 12  Drug-drug interactions with Isoniazid (likely in the HIRIF setting) requiring change of 
medication165 
Drug category Drugs affected by Isoniazid Comments 
Anti-convulsants Phenytoin, carbamazepine, valproic 
acid  
Isoniazid decreases the clearance of these 
medications, and may increase the drug 
level in the blood. Blood levels of these 
drugs should be measured before and 
during treatment with INH. Additionally, 
the patient should be monitored closely for 
any sign or symptom of toxicity and the 
dose should be adjusted accordingly. 
Concomitant intake of phenytoin, 
carbamazepine and valproic acid may 
increase the hepatotoxicity of isoniazid.  
 Phenobarbital  Concomitant use of phenobarbital with 
INH may lead to increased hepatotoxicity. 
Sedatives Benzodiazepines (i.e. diazepam, 
flurazepam, triazolam, midazolam) 
INH may decrease the hepatic metabolism 
of benzodiazepines resulting in more 
elevated concentrations of these drugs in 
the blood. The patient should be observed 
closely for any sign of toxicity and the dose 
should be adjusted accordingly.  
Neuroleptics  Chlorpromazine, haloperidol   Concomitant use of chlorpromazine with 
INH may compromise the metabolism of 
INH. These patients should be closely 
observed for INH toxicity. Concomitant 
use of haloperidol and INH may increase 
the level of haloperidol. Patients should be 
carefully monitored for possible 
haloperidol toxicity and the dose adjusted 
accordingly.  
Anticoagulants  Coumadin and inadione derivatives 
(warfarin) 
Concomitant use of these medications with 
INH may result in increased concentrations 
in plasma and thus increased risk of 
bleeding. Therefore, patients taking INH 
should be closely monitored. 
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Narcotics Alfentanil, enflurane  Prolonged use of INH may increase 
duration of alfentanil in plasma; therefore 
the dose of this drug should be adjusted 
accordingly. INH may increase the 
formation of inorganic fluoride which may 
be nephrotoxic when used concomitantly 
with enflurane. 
Other Theophylline  Concomitant use of INH with this drug 
may result in increased level of 
theophylline in the blood, therefore 
theophylline levels should be monitored 
closely.  
 Procainamide Concomitant use of this drug with INH 
may result in increased plasma 
concentration of INH. These patients 
should be closely monitored for signs and 
symptoms of INH toxicity.  
 Corticosteroids (e.g, prednisone)  In patients who are rapid acetylators, 
concomitant use of corticosteroids may 
decrease exposure to INH, and therefore 
doses of INH should be adjusted 
accordingly 
 Acetaminophen, paracetamol Concurrent use of these medications with 
INH may increase the risk of 
hepatotoxicity.  
 Aluminum hydroxide  Interferes with INH absorption. While 
receiving INH therapy, acid suppressant 
drugs or antacids that do not contain 
aluminum hydroxide should be used.  
 Disulfiram Concomitant use of this medication with 
INH may increase the incidence of side 
effects of the central nervous system. 
Dosing for Disulfiram should be reduced or 
discontinued if necessary.  
 Hepatotoxic medications The use of INH with other hepatotoxic 
(non anti-TB) drugs should be avoided 
because they increase the possibility of 
hepatotoxicity.  
 Neurotoxic medications The use of INH with neurotoxic drugs 
should be avoided because may lead to an 
additive neurotoxic effect.  
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Table 13  Drug-drug interactions with Pyrazinamide (likely in the HIRIF setting) requiring change of 
medication166 
Drug category Drugs affected by pyrazinamide Comments 
Anti-infectives  Fluroquinolones  Concomitant use of Pyrazinamide and ofloxacin 
and Levofloxacin has been associated with an 
increase in adverse events (hepatic, 
gastrointestinal and musculoskeletal) resulting in 
discontinuation of therapy.  
Concomitant use of these medications is not 
recommended. However, when deemed 
necessary, it should be done under close medical 
vigilance. Patients will not be allowed to 
participate in HIRIF if on these drugs.  
Anti-gout  Allopurinol Allopurinol increases the AUC (area under the 
curve) of the pyrazinamide metabolite, 
pyrazinoic acid, which inhibits the elimination of 
urates. Therefore, allopurinol is not effective in 
treating hyperuricemia associated with 
pyrazinamide.  
Other Probenecid  There is a complex pharmacokinetic and 
pharmacodynamic interaction between these 
medications. An adequate dose of probenecid 
when used concomitantly with pyrazinamide has 
not been determined; therefore concomitant use 
should be avoided.  
 Hepatotoxic medications The use of pyrazinamide with other hepatotoxic 
(non anti-TB) drugs should be avoided because it 
increases the possibility of hepatotoxicity. 
  
Table 14  Drug-drug interactions with Ethambutol (likely in the HIRIF setting) requiring change of 
medication167 
Drug category Drugs affected by Ethambutol  Comments 
Antacids  Antacids containing aluminun 
hydroxide 
While receiving ethambutol therapy, acid suppressant 
drugs or antacids that do not contain aluminum 
hydroxide should be used. 
Anti-gout Uricosurics  
 
 
 
 
 
It may be necessary to increase the dose of uricosuric 
medications because ethambutol competes with uric 
acid for renal excretion.  
 Disulfiram Concomitant use of ethambutol with disulfiram may 
increase the risk for ocular toxicity. 
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17.5 Package Inserts 
17.5.1 Rifadin 
SUMMARY OF PRODUCT CHARACTERISTICS: 
1. NAME OF THE MEDICINAL PRODUCT 
Rifadin 150mg Capsules 
 
2. QUALITATIVE AND QUANTITATIVE COMPOSITION 
Rifampicin Ph Eur 150 mg 
For a full list of excipients, see section 6.1. 
 
3. PHARMACEUTICAL FORM 
Capsule, hard. 
The gelatine capsule is composed of a red half and a blue half. 
 
4. CLINICAL PARTICULARS 
4.1 Therapeutic indications 
Indications for use 
 
Tuberculosis: In combination with other active anti-tuberculosis drugs in the treatment of all 
forms of tuberculosis, including fresh, advanced, chronic and drug resistant cases. Rifadin is also 
effective against most atypical strains of Mycobacteria. 
 
Leprosy: In combination with at least one other active anti-leprosy drug in the management of 
multibacillary and paucibacillary leprosy to effect conversion of the infectious state to a non-
infectious state.  
 
Other Infections: In the treatment of Brucellosis, legionnaires Disease, and serious staphylococcal 
infections. To prevent emergence of resistant strains of the infecting organisms, Rifadin should be 
used in combination with another antibiotic appropriate for the infection. 
 
Prophylaxis of meningococcal meningitis: For the treatment of asymptomatic carriers of N. 
meningitides to eliminate meningococci from the nasopharynx. 
 
Haemophilus influenza: For the treatment of asymptomatic carriers of H. influenza and as 
chemoprophylaxis of exposed children, 4 years of age or younger. 
 
4.2 Posology and method of administration 
Recommended Dosage 
 
For oral administration 
 
The daily dose of Rifadin, calculated from the patient’s body weight, should preferably be taken 
at least 30 minutes before a meal or 2 hours after a meal to ensure rapid and complete absorption. 
 
Tuberculosis: 
Rifadin should be given with other effective anti-tuberculosis drugs to prevent the possible 
emergence of rifampicin-resistant strains of Mycobacteria. 
Page 158 of 207 AJRCCM Articles in Press. Published on 29-June-2018 as 10.1164/rccm.201712-2524OC 
 Copyright © 2018 by the American Thoracic Society 
DMID Protocol 11-0050  V7.0 September 25, 2014 
 
108 
RIFADIN 150mg label-EU. 2010 ed: Sanofi-Aventis S.p.A.  
 
Adults: The recommended single daily dose in tuberculosis is 8-12 mg/kg. 
 
Usual Daily dose: Patients weighing less than 50 kg – 450 mg. Patients weighing 50 kg or more – 
600 mg. 
 
Children: In children, oral doses of 10-20 mg/kg body weight daily are recommended, although a 
total daily dose should not usually exceed 600 mg. 
 
Leprosy: 
600 mg doses of rifampicin should be given once per month. Alternatively, a daily 
regimen may be used. The recommended single daily dose is 10 mg/kg. 
 
Usual daily dose: Patients weighing less than 50 kg - 450 mg. Patients weighing 
50 kg or more - 600 mg. 
 
In the treatment of leprosy, rifampicin should always be used in conjunction with at 
least one other antileprosy drug, 
 
Brucellosis, Legionnaires Disease or serious staphylococcal infections: 
 
Adults: The recommended daily dose is 600-1200 mg given in 2 to 4 divided doses, 
together with another appropriate antibiotic to prevent the emergence of resistant 
strains of the infecting organisms. 
 
Prophylaxis of meningococcal meningitis: 
Adults: 600 mg twice daily for 2 days. 
 
Children (1 - 12 years): 10 mg/kg twice daily for 2 days. 
 
Children (3 months - 1 year): 5 mg/kg twice daily for 2 days. 
 
Prophylaxis of Haemophilus influenza: 
 
Adults and children: For members of households exposed to H. influenzae B disease 
when the household contains a child 4 years of age or younger, it is recommended that all 
members (including the child) receive rifampicin 20 mg/kg once daily 
(maximum daily dose 600 mg) for 4 days. 
Index cases should be treated prior to discharge from hospital. 
 
Neonates (1 month): 10 mg/kg daily for 4 days. 
 
Impaired liver function: 
A daily dose of 8 mg/kg should not be exceeded in patients with impaired liver 
function. 
 
Use in the elderly: 
In elderly patients, the renal excretion of rifampicin is decreased proportionally with 
physiological decrease of renal function; due to compensatory increase of liver 
excretion, the terminal half-life in serum is similar to that of younger patients. 
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However, as increased blood levels have been noted in one study of rifampicin in 
elderly patients, caution should be exercised in using rifampicin in such patients, 
especially if there is evidence of impaired liver function. 
4.3 Contraindications 
 
Rifadin is contra-indicated in patients who: 
x are hypersensitive to any of the rifamycins or any of the excipients (see 
section 6.1); 
x have jaundice; 
x are concurrently receiving saquinavir/ritonavir therapy (see section 4.5 
Interactions). 
4.4 Special warnings and precautions for use 
 
Rifampicin should be given under the supervision of a respiratory or other 
suitably qualified physician. 
 
Cautions should be taken in case of renal impairment if dose > 600 mg/day. 
 
All tuberculosis patients should have pre-treatment measurements of liver 
function. 
 
Adults treated for tuberculosis with rifampicin should have baseline 
measurements of hepatic enzymes, bilirubin, serum creatinine, a complete 
blood count, and a platelet count (or estimate). 
Baseline tests are unnecessary in children unless a complicating condition is 
known or clinically suspected. 
 
Patients with impaired liver function should only be given rifampicin in cases 
of necessity, and then with caution and under close medical supervision. In 
these patients, lower doses of rifampicin are recommended and careful 
monitoring of liver function, especially serum alanine aminotransferase (ALT) 
and serum aspartate aminotransferase (AST) should initially be carried out 
prior to therapy, weekly for two weeks, then every two weeks for the next six 
weeks. If signs of hepatocellular damage occur, rifampicin should be 
withdrawn. 
 
Rifampicin should also be withdrawn if clinically significant changes in 
hepatic function occurs. The need for other forms of antituberculosis therapy 
and a different regimen should be considered. Urgent advice should be 
obtained from a specialist in the management of tuberculosis. If rifampicin is 
re-introduced after liver function has returned to normal, liver function should 
be monitored daily. 
In patients with impaired liver function, elderly patients, malnourished 
patients, and possibly, children under two years of age, caution is particularly 
recommended when instituting therapeutic regimens in which isoniazid is to 
be used concurrently with Rifadin. If the patient has no evidence of preexisting 
liver disease and normal pre-treatment liver function, liver function 
tests need only be repeated if fever, vomiting, jaundice or other deterioration 
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in the patient’s condition occur. 
 
Patients should be seen at least monthly during therapy and should be 
specifically questioned concerning symptoms associated with adverse 
reactions. 
 
In some patients hyperbilirubinaemia can occur in the early days of treatment. 
This results from competition between rifampicin and bilirubin for hepatic 
excretion. 
 
An isolated report showing a moderate rise in bilirubin and/or transaminase 
level is not in itself an indication for interrupting treatment; rather the decision should be made 
after repeating the tests, noting trends in the levels and 
considering them in conjunction with the patient’s clinical condition. 
 
Because of the possibility of immunological reaction including anaphylaxis 
(see section 4.8 Undesirable effects) occurring with intermittent therapy (less 
than 2 to 3 times per week) patients should be closely monitored. Patients 
should be cautioned against interrupting treatment. 
 
Rifampicin has enzyme induction properties that can enhance the metabolism 
of endogenous substrates including adrenal hormones, thyroid hormones and 
vitamin D. Isolated reports have associated porphyria exacerbation with 
rifampicin administration. 
 
Rifadin capsules may produce a reddish coloration of the urine, sweat, sputum 
and tears, and the patient should be forewarned of this. Soft contact lenses 
have been permanently stained (see section 4.8). 
 
All patients with abnormalities should have follow up examinations, including 
laboratory testing, if necessary. 
 
4.5 Interaction with other medicinal products and other forms of interaction 
 
Cytochrome P-450 enzyme interaction 
 
Rifampicin is a potent inducer of certain cytochrome P-450 enzymes. 
Coadministration of rifampicin with other drugs that are also metabolised 
through these cytochrome P-450 enzymes may accelerate the metabolism and 
reduce the activity of these other drugs. Therefore, caution should be used 
when prescribing rifampicin with drugs metabolised by cytochrome P-450. To 
maintain optimum therapeutic blood levels, dosages of drugs metabolised by 
these enzymes may require adjustment when starting or stopping 
concomitantly administered rifampicin. 
Examples of drugs metabolised by cytochrome P-450 enzymes are: 
x Antiarrhythmics (e.g. disopyramide, mexiletine, quinidine, propafenone, 
tocainide), 
x Antiepileptics (e.g. phenytoin), 
x Hormone antagonist (antiestrogens e.g. tamoxifen, toremifene, gestinone), 
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x Antipsychotics (e.g. haloperidol, aripiprazole), 
x Anticoagulants (e.g. coumarins), 
x Antifungals (e.g. fluconazole, itraconazole, ketoconazole, voriconazole), 
x Antivirals (e.g. saquinavir, indinavir, efavirenz, amprenavir, nelfinavir, 
x atazanavir, lopinavir, nevirapine), 
x Barbiturates 
x Beta-blockers (e.g. bisoprolol, propanolol), 
x Anxiolytics and hypnotics (e.g. diazepam, benzodiazepines, zolpicolone, 
x zolpidem), 
x Calcium channel blockers (e.g. diltiazem, nifedipine, verapamil, 
x nimodipine, isradipine, nicardipine, nisoldipine), 
x Antibacterials (e.g. chloramphenicol, clarithromycin, dapsone, 
x doxycycline, fluoroquinolones, telithromycin), 
x Corticosteroids 
x Cardiac glycosides (digitoxin, digoxin), 
x Clofibrate, 
x Systemic hormonal contraceptives 
x Oestrogen, 
x Antidiabetic (e.g. chlorpropamide, tolbutamide, sulfonylureas, 
x rosiglitazone), 
x Immunosuppressive agents (e.g. ciclosporin, sirolimus, tacrolimus) 
x Irinotecan, 
x Thyroid hormone (e.g. levothyroxine), 
x Losartan, 
x Analgestics (e.g. methadone, narcotic analgesics), 
x Praziquantel, 
x Progestogens, 
x Quinine, 
x Riluzole, 
x Selective 5-HT3 receptor antagonists (e.g. ondansetron 
x Statins metabolised by CYP 3A4 (e.g. simvastatin), 
x Theophylline, 
x Tricyclic antidepressants (e.g. amitriptyline, nortriptyline), 
x Cytotoxics (e.g. imatinib), 
x Diuretics (e.g. eplerenone) 
 
Patients on oral contraceptives should be advised to use alternative, nonhormonal methods of 
birth control during Rifadin therapy. Also diabetes may 
become more difficult to control. 
 
Other Interactions 
 
When rifampicin is given concomitantly with the combination 
saquinavir/ritonavir, the potential for hepatotoxicity is increased. Therefore, 
concomitant use of Rifadin with saquinvir/ritonavir is contraindicated (see 
section 4.3 Contraindications). 
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When the two drugs were taken concomitantly, decreased concentrations of 
atovaquone and increased concentrations of rifampicin were observed. 
 
Concurrent use of ketoconazole and rifampicin has resulted in decreased 
serum concentrations of both drugs. 
 
Concurrent use of rifampicin and enalapril has resulted in decreased 
concentrations of enalaprilat, the active metabolite of enalapril. Dosage 
adjustments should be made if indicated by the patient's clinical condition. 
 
Concomitant antacid administration may reduce the absorption of rifampicin. 
Daily doses of rifampicin should be given at least 1 hour before the ingestion 
of antacids. 
 
When rifampicin is given concomitantly with either halothane or isoniazid, the 
potential for hepatotoxicity is increased. The concomitant use of rifampicin 
and halothane should be avoided. Patients receiving both rifampicin and 
isoniazid should be monitored closely for hepatotoxicity. 
 
If p-aminosalicylic acid and rifampicin are both included in the treatment 
regimen, they should be given not less than eight hours apart to ensure 
satisfactory blood levels. 
 
Interference with laboratory and diagnostic tests 
 
Therapeutic levels of rifampicin have been shown to inhibit standard 
microbiological assays for serum folate and Vitamin B12. Thus alternative 
assay methods should be considered. Transient elevation of BSP and serum 
bilirubin has been reported. Rifampicin may impair biliary excretion of 
contrast media used for visualization of the gallbladder, due to competition for 
biliary excretion. Therefore, these tests should be performed before the 
morning dose of rifampicin. 
 
4.6 Pregnancy and lactation 
 
Pregnancy 
At very high doses in animals rifampicin has been shown to have teratogenic 
effects. There are no well controlled studies with rifampicin in pregnant 
women. Although rifampicin has been reported to cross the placental barrier 
and appear in cord blood, the effect of rifampicin, alone or in combination 
with other antituberculosis drugs, on the human foetus is not known. 
Therefore, Rifadin should be used in pregnant women or in women of child 
bearing potential only if the potential benefit justifies the potential risk to the 
fetus. When Rifadin is administered during the last few weeks of pregnancy 
it may cause post-natal hemorrhages in the mother and infant for which 
treatment with Vitamin K1 may be indicated. 
 
Lactation 
Rifampicin is excreted in breast milk, patients receiving rifampicin should not 
breast feed unless in the physician’s judgment the potential benefit to the 
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patient outweighs the potential risk to the infant. 
 
4.7 Effects on ability to drive and use machines 
 
No studies on the effects on the ability to drive and use machines have been 
performed. 
 
4.8 Undesirable effects 
 
Reactions occurring with either daily or intermittent dosage regimens include: 
 
Cutaneous reactions which are mild and self-limiting and do not appear to be 
hypersensitivity reactions. Typically they consist of flushing and itching with 
or without a rash. Urticaria and more serious hypersensitivity cutaneous 
reactions have occurred but are uncommon. Exfoliate dermatitis, pemphigoid 
reaction, erythema multiform including Stevens-Johnson syndrome, Lyells 
syndrome and vasculitis have been reported rarely. 
 
Gastrointestinal reactions consist of anorexia, nausea, vomiting, abdominal 
discomfort and diarrhea. Pseudomembranous colitis has been reported with 
rifampicin therapy. 
 
Hepatitis can be caused by rifampicin and liver function tests should be 
monitored (see section 4.4. Special warnings and precautions for use). 
 
Central Nervous System: Psychoses have been rarely reported. 
 
Thrombocytopenia with or without purpura may occur, usually associated with 
intermittent therapy, but is reversible if drug is discontinued as soon as 
purpura occurs. Cerebral hemorrhage and fatalities have been reported when 
rifampicin administration has been continued or resumed after the appearance 
of purpura. 
 
Disseminated intravascular coagulation has also been rarely reported. 
 
Eosinophilia, leucopenia, edema, muscle weakness and myopathy have been 
reported to occur in a small percentage of patients treated with rifampicin. 
Agranulocytosis has been reported very rarely reported. 
Rare reports of adrenal insufficiency in patients with compromised adrenal 
function have been observed. 
 
Reactions usually occurring with intermittent dosage regimens and probably of 
immunological origin include: 
 
x ‘Flu Syndrome’ consisting of episodes of fever, chills, headache, dizziness, 
and bone pain appearing most commonly during the 3rd to the 6th monthly 
of therapy. The frequency of the syndrome varies but may occur in up to 
50 % of patients given once-weekly regimens with a dose of rifampicin of 
25 mg/kg or more. 
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x Shortness of breath and wheezing. 
 
x Decrease in blood pressure and shock. 
 
x Anaphylaxis. 
 
x Acute hemolytic anemia. 
 
x Acute renal failure usually due to acute tubular necrosis or acute interstitial nephritis. 
 
If serious complications arise, e.g. renal failure, thrombocytopenia or 
hemolytic anemia, rifampicin should be stopped and never restarted. 
 
Occasional disturbances of the menstrual cycle have been reported in women 
receiving long-term anti-tuberculosis therapy with regimens containing 
rifampicin. 
 
Rifampicin may produce a reddish coloration of the urine, sweat, sputum and 
tears. The patient should be forewarned of this. Soft contact lenses may be 
permanently stained. 
 
4.9 Overdose 
 
Human Experience 
 
Signs and Symptoms: 
Nausea, vomiting, abdominal pain, pruritus, headache and increasing lethargy 
  will probably occur within a short time after acute ingestion; unconsciousness 
may occur when there is severe hepatic disease. Transient increases in liver 
enzymes and/or bilirubin may occur. Brownish-red or orange coloration of 
the skin, urine, sweat, saliva, tears and feces will occur, and its intensity is 
proportional to the amount ingested. Facial or periorbital edema has also 
been reported in pediatric patients. Hypotension, sinus tachycardia, 
ventricular arrhythmias, seizures and cardiac arrest were reported in some fatal 
cases. 
The minimum acute lethal or toxic dose is not well established. However, 
nonfatal acute overdoses in adults have been reported with doses ranging from 
9 to 12 g rifampicin. Fatal acute overdoses in adults have been reported with 
doses ranging from 14-60 g. Alcohol or a history of alcohol abuse was 
involved in some of the fatal and nonfatal reports. 
Nonfatal overdoses in pediatric patients ages 1 to 4 years old of 100 mg/kg 
for one to two doses have been reported. 
 
Management: 
Intensive supportive measures should be instituted and individual symptoms 
treated as they arise. Since nausea and vomiting are likely to be present, 
gastric lavage is probably preferable to induction of emesis. Following 
evacuation of the gastric contents, the instillation of activated charcoal slurry 
into the stomach may help absorb any remaining drug from the gastrointestinal 
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tract. Antiemetic medication may be required to control severe nausea and 
vomiting. Active diuresis (with measured intake and output) will help promote 
excretion of the drug. Hemodialysis may be of value in some patients. 
 
5. PHARMACOLOGICAL PROPERTIES 
 
5.1 Pharmacodynamic properties 
 
ATC Code: J04AB02 Antimycobacterials, antibiotics 
 
Rifampicin is an active bactericidal antituberculosis drug which is particularly active 
against the rapidly growing extracellular organisms and also has bactericidal activity 
intracellularly. Rifampicin has activity against slow and intermittently-growing 
M. Tuberculosis. 
 
Rifampicin inhibits DNA-dependent RNA polymerase activity in susceptible cells. 
Specifically, it interacts with bacterial RNA polymerase but does not inhibit the 
mammalian enzyme. Cross-resistance to rifampicin has only been shown with other 
rifamycins. 
 
5.2 Pharmacokinetic properties 
 
Rifampicin is readily absorbed from the gastrointestinal tract. Peak serum 
concentrations of the order of 10 μg/ml occur about 2 to 4 hours after a dose of 
10 mg/kg body weight on an empty stomach. 
Absorption of rifampicin is reduced when the drug is ingested with food. 
 
The pharmacokinetics (oral and intravenous) in children are similar to adults. 
 
In normal subjects the biological half-life of rifampicin in serum averages 
about 3 hours after a 600 mg dose and increases to 5.1 hours after a 900 mg 
dose. With repeated administration, the half-life decreases and reaches 
average values of approximately 2-3 hours. At a dose of up to 600 mg/day, it 
does not differ in patients with renal failure and consequently, no dosage 
adjustment is required. 
 
Rifampicin is rapidly eliminated in the bile and an enterophepatic circulation 
ensues. During this process, rifampicin undergoes progressive deacetylation, 
so that nearly all the drug in the bile is in this form in about 6 hours. This 
metabolite retains essentially complete antibacterial activity. Intestinal 
reabsorption is reduced by deacetylation and elimination is facilitated. Up to 
30 % of a dose is excreted in the urine, with about half of this being 
unchanged drug. 
 
Rifampicin is widely distributed throughout the body. It is present in effective 
concentrations in many organs and body fluids, including cerebrospinal fluid. 
Rifampicin is about 80 % protein bound. Most of the unbound fraction is not 
ionized and therefore is diffused freely in tissues. 
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5.3 Preclinical safety data 
 
Not applicable 
 
6. PHARMACEUTICAL PARTICULARS 
 
6.1 List of excipients 
 
Corn starch Ph Eur 
Magnesium stearate Ph Eur 
 
6.2 Incompatibilities 
 
None stated 
 
6.3 Shelf life 
 
4 years from date of manufacture 
 
6.4 Special precautions for storage 
 
Store below 25oC. 
Protect from light and moisture. 
6.5 nature and contents of container 
 
Amber glass bottles of 100 capsules. 
 
Blister packs of 100 capsules in cardboard cartons. Blister material is aluminum foil 
/ PVDC (Aluminium 0.025 mm; PVDC 20 gsm) and transparent PVC / PVDC foil 
(PVC 0.25 mm; PVDC 60 gsm). 
 
6.6 Special precautions for disposal 
 
No special requirements. 
 
7. MARKETING AUTHORISATION HOLDER 
 
Aventis Pharma Limited 
Trading as Marion Merrell or Aventis Pharma 
One Onslow Street 
Guildford 
Surrey 
GU1 4YS 
UK 
 
Or trading as 
 
Sanofi-aventis 
One Onslow Street 
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9th April 2005 
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18 November 2011 
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17.5.2 FDCs 
Products: 4 FDC-B and 4 FDC  
RIFAMPICIN 150 mg, ISONIAZID 75 mg, PYRAZINAMIDE 400 mg and 
ETHAMBUTOL 275 mg in a fixed dose combination tablet  
Uses:  
An optional component of several anti-TB chemotherapeutic regimens currently recommended by 
WHO.  
Contraindications and Precautions:  
•Preparation not suitable for use in children  
•Not appropriate for intermittent therapy in these drug strengths  
•Known hypersensitivity to the drugs  
 
See also individual monographs for Rifampicin, Isoniazid, Pyrazinamide and Ethambutol below:  
Dose:  
Use for initial (intensive) phase of treatment in place of the single tablets: By 
mouth, ADULT  
•30-37 kg 2 tablets daily for 2 months  
•38-54 kg 3 tablets daily for 2 months  
•55-70 kg 4 tablets daily for 2 months  
•71 kg or more 5 tablets daily for 2 months 
RIFAMPICIN  
General information  
A semisynthetic derivative of rifamycin, a complex macrocyclic antibiotic that inhibits ribonucleic acid 
synthesis in a broad range of microbial pathogens. It has bactericidal action and a potent sterilizing effect 
against tubercle bacilli in both cellular and extracellular locations. Rifampicin is lipid-soluble. Following 
oral administration, it is rapidly absorbed and distributed throughout the cellular tissues and body fluids; 
if the meninges are inflamed, significant amounts enter the cerebrospinal fluid. A single dose of 600 mg 
produces a peak serum concentration of about 10 micrograms/ml in two to four hours, which 
subsequently decays with a half-life of two to three hours. It is extensively recycled in the enterohepatic 
circulation, and metabolites formed by deacetylation in the liver are eventually excreted in the feces. 
Since resistance readily develops, rifampicin must always be administered in combination with other 
effective antimycobacterial agents.  
Clinical information  
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Uses  
A component of all six and eight month anti-TB chemotherapeutic regimens currently 
recommended by WHO; Leprosy  
 
Dosage and administration  
Rifampicin should preferably be given at least 30 minutes before meals, since absorption is reduced when 
it is taken with food. Rifampicin should be given as combination therapy Adults and children: 10 mg/kg 
daily, or 2 or 3 times weekly (maximum dose, 600 mg daily)  
 
Contraindications  
Known hypersensitivity to rifamycins 
Jaundice  
 
Precautions  
Serious immunological reactions resulting in renal impairment, hemolysis or thrombocytopenia are on 
record in patients who resume taking rifampicin after a prolonged lapse of treatment. In this rare situation 
it should be immediately and definitely withdrawn.  
Careful monitoring of liver function is required in the elderly, and in patients who are alcohol-
dependent, have hepatic disease or are on prolonged therapy.  
Reduce dose in renal impairment.  
Patients should be warned that treatment may produce reddish coloration of urine, tears, saliva and 
sputum, and that contact lenses may be irreversibly stained.  
Patients or their care-givers should be told how to recognize signs of liver disorders and advised to 
discontinue treatment and seek immediate medical attention if symptoms such as persistent nausea, 
vomiting, malaise or jaundice develop.  
Use in pregnancy  
Whenever possible, the six month regimen based upon isoniazid, rifampicin and pyrazinamide should be 
used. Vitamin K should be administered to the infant at birth because of the risk of postnatal hemorrhage.  
 
Adverse effects  
Rifampicin is well tolerated by most patients at currently recommended doses, although gastrointestinal 
tolerance can be unacceptably severe. Other adverse effects (skin rashes, fever, influenza-like syndrome 
and thrombocytopenia) are more likely to occur with intermittent administration. Exfoliative dermatitis is 
more frequent in HIV-positive TB patients. Temporary oliguria, dyspnea and hemolytic anemia have also 
been reported in patients taking the drug three times weekly. These reactions usually subside if the 
regimen is changed to one with daily dosage. Moderate rises in serum concentrations of bilirubin and 
transaminases, which are common at the outset of treatment, are often transient and without clinical 
significance. However, dose-related hepatitis can occur which is potentially fatal. It is consequently 
important not to exceed the maximum recommended daily dose of 10 mg/kg (600 mg).  
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Drug interactions  
Rifampicin induces hepatic enzymes, and may increase the dosage requirements of drugs metabolized in 
the liver. These include corticosteroids, steroid contraceptives, oral hypoglycemic agents, oral 
anticoagulants, phenytoin, cimetidine, cyclosporin and digitalis glycosides. Since rifampicin reduces the 
effectiveness of the oral contraceptive pill, women should consequently be advised to choose between one 
of the following two options for contraception. Following consultation with a physician, she could take an 
oral contraceptive pill containing a higher dose of estrogen (50mcg). Alternatively she could use a 
nonhormonal method of contraception throughout rifampicin treatment and for at least one month 
subsequently. 
ISONIAZID  
General information  
Isoniazid, the hydrazide of isonicotinic acid is highly bactericidal against replicating tubercle bacilli. It is 
rapidly absorbed and diffuses readily into all fluids and tissues. The plasma half-life, which is genetically 
determined, varies from less than one hour in fast acetylators to more than three hours in slow acetylators. 
It is largely excreted in the urine within 24 hours, mostly as inactive metabolites.  
Clinical information  
Uses  
Tuberculosis treatment, in combination with other drugs  
Tuberculosis prophylaxis and occasionally to prevent:  
• transmission to close contacts at high risk of disease  
• progression of infection to primary complex in recently infected, asymptomatic individuals  
• recrudescence of infection in immunodeficient individuals.  
 
 
Dosage and administration  
By mouth, ADULT and CHILD  
•5 mg/kg (4–6 mg/kg) daily (maximum, 300 mg daily)  
•or 10 mg/kg 3 times weekly 
•or 15 mg/kg twice weekly  
 
Tuberculosis, treatment in critically ill patients unable to take oral therapy (combination therapy), use 
intramuscular injection , ADULT 200–300 mg as single daily dose; CHILD 10– 20 mg/kg daily  
Tuberculosis, prophylaxis, by mouth  
•ADULT 300 mg daily for at least 6 months  
•CHILD 5 mg/kg daily for at least 6 months  
 
Note: Isoniazid should be taken on an empty stomach; if taken with food to reduce 
gastrointestinal irritation, oral absorption and bioavailability may be impaired  
 
Contraindications  
• Known hypersensitivity  
• Drug induced hepatic disease  
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Precautions  
• Hepatic impairment (monitor hepatic function)  
• Malnutrition  
• Chronic alcohol dependence  
• Chronic renal failure  
• Diabetes mellitus  
• HIV infection—prophylactic pyridoxine 10 mg daily required because risk of peripheral neuritis  
• Epilepsy (isoniazid may provoke attacks)  
• Slow acetylator status (increased risk of adverse effects)  
• History of psychosis  
• Pregnancy  
• Breast-feeding  
• Porphyria  
 
Note: Patients at risk of peripheral neuropathy as a result of malnutrition, chronic alcohol 
dependence or diabetes should additionally receive pyridoxine, 10 mg daily.  
Note: For liver disorders, patients or their care-givers should be told how to recognize signs of liver 
disorder, and advised to discontinue treatment and seek immediate medical attention if symptoms such 
as nausea, vomiting, malaise or jaundice develop  
 
Adverse effects  
Isoniazid is generally well tolerated at recommended doses. Systemic or cutaneous hypersensitivity 
reactions occasionally occur during the first weeks of treatment. The risk of peripheral neuropathy is 
excluded if vulnerable patients receive daily supplements of pyridoxine. Other less common forms of 
neurological disturbance, including optic neuritis, toxic psychosis and generalized convulsions, can 
develop in susceptible individuals, particularly in the later stages of treatment and occasionally necessitate 
the withdrawal of isoniazid. Hepatitis is an uncommon but potentially serious reaction that can usually be 
averted by prompt withdrawal of treatment. More often, however, a sharp rise in serum concentrations of 
hepatic transaminases at the outset of treatment is not of clinical significance, and usually resolves 
spontaneously during continuation of treatment.  
Drug interactions  
Isoniazid tends to raise plasma concentrations of phenytoin and carbamazepine by inhibiting their 
metabolism in the liver. The absorption of isoniazid is impaired by aluminium hydroxide.  
Overdosage  
Nausea, vomiting, dizziness, blurred vision and slurring of speech occur within 30 minutes to three hours 
of overdosage. Massive poisoning results in coma preceded by respiratory depression and stupor. Severe 
intractable seizures may occur. Emesis and gastric lavage can be of value if instituted within a few hours 
of ingestion. Subsequently, hemodialysis may be of value. Administration of high doses of pyridoxine is 
necessary to prevent peripheral neuritis.  
 
Storage  
Tablets should be kept in well-closed containers, protected from light. Solution of injection should be 
stored in ampoules protected from light. 
PYRAZINAMIDE  
Page 172 of 207 AJRCCM Articles in Press. Published on 29-June-2018 as 10.1164/rccm.201712-2524OC 
 Copyright © 2018 by the American Thoracic Society 
DMID Protocol 11-0050  V7.0 September 25, 2014 
 
122 
FDC label/patient leaflet, Macleods Pharmaceuticals Ltd, WHO prequalification.  
General information  
A synthetic analogue of nicotinamide that is only weakly bactericidal against M. tuberculosis, but has 
potent sterilizing activity, particularly in the relatively acidic intracellular environment of macrophages 
and in areas of acute inflammation. It is highly effective during the first two months of treatment while 
acute inflammatory changes persist and its use has enabled treatment regimens to be shortened and the 
risk of relapse to be reduced.  
It is readily absorbed from the gastrointestinal tract and is rapidly distributed throughout all tissues and 
fluids. Peak plasma concentrations are attained in two hours and the plasma half-life is about 10 hours. It 
is metabolised mainly in the liver and is excreted largely in the urine.  
Clinical information  
Uses  
A component of all six and eight month anti-TB chemotherapeutic regimens currently 
recommended by WHO.  
Dosage and administration  
By mouth:  
 
Adults and children (for the first two or three months) 25 mg/kg daily 35 mg/kg three times weekly 50 
mg/kg two times weekly  
 
Contraindications  
•Known hypersensitivity 
•Severe hepatic impairment  
•Porphyria  
 
Precautions  
•Hepatic impairment (monitor hepatic function)  
•Patients with diabetes mellitus (monitored blood glucose--concentrations may change suddenly  
•Gout may be exacerbated.  
 
Use in pregnancy  
Although the safety of pyrazinamide in pregnancy has not been established, the six month regimen 
based upon isoniazid, rifampicin and pyrazinamide should be used whenever possible.  
 
Adverse effects  
Pyrazinamide in usually well tolerated. Hypersensitivity reactions are rare, but some patients 
complain of slight flushing of the skin.  
Moderate rises in serum transaminase concentrations are common during the early phases of 
treatment. Severe hepatotoxicity is rare.  
As a result of inhibition of renal tubular secretion, a degree of hyperuricemia usually occurs, but this is 
often asymptomatic. Gout requiring treatment with allopurinol occasionally develops. Arthralgia, 
particularly of the shoulders, commonly occurs and is responsive to simple analgesics. Both 
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hyperuricemia and arthralgia may be reduced by prescribing regimens with intermittent administration of 
pyrazinamide.  
Note: Patients and their care-givers should be told how to recognize signs of liver disorder, and advised 
to discontinue treatment and seek immediate medical attention if symptoms such as persistent nausea, 
vomiting, malaise or jaundice develop.  
Overdosage  
Little had been recorded on the management of pyrazinamide overdose. Acute liver damage and 
hyperuricemia have been reported. Treatment is essentially symptomatic. Emesis and gastric lavage may 
be of value if undertaken within a few hours of ingestion. There is no specific antidote and treatment is 
supportive.  
 
Storage  
Tablets should be stored in tightly closed containers, protected from light.  
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ETHAMBUTOL  
General information  
A synthetic congener of 1,2-ethanediamine that is active against M. tuberculosis, M. bovis and some non-
specific mycobacteria. It is used in combination with other anti-TB drugs to prevent or delay the 
emergence of resistant strains.  
It is readily absorbed from the gastrointestinal tract. Plasma concentrations peak in 2-four hours and 
decay with a half-life of three to four hours. Ethambutol is excreted in the urine both unchanged and as 
inactive hepatic metabolites.  
About 20% is excreted in the feces as unchanged drug.  
Clinical information  
Uses  
An optional component of several anti-TB chemotherapeutic regimens currently recommended by 
WHO.  
 
Dosage and administration  
By mouth: Adults: 15 mg/kg daily 30 mg/kg three times weekly, or 45 mg/kg (40-50 mg/kg) twice a week  
Children: 15 mg/kg daily  
Dosage must always be carefully calculated on a weight basis to avoid toxicity, and should be reduced 
in patients with impaired renal function.  
 
Contraindications  
• Known hypersensitivity  
• Pre-existing optic neuritis from any cause  
• Inability to report symptomatic visual disturbances—children under 5 years)  
• Severe renal impairment  
 
Precautions  
• Visual disturbances—ocular examination recommended before and during treatment (see note below)  
• Reduce dose in renal impairment and monitor plasma concentration  
• Use in the elderly  
 
Note: Patients should report visual disturbances immediately and discontinue treatment; children who are 
incapable of reporting symptomatic visual changes accurately should be given alternative therapy, as 
should, if possible, any patient who cannot understand  
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warnings about visual adverse effects  
Whenever possible, renal function should assessed before treatment.  
 
Use in pregnancy  
The six month regimen based upon isoniazid, rifampicin and pyrazinamide should be used. If a fourth 
drug is needed during the initial phase, ethambutol should be preferred to streptomycin.  
 
Adverse effects  
Dose-dependent optic neuritis can readily result in impairment of visual acuity and color vision. Early 
changes are usually reversible, but blindness can occur if treatment is not discontinued promptly.  
Signs of peripheral neuritis occasionally develop in the legs.  
 
Overdosage  
Emesis and gastric lavage may be of value if undertaken within a few hours of ingestion. Subsequently, 
dialysis may be of value. There is no specific antidote and treatment is supportive.  
Storage  
Tablets should be stored in well-closed containers.
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Pyridoxine 50mg. IQFARMA. Instituto Quimioterápico S.A. 
 
 
17.5.3 Pyridoxine 
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17.6 Adverse Event grading 
Figure 8. Division of Microbiology and Infectious Diseases (DMID) Adult Toxicity Table, November 2007, Draft 
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17.7 Point Estimates and Confidence Intervals for Frequency of AEs or SAEs 
Below we present point estimates and 80% and 90% binomial confidence intervals (CIs) for rates of 
AEs/SAEs. These represent the frequency that will be observed when the study recruitment is completed. 
Since the events will likely occur prior to the end of recruitment, the observed frequency of toxicity at any 
point during the study will be higher than this, but these estimates provide, at least, a lower bound.  
We provide CIs with 80% and 90% confidence around point estimates of frequency of AEs/SAEs in all 
arms (Table 15) and frequency of AEs/SAEs in a single arm (Table 16). In each table, we also provide 
estimates for the overall study (n=180) and estimates for single arms (as if data were unblended and we 
knew in which arm events occurred). 
 
Table 15 Point estimates and binomial confidence intervals of toxicity in HIRIF, full study (remains 
blinded) 
Observed events, N 
 
Point Estimate Lower 80% CI Upper 80% CI 
1,180 
 
0.005555556 0.0005851649 0.0214368369 
2,180 
 
0.01111111 0.002958368 0.029296637 
3,180 
 
0.01666667 0.006137957 0.036737262 
4,180 
 
0.02222222 0.009727259 0.043917538 
5,180 
 
0.02777778 0.01357388 0.05091537 
 
Observed events, N 
 
Point Estimate Lower 90% CI Upper 90% CI 
1,180 
 
0.005555556 0.0002849221 0.0260823033 
2,180 
 
0.01111111 0.00197778 0.03456159 
3,180 
 
0.01666667 0.004557748 0.042510022 
4,180 
 
0.02222222 0.007625414 0.050128307 
5,180 
 
0.02777778 0.01100769 0.05751495 
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Table 16  Point estimates and binomial confidence intervals of toxicity in HIRIF, single arm (if 
unblinded, and could know distribution within arms) 
Observed events, n Point Estimate Lower 80% CI Upper 80% CI 
1,60 0.01666667 0.001754468 0.063287383 
2,60 0.03333333 0.008898553 0.086278042 
3,60 0.05 0.01850794 0.10796524 
 
Observed events, n Point Estimate Lower 90% CI Upper 90% CI 
1,60 0.01666667 0.0008545229 0.0766399949 
2,60 0.03333333 0.005954897 0.101235895 
3,60 0.05 0.01376516 0.12418721 
 
As noted in the protocol text, if we see one event while the data are still blinded (i.e., 1/180), the best 
estimate of the minimum overall rate of toxicity in the study is 0.5% but is compatible with a rate of 2.6% 
with a 90% CI. With 4 events the estimate becomes compatible with a rate of 5%, though the best 
estimate is still 2.2%. With 5 events the lower bound finally exceeds 1%. 
The challenge is that the arm in which the event occurs in them has a minimum rate of toxicity of 1.7% 
with 90% bounds of 0.001-7.7%. If we wait till we see two events this increases to 3.3% with bounds of 
0.006-10%. With three events the lower bound is 1.4%. 
So we chose three accumulated events as halting criteria b, for which full SMC should be convened; if all 
of 3 events had occurred in one arm, the point estimate would be 5% while the lower bound exceeds 1% 
whether all events were in one arm or not. In neither case at this sample size is the upper bound below 
6%; and we have to accept a CI compatible with toxicity rates of 10-12% with this approach. Although 
these frequency estimates are minimal, we note that the accumulating data seen by the SMC (with 
denominators lower than 60 or 180) would have a lower degree of confidence than those reported in the 
tables above.  
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